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Aerosol electrostatics is an important property of pharmaceutical aerosols. The
electrostatic properties of pMDI aerosols have been shown to be a function of both
formulation and packaging components. The modified ELPI enables measurement of
aerosol charge as a function of particle size, and the simultaneous determination of the
mass distribution using chemical analysis. However, in order to fully assess the cause and
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effects of aerosol electrostatics in terms of its biological and regulatory implications, it is
necessary to understand the basic charging mechanisms inside the pMDI formulation.
Electrical resistivity and zeta potential measurements confirmed the presence of
charged species within HFA based solutions and suspensions although the nature of these
species remains unknown. These measurements were influenced by the cosolvent
concentration and to a lesser extent by the presence of soluble drug and surfactant. The
mean electrical resistivity of a 7% ethanol / 93% HFA 134a blend (0.83 ± 0.02 MΩ.cm)
was significantly lower than that reported for HFA 134a (180 MΩ.cm). Albuterol sulfate
demonstrated a positive zeta potential (75.9 ± 26.2 mV) in HFA 134a. Pilot molecular
modeling studies, in conjunction with the analysis of particle interactions using HINT,
provided an improved understanding of the possible interactions within albuterol sulfate
HFA suspension pMDIs. The predominantly negative (-7597 ± 2063) HINT score signified
unfavorable interactions between albuterol sulfate and HFA 134a molecules.
Systematic investigations of the electrical properties of HFA solution and
suspension pMDIs using the modified ELPI demonstrated that the electrical properties
were a function of the formulation type (solution/suspension), formulation components and
particle size. Experimental BDP solution pMDIs produced predominantly electropositive
aerosols (net charge: 160 ± 30 pC) while albuterol sulfate pMDIs produced bipolar charged
aerosol clouds (net charge: -162 ± 277 pC). Finally, the modified ELPI was recalibrated
using commercially available polydisperse pMDIs as calibration aerosols with a reference
Andersen cascade impactor. The mean cut-off diameters for stages 4-12 obtained following
recalibration of the modified ELPI were 0.44, 0.56, 0.70, 1.01, 1.40, 2.12, 3.03, 4.75, 6.37
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μm, respectively in comparison to those reported by the manufacturer (0.16, 0.27, 0.39,
0.62, 0.96, 1.62, 2.42, 4.05, 6.67 μm, respectively).

I. INTRODUCTION

I.A. Significance and Background
Aerosol clouds produced by pressurized metered dose inhalers (pMDIs) are
electrically charged and these charges may influence particle deposition behavior in the
respiratory tract and valved holding chambers (VHCs) (Melandri et al. 1983, Peart et al.
1998, Bisgaard et al. 2002). In fact, VHCs made from electrically conductive or
electrostatically dissipative material are now commercially available and have been
suggested to improve drug delivery from pMDIs by minimizing electrostatic loss of drug
in the chamber (Mitchell et al. 2004, Louca et al. 2006, Rau et al. 2006). Electrostatic
properties of pMDI aerosol clouds have been shown to be a function of both formulation
and packaging components (Peart et al. 1998). However, electrical properties of the
formulation within the pMDI canister are not well characterized, primarily due to a lack of
consensus on charge generation mechanisms and the experimental difficulties associated
with the measurement of electrical properties in non-aqueous liquefied propellants (Sidhu
et al. 1993, Sandstrom et al. 1994, Rogueda 2002, Traini et al. 2005). In order to fully
assess the cause and effects of pMDI aerosol electrostatics in terms of its biological and
regulatory implications, it is necessary to understand the basic charging mechanisms inside
the pMDI formulation.
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Electrical measurements in chlorofluorocarbon (CFC) and hydrofluoroalkane
(HFA) containing formulations are challenging due to the need to maintain the propellants
under pressure. Earlier studies have employed electrophoretic mobility measurements to
demonstrate that drug particles suspended in model non-pressurized chlorinated solvents
and CFC propellants can acquire surface charges (Wyatt and Vincent 1989, Sidhu et al.
1993). A limited number of studies have reported determination of zeta potential using
electrophoretic mobility measurements for drug suspensions in a model non-pressurized
HFA solvent, e.g., 2H,3H-perfluoropentane (HPFP), however, the role of surface charges
in HFA based suspension pMDIs remains poorly understood (Rogueda 2002).
Although aerodynamic particle size is the major parameter influencing drug
deposition from pMDIs, studies using animals, hollow-cast lung models, humans and
theoretical lung models have demonstrated the importance of electrostatic charge on the
deposition of aerosols in the respiratory tract (Fraser 1966, Chan et al. 1978, Melandri et
al. 1983). The effect of electrostatic charge on particle size characterization methods is not
known. It is therefore necessary to evaluate aerosol electrostatic properties in relation with
the particle size distribution. With the introduction of the Electrical Low Pressure Impactor
(ELPI), it is possible to measure the charge distribution of aerosols as a function of particle
size and simultaneously determine the mass distribution using chemical analysis (Glover
and Chan 2004a, Keil 2005, Kwok et al. 2005). Electrostatic charge characterization of
commercial HFA based solution and suspension pMDIs using a modified ELPI has
previously been reported (Kwok et al. 2005), however, a systematic study investigating the
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differences in the electrostatic charging characteristics of solution and suspension HFA
pMDIs is lacking.
This research project will focus on the particle interactions and, in particular,
electrostatic interactions within hydrofluoroalkane based pMDI formulations in relation to
their aerosol electrostatic properties.

I.B. Particle Interactions within Pressurized Metered Dose Inhalers
In order to better understand the formulation effects on electrical properties of
pMDI aerosols, the particle interactions inside the pMDI formulation itself need to be
considered. Most pMDIs are formulated as suspensions of micronized drug in liquefied
propellant blends (Farr et al. 1994). Surfactants, e.g., lecithin, oleic acid and sorbitan
trioleate have traditionally been used to stabilize these inherently unstable systems, which
have a tendency to form agglomerates as a result of attractive particle-particle interactions
such as van der Waals forces (Farr et al. 1994). According to DLVO theory, suspension
stability is governed by the steric and / or electrostatic repulsive forces exceeding the
attractive forces (Derjaguin and Landau 1941, Verwey and Overbeek 1948). Although
traditional DLVO theory has been used to explain suspension stability within aqueous
systems on the basis of van der Waals attractive forces and electrostatic repulsion, its
application to non-aqueous systems, e.g., pMDI suspensions has not been validated
(Vervaet and Byron 1999). The extent to which the above-mentioned forces influence
particle interactions within the pMDI suspension is considered to vary depending on
surface chemistry and morphology of drug, excipients and packaging components, e.g.,
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canister coating material (Parsons et al. 1992, Clarke et al. 1993). Conventional wisdom
states that suspension stability is predominantly achieved using surfactants via steric
repulsion in non-aqueous media (Vervaet and Byron 1999). In such non-aqueous systems,
due to the low dielectric constant and low ionic strengths within the suspensions,
electrostatic repulsive forces are considered to be negligible (Pugh et al. 1983).
The formulation and device components of the pMDI have undergone major
modifications due to the transition from the ozone-depleting CFCs to the ozone-friendly
HFA propellants (Thiel 1996, Leach 2005). The difference in physicochemical properties
of HFA and CFC propellants, particularly the solvent characteristics, has necessitated the
use of different salt forms of drugs and the inclusion of polar cosolvents such as ethanol to
dissolve surfactants traditionally used in CFC based pMDIs (Byron et al. 1994, Tzou et al.
1997, Jannick 2006). Solubility of water in HFAs is higher than that in CFCs, and HFA
based pMDIs show an increased tendency for water ingress (Gelotte and Shaheed 1998,
Williams 1999). HFA based suspension pMDIs also have a greater propensity for drug
adhesion to the canister inner surface than CFC based suspensions and the use of
fluorocarbon polymer coating such as PTFE (polytetrafluoroethylene) on the canister inner
surfaces to minimize drug adhesion has been documented in the patent literature (Ashurst
et al. 2000a, Ashurst et al. 2000b, Britto 2000, Britto 2001, Riebe et al. 2003). Novel
suspension stabilizers to improve HFA based pMDI suspension stability have also been
investigated (Stefely 2002, Looker et al. 2003). The addition of polymers, e.g.,
polyethylene glycol (PEG) and polyvinylpyrollidone (PVP) to formoterol fumarate
dihydrate (FFD) suspensions in HPFP has been shown to decrease the attractive forces
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between FFD particles, measured using atomic force microscopy (AFM), presumably via
steric hindrance by polymer adsorption on to the particle surface (Rogueda 2002).
Traini et al. have suggested an alternative approach to DLVO theory in order to
explain particle interactions within HFA propelled suspension pMDIs on the basis of
surface energetics, proposed by van Oss (van Oss 1994, Traini et al. 2005). This
alternative surface component approach considers short range Lewis acid-base (electron
donor or electron acceptor) interactions including hydrogen bonding, in addition to
dispersive van der Waals and the long range electrostatic repulsive forces, to explain
particle interactions in pMDI suspensions (Traini et al. 2005). Particle interactions between
drug, canister and polymeric coating materials in HPFP have been investigated; contact
angle measurements were employed to determine the surface energy parameters while
AFM measurements were used to determine the cohesive-adhesive interactions (Traini et
al. 2006). Experimentally determined adhesion energies between albuterol sulfate particles
and inner surfaces of pMDI canisters such as aluminum, anodized aluminum, and PTFE,
using AFM have been correlated with theoretical calculations of adhesion energies using
the surface component approach (Traini et al. 2006). These studies demonstrated that
adhesion of drug particles to canister material was dependent on both the dispersive and
polar components of particle interactions in an HPFP environment thus suggesting that
partially fluorinated liquids are not apolar and that their weakly polar nature may also play
an important role in particle interactions within pMDIs (Traini et al. 2006).
In their approach, Traini et al. assumed that the electrostatic component of particle
interactions within HFA based suspension pMDIs was negligible, based upon the absence
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of appreciable ionic concentration (Traini et al. 2005). However, this may not be entirely
applicable to all HFA based formulations, which are more likely to form ionic species
since they are relatively polar. The dielectric constant of a dispersion medium determines
the dissociation of the electrolytes present in the solvent. Non-aqueous solvents may be
categorized in terms of their dielectric constant (ε) into non-polar (ε ≤ 5), weakly polar (5 <
ε ≤ 12), moderately polar (12 < ε ≤ 40) and polar (ε > 40) (Delgado et al. 2005). Thus,
propellants used in pMDI formulations may be classified on the basis of their dielectric
constant as non-polar, e.g., CFC 11, CFC 12 or weakly polar, e.g., HFA 134a, HFA 227
solvents. Inclusion of ethanol as a cosolvent would increase the dielectric constant and the
polarity of the dispersion medium, which in turn could influence ionic dissociation. The
solubility of water in HFA 134a alone has been reported to be 2200 ppm (Pischtiak 2000a)
while that in a 10% ethanol / 90% HFA 134a blend is much higher (13500 ppm; Gelotte
and Shaheed 1998). The presence of water in these systems may also possibly influence
the formation of ionic species and a subsequent increase in the conductivity of the ethanol /
HFA blend. Although conventional wisdom suggests that steric repulsion is the only
effective means for stabilization of non-aqueous suspension pMDIs (Vervaet and Byron
1999), the role of electrostatic charge in the relatively polar HFA based suspension pMDIs
remains to be investigated.

I.C. Electrostatic Interactions within Non-Aqueous Systems
Comprehensive reviews addressing the mechanisms involving charge generation
and electrostatic stabilization in non-aqueous systems have been published (Lyklema 1968,
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Fowkes et al. 1982, Morrison 1993). Charging mechanisms in non-aqueous dispersions
may involve: 1) acid-base mechanisms where proton or hydroxyl ions are potential
determining ions (in protic liquids), or electron transfer mechanisms in aprotic liquids, 2)
surface group dissociation, or 3) adsorption of uncharged electrolyte onto the particle
followed by ion exchange with surface groups and dissociation of charged electrolytes, the
most common ion exchanged being a proton (Morrison 1993).
While complete dissociation of electrolytes can be expected for polar solvents,
incomplete dissociation of electrolytes is observed in moderately polar liquids, i.e., the
concentration of charged ionic species may be lower than the concentration of the
electrolytes present (Delgado et al. 2005). In weakly polar liquids, limited dissociation of
electrolytes capable of forming large charged species, e.g., micelles or polymers, can occur
(Morrison 1993). However the ionic concentration in such systems, which may be obtained
from conductivity measurements, would be expected to be very low (Delgado et al. 2005).
Most of the studies investigating electrical charges in non-aqueous dispersions have
investigated carbon black suspensions in hydrocarbons such as mineral oil, xylene,
benzene with dispersants, e.g., sodium diethylhexylsulfosuccinate, calcium diisopropylsalicylate, and various salicylates and succinimides. It has been suggested that charge
forming species in these suspensions are inverse micelles formed by the dispersants. Trace
amounts of water could enhance the formation of inverse micelles by forming links
between the hydrophilic portions within the micelle in non-aqueous systems. These large
association structures may spontaneously dissociate on the application of an electric field
and give rise to electrical conductivity in non-aqueous media (Morrison 1993). Although
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inverse micelle formation has been reported in CFCs (Matthews and Hirschhorn 1953),
similar formation of inverse micelles has not been documented for HFA based suspensions
containing a series of surfactants (Blondino 1995).
The influence of trace quantities of water on the surface charge of both hydrophilic
solids like titanium dioxide and hydrophobic particles such as carbon black dispersed in
non-aqueous solvents, e.g., p-xylene, cyclohexane, n-heptane has been reported (McGown
and Parfitt 1966). Charge reversal of suspended titanium dioxide particles in p-xylene
containing Aerosol OT (sodium diethylhexyl sulfosuccinate) from negative to positive was
observed on moisture adsorption (McGown and Parfitt 1966). Romo has also shown that
while charge reversal was observed for α-alumina dispersed in alcohol in the presence of
water with a subsequent decrease in suspension stability, there was minimal effect of
moisture on the surface charge of aluminum hydroxide (Romo 1966). The presence of
water has also been implicated in the charging of surfaces in non-aqueous media by
making the dispersion medium either acidic or basic via proton transfer (Lyklema 1968).
Electrical resistivity of CFC and HFA refrigerants have been reported; CFCs were
found to be stronger insulators (poor conductors) than HFAs. The resistivity of CFC 12
was determined to be 0.51x106 MΩ.cm, while that of HFA 134a was 108.9 MΩ.cm
(Meurer et al. 2001). Electrical resistivity of these refrigerants has been found to be
dependent on water content and other impurities as well as the applied field strength
(Meurer et al. 2001). Resistivity of pharmaceutical grade HFA 134a has been reported to
be 180 MΩ.cm (Solvay Fluor Product Bulletin 2001), which is comparable to that of
refrigerant 134a (108.9 MΩ.cm). HFA based pMDIs are relatively polar in nature due to
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the presence of polar cosolvents and susceptible to water ingress as well; these factors
would be expected to decrease the resistivity of HFA 134a containing formulations.
Electrical resistivity measurements therefore could provide an indication of charged
species in the solution and aid in understanding charging mechanisms in propellant
containing formulations; such measurements have not yet been undertaken.

I.C.1. Measurement of Surface Charge in Non-Aqueous Systems
Surface charge in non-aqueous systems can be determined using techniques
including electroacoustic measurements, electrodeposition and electrophoretic mobility
measurements (Wyatt and Vincent 1989, Morrison et al. 1991, Larson et al. 1992, Hunter
1998).
Electroacoustic characterization of colloidal dispersions can be used to determine
dynamic mobility of charged particles. The technique is based on the generation of an
ultrasonic wave by application of an alternating electric field to a colloidal suspension
(Hunter 1998), and is also called the electrokinetic sonic amplitude (ESA) effect.
Application of an electrical field causes oscillation of charged particles; these oscillations
generate tiny acoustic dipoles, which cancel each other in the bulk of the suspension, but
near the electrodes no such cancellation occurs. Instead, these tiny acoustic dipoles form an
ultrasonic wave near the electrodes, which propagates at a particular amplitude and phase
angle that can be related to the magnitude and polarity of the dynamic mobility of charged
particles. This technique may be used for determination of zeta potential of colloidal
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suspensions and is especially advantageous for measurements in concentrated suspensions
(particle concentrations in excess of 1% by volume) (Hunter 1998).
Electrodeposition is a quantitative method to determine the average charge to mass
ratio of suspended particles by applying a constant potential (e.g., a high electric field
potential of 1 kV) between two parallel plate electrodes (electrode gap: 1 mm) for a known
amount of time (3 - 6 sec) (Larson et al. 1992). The total number of electric charges
passing through the cell is calculated and the mass of the particles plated on the electrode
can be calculated from the electrode area and the concentration of particles in suspension
(Larson et al. 1992).
Morrison et al. reported a technique to measure the charge on particles dispersed in
insulating fluids. A sample of the dispersion to be tested is placed on a porous support or
filter with a pore size sufficient to hold the particles but allows a rapid flow of the liquid
(Morrison et al. 1991). As the insulating fluid is forced through the dispersion, the charged
particles are collected on the filter while the countercharges are carried away and collected
in a Faraday cup. The potential produced on the Faraday cup as the oil drains through the
orifice is measured. Since the number of countercharges is the same as the number of
charges on all the particles, and the mass of all the particles in the dispersion is known, the
average charge to mass ratio can be calculated (Morrison et al. 1991). However, these
techniques are challenging to adapt for measurements in pressurized formulations.
Surface charge of non-aqueous suspensions, including pMDI formulations, has also
been determined by measuring the electrophoretic mobility of the suspended particles
using either Laser Doppler Velocimetry (LDV) or phase analysis light scattering (PALS),
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which is a variation of LDV (Wyatt and Vincent 1989, Morrison 1993, Sidhu et al. 1993).
Electrophoresis is the movement of charged particles or polyelectrolytes, immersed in a
liquid, under the influence of an external electric field (Delgado et al. 2005). Charged
particles in suspension attract oppositely charged ions (countercharges) from the bulk of
the dispersion medium. The countercharges in the vicinity of the particle form a tightly
bound layer at the particle surface called the Stern layer. The liquid associated with the
tightly bound layer of ions remains stationary with respect to the particle. The potential at
the boundary of this stationary liquid layer and the bulk of the medium is called the
electrokinetic or zeta potential. Delgado et al. have reviewed the status and recent progress
in the understanding of electrokinetic theory and have given practical recommendations
regarding electrokinetic measurement and interpretation of the results obtained (Delgado et
al. 2005). For uniform and weak electric fields, a linear relationship exists between steadystate electrophoretic velocity, v and the applied field, E:
v = μ.E

Equation I.C.1.1

where μ is the electrophoretic mobility. In order to obtain zeta potential from
measurements of electrophoretic mobility, it is essential to know the thickness of the
electrical double layer, i.e., the layer of counterions around the charged particle, κ-1, and
the particle radius, a (Delgado et al. 2005). The value of κ is given by:
1/ 2

⎧ N 2 2 ⎫
⎪⎪ ∑ e z i ni ⎪⎪
κ = ⎨ i =1
⎬
⎪ ε rs ε 0 kT ⎪
⎪⎭
⎪⎩

Equation I.C.1.2
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with e, the elementary charge; zi and ni, the charge number and number concentration of
ion i (the solution contains N ionic species), respectively; εrs, the relative permittivity of the
electrolyte solution; ε0, the electric permittivity of vacuum; k, the Boltzmann constant; T,
the thermodynamic temperature (Delgado et al. 2005).
Zeta potential can be calculated from the measured electrophoretic mobility using
Henry’s equation (Equation I.C.1.3):

μ=

2ε rs ε 0ζf (κa)
3η

Equation I.C.1.3

where ζ is zeta potential and η is the viscosity of the solution. In order to calculate κ, the
conductivity of the solution as well as knowledge of the mobilities and valences of the
ionic species present in the solution is required. The electrokinetic equations derived by
Smoluchowski, for non-conducting particles, are valid for particles of any shape or pores
inside a solid, provided the radius, a, largely exceeds the Debye length, κ-1 (electrical
double layer around charged particle is ‘thin’ due to high ionic concentration in the
dispersion medium). The Helmholtz-Smoluchowski (HS) equation for electrophoresis is:

μ=

ε rs ε 0ζ
η

Equation I.C.1.4

Smoluchowski, however, did not consider the case of strongly curved surfaces, i.e., the
presence of a large double layer (Delgado et al. 2005). When κa << 1 (electrical double
layer around the charged particle is ‘thick’ due to low ionic concentration in the dispersion
medium), the Hückel approximation as shown in Equation I.C.1.5 is applied.

μ=

2ε rs ε 0ζ
3η

Equation I.C.1.5
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The theories relating to electrokinetic potential assume that the equations relating
electrophoretic mobility to zeta potential are applicable to any liquid characterized by two
important properties: the electrical permittivity (εrsε0) and the viscosity (η). Although
surface charges acquired in weakly polar or non polar solvents are much lower compared
to those found in aqueous systems, because of the very low electrical double layer
capacitance, the value of surface potential is of the same order of magnitude as in aqueous
systems. Further, due to the low ionic concentration in these systems, surface potential
decays slowly with distance. As a consequence of this, the surface potential is considered
to be approximately equal to the zeta potential (Delgado et al. 2005).

I.C.2. Surface Charge of Particles Dispersed in Non-Aqueous, Non-Pressurized and
Pressurized Solvents

A limited number of studies have been undertaken to investigate the surface charge
of drug particles suspended in model non-aqueous, non-pressurized as well as pressurized
chlorinated solvents using an electrophoretic mobility technique (Clarke et al. 1993).
However, there remains a lack of consensus on the range of zeta potential values that
would be preferred for stable suspensions in non-aqueous media. Zeta potential values
greater than 50 mV have been suggested in order to obtain stable suspensions in nonaqueous media (Fowkes et al. 1982), while Pugh et al. have reported zeta potential values
in excess of 100 mV for stable dispersions of carbon black in non-aqueous solvents (Pugh

et al. 1983).
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Wyatt and Vincent determined the electrophoretic mobility of drug substances in a
model CFC propellant, trichlorotrifluoroethane (P113), a liquid at room temperature, by
PALS (Wyatt and Vincent 1989). The PALS technique uses the phase shift of the light
scattered by the moving particles with respect to the reference beam instead of the Doppler
frequency shift caused by the moving particles with respect to their velocity (Malvern
Zetasizer Nano ZS Manual 2003). This technique is therefore much more sensitive in
detecting small changes in mobility of charged suspended particles in the presence of other
electrokinetic effects. The authors found that certain drugs possessed inherent charge,
which could be modified by suitable excipients while other drug substances did not show
measurable electrophoretic mobility but charge could be induced on these particles in the
suspension in the presence of surfactants like lecithin. Unfortunately, the nature of the
drugs tested was not disclosed.
Clarke et al. studied particle interactions in model pMDI suspensions in the
presence of surfactants, e.g., albuterol base suspensions in P113 in the presence of oleic
acid or sorbitan trioleate (Clarke et al. 1993). The adsorption of oleic acid on the albuterol
base surface suspended in P113 was investigated using radiolabeled oleic acid as well as
attenuated transmittance spectroscopy (ATS) coupled with Fourier Transform Infra-Red
(FTIR) spectrometry. The oleic acid fraction adsorbed to albuterol increased with an
increase in the initial oleic acid concentration (concentration range studied: 0.005 - 0.100
%w/v). The corresponding increase in the intensity of the asymmetric stretch of the oleate
ion observed in the ATS-FTIR studies suggested that the interaction between oleic acid
and albuterol base involved an acid-base mechanism, i.e., donation of a proton from oleic
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acid to albuterol with the formation of an ion-pair. The electrophoretic mobility of
albuterol base in P113, measured using LDV (ZetaSizer), was determined to be negative
and the magnitude increased (electrophoretic mobility: 2.0x10-10 - 0.2x10-10 m2/V.s) with
increasing oleic acid concentration, which was hypothesized to be due to the presence of
oleate ion at the electrical double layer (Clarke et al. 1993).
Adsorption of sorbitan trioleate, a non-ionic surfactant, to albuterol base suspended
in P113 appeared to increase with initial surfactant or adsorbate concentration (0.025 0.160 %w/v) with respect to the adsorbent; however, no evidence of chemical interaction
was found from the FTIR studies (Clarke et al. 1993). The authors also observed that there
was no appreciable change in the electrophoretic mobility of albuterol base in P113
(1.2x10-10 - 2.5x10-10 m2/V.s) as the concentration of sorbitan trioleate was increased. The
authors suggested that sorbitan trioleate adsorbed on to the albuterol base surface by a
physical mechanism such as hydrogen bonding (Clarke et al. 1993). Zeta potentials
measured for the albuterol base suspensions in P113 containing either oleic acid or sorbitan
trioleate were much lower (albuterol / oleic acid system: 0.9 - 9.0 mV; albuterol / sorbitan
trioleate system: 5.0 - 10.5 mV) than those reported for stable non-aqueous suspensions.
The authors suggested that the electrostatic repulsion forces alone may not be effective and
steric stabilization possibly plays a major role in stabilization of the suspensions studied
(Clarke et al. 1993).
Electrophoretic properties of lactose and salbutamol sulfate suspensions in dried
chloroform, chloroform and P113 have also been investigated using a non-aqueous
electrophoresis cell coupled with LDV (Sidhu et al. 1993). Zeta potentials were calculated
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from electrophoretic mobilities using the Hückel equation. Lactose was found to have a
negative zeta potential (-23 ± 3 mV) in chloroform, which decreased in magnitude (-5 ± 2
mV) when dispersed in dry chloroform. In contrast, salbutamol sulfate was found to
exhibit a positive zeta potential in chloroform (34 ± 5 mV), the magnitude of zeta potential
(55 ± 2 mV) increased when dry chloroform was used (Sidhu et al. 1993).
Sidhu et al. also studied the effect of the addition of two surfactants, lecithin and
Span 85 (sorbitan trioleate), at varying concentrations on particle charge in chloroform
based dispersions (Sidhu et al. 1993). The addition of lecithin to the lactose / chloroform
dispersion caused the lactose surface charge to reverse from negative to positive, with a
maximum zeta potential reported at 0.01 %w/v lecithin; further increase in lecithin
concentration (to 1 %w/v) had no additional effects. Addition of Span 85 showed similar
trends, with a charge reversal from negative to positive observed at concentrations
exceeding 0.001 %w/v. In contrast, the addition of lecithin to salbutamol sulfate
suspensions in chloroform caused the zeta potential to become less positive; the zeta
potential was reduced from +34 mV to +12 mV in the presence of 1% lecithin. Again
similar trends were observed upon the addition of Span 85 (Sidhu et al. 1993). The authors
concluded that the potential surrounding the charged particles was dependent upon the
relative polarity of the solid and the dispersion media and on the type and concentration of
the surfactant used. Furthermore, they considered lecithin and Span 85 to be positively
charged and adsorbed to the negative lactose surface causing charge reversal, while the
reduced zeta potential observed with salbutamol sulfate was believed to be due to double
layer shielding effects. However, the measurements were conducted in non-pressurized
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systems, and the authors failed to address the distribution of the surfactants between the
drug particles and the solvents.
Sandstrom et al. characterized the surface charge of salbutamol base suspensions in
propellant blends of CFC 11 and CFC 12 by the measurement of electrophoretic mobility
using a modified electrophoresis cell, which allowed pressurized samples to be analysed
(Sandstrom et al. 1994). The mobilities of particles in salbutamol base suspensions without
oleic acid were 0.02x10-8 m2/V.s in CFC 11 and increased to 0.12x10-8 m2/V.s in propellant
blend CFC 11 and CFC 12 (50:50) and 0.14x10-8 m2/V.s in a 30:70 propellant blend CFC
11 and CFC 12 (Sandstrom et al. 1994). Electrophoretic mobilities of salbutamol
suspensions in propellant blends (different CFC 11: CFC 12 ratios) with increasing oleic
acid concentrations were also investigated. The electrophoretic mobility of the particles
initially increased with increase in oleic acid concentration, however, after reaching a
maximum value, further increase in the concentration of oleic acid decreased the mobility
and caused a corresponding increase in particle size of the dispersion. The authors
hypothesized, and in a later paper illustrated, that oleic acid affected the mobility of
salbutamol base suspensions in propellants by monolayer adsorption at low concentration
and multilayer adsorption at high concentrations (Eriksson et al. 1995). A solvent series
based upon the polarizability and on the dipole moment of the solvent molecules was
constructed to estimate the acid-base character of the propellants. It was concluded that
the type and amount of surfactant and the propellant blend played an important role in the
formation of surface charge (Sandstrom et al. 1994).
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Although attempts have been made to measure surface charge in HFA based
suspensions, the role of electrostatics in these relatively polar systems remains poorly
understood. The zeta potential of albuterol sulfate suspensions in a model HFA propellant,
HPFP was found to be 33 ± 6 mV, while that of formoterol fumarate dihydrate (FFD) in
HPFP was 75 ± 6 mV. The surface charge of these drugs in a pressurized propellant HFA
227 was also investigated; since it was difficult to establish stable signals for zeta potential
measurements of FFD in HFA 227, the author reported two maxima, 19.9 and 40.6 mV,
for the zeta potential of FFD in HFA 227. The zeta potential of FFD-HFA 227 suspensions
increased up to 145 mV in the presence of small amounts of added water (Rogueda 2002).
However, AFM measurements performed by the author to determine particle interactions
within suspensions of albuterol sulfate and formoterol fumarate dihydrate (FFD) in model
HFA propellant, HPFP could not confirm the presence of any long range electrostatic
repulsive forces (Rogueda 2002).
In summary, it has been demonstrated that drug particles in suspension pMDIs can
acquire surface charges that can be measured using electrophoretic mobility studies. In
addition, it has also been shown that any surface charge is dependent upon the drug, the
type and concentration of the surfactant, and the propellant composition. In order to
understand the origin of charge in HFA based pMDI formulations, it is important to
investigate any soluble ionic species due to which charges can arise by surface dissociation
or adsorption (Rogueda 2005a). The presence of polar impurities, e.g., moisture as well as
the inclusion of polar cosolvents could increase the polarity of HFA formulations and may
influence charge formation. Taken together, the various formulation factors, which affect
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the polarity of HFA based pMDIs, may play a role in charge formation inside these
formulations.

I.D. Characterization of Electrostatic Properties of Pharmaceutical Aerosols

Electrical charges in pharmaceutical aerosols are generated by frictional contact or
triboelectrification owing to the relative movement of particles against the device
components (Byron et al. 1997). Triboelectrification is a complex surface phenomenon and
the electrostatic charges acquired by pharmaceutical aerosols are influenced by both the
formulation components as well as the device components (Byron et al. 1997, Peart et al.
1998). Electrostatic properties of dry powder inhalers (DPIs) and pressurized metered dose
inhalers (pMDIs) have been characterized using the aerosol electrometer (a filter housed
within a Faraday Cage), which measures the fine particle dose (particle size < 5 μm when
operated at 30 L/min) charge. Byron et al. characterized the electrostatic charge acquired
by aerosols produced by Bricanyl® and Pulmicort® Turbohalers, as well as experimental
DPI formulations aerosolized using the Dryhaler DPI, using the aerosol electrometer and
found that the inhaler components and the powder deaggregation mechanisms influenced
the fine particle dose charge of the aerosols (Byron et al. 1997). Peart et al. have
demonstrated that there is a significant difference between the electrostatic charge of
aerosols produced by CFC and HFA suspension pMDIs (Peart et al. 1998). Electrostatic
properties of pMDI aerosol clouds have been shown to be a function of both formulation
and packaging components (Peart et al. 1998). The aerosol electrometer, however, does not
differentiate bipolar aerosol clouds and chemical analysis of the fine particle dose is not
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possible due to the method of dose capture (Peart et al. 1998). Hence, the relationship
between aerosol charge and the drug mass cannot be elucidated using this technique.
Simultaneous particle charge and size determination has been achieved using
dynamic as well as static charge measurement techniques. Dynamic particle charge
measurement techniques are based on the principle of electrical mobility of charged
particles; charged particles in motion have certain electrical mobility, which depends on
the number of elementary charges on the particles as well as the particle size. The bipolar
charge measurement system and electrical single particle aerodynamic relaxation time
(ESPART) analyzer operate on this principle (Balachandran et al. 2003, Ali et al. 2007). In
the bipolar charge measurement system, a DC electric field is applied perpendicular to the
direction of flow of the aerosol particles; the charge on the particles is measured based on
their electrical mobility while particle size is determined using phase Doppler anemometry
(Balachandran et al. 2003).
In the ESPART analyzer, aerosol particles are drawn vertically downwards into the
sensing volume of the instrument at a rate of 1 L/min; the aerosol particles cross the path
of two converging laser beams as they move vertically down while simultaneously being
subjected to an alternating electric field, which causes charged particles to oscillate in the
horizontal direction (Ali et al. 2007). The phase lag of the particle motion, with respect to
the AC field, is used to determine the aerodynamic diameter while the polarity and
magnitude of particle charge is obtained from the direction and amplitude of its electrical
migration velocity with respect to the electric field (Ali et al. 2007). However, the
disadvantage of both the above-mentioned techniques is that the particle size determination
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is not drug specific. In addition, the flow rate, at which the ESPART operates, favors
charge measurement of stable continuous aerosols and is considered to be of limited use in
the electrostatic characterization of short lived bursts typical of pMDI aerosol particles
(Mitchell et al. 2007).

I.E. Electrical Low Pressure Impactor

The Electrical Low Pressure Impactor (ELPI) overcomes some of the abovementioned limitations as it enables the measurement of the net inherent charge of aerosols
as a function of particle size. Briefly the ELPI consists of a 13-stage low-pressure impactor
with the lower 12 stages connected to a multichannel electrometer and a corona charger
situated atop the impactor. The ELPI was originally designed to determine the size
distribution of aerosols by subjecting them to a high voltage of approximately +5 kV via
the corona charger; particle concentrations of the aerosols are determined from the
electrical current induced by the charged particles depositing on the electrically isolated
impactor stages (Keskinen et al. 1992). Previous studies have modified the ELPI to enable
determination of inherent aerosol charge while simultaneously measuring particle size by
chemical analysis (Glover and Chan 2004a, Orban and Peart 2004, Telko et al. 2007). In
the modified set-up of the ELPI, the corona charger is removed, which enables
measurement of the net inherent charge of the aerosol particles impacting on each stage for
stages 1 - 12 of the ELPI. Furthemore, the particle size distribution can be simultaneously
determined by chemical analysis of drug deposited on all impaction stages (Glover and
Chan 2004a). Most of the studies to date have used the modified ELPI to investigate the
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inherent electrostatic charge of commercially available pharmaceutical aerosols (Glover
and Chan 2004a, Orban and Peart 2004, Keil 2005, Telko et al. 2007); a limited number of
studies have investigated the particle sizing ability of the ELPI in comparison to standard
compendial sizing techniques (Orban and Peart 2004, Keil 2005, Telko et al. 2007).

I.E.1. Electrostatic Charge Characterization of Pharmaceutical Aerosols using the
Electrical Low Pressure Impactor (ELPI)

The modified ELPI has been employed to characterize electrostatic charge of
pressurized metered dose inhalers (Glover and Chan 2004a, Orban and Peart 2004, Kwok et

al. 2005, Kwok et al. 2006), dry powder inhalers (Glover and Chan 2004b, Mikkanen et al.
2004, Telko et al. 2007, Young et al. 2007, Kwok and Chan 2008) and nebulizers (Kwok
and Chan 2004) as a function of particle size. The electrostatic charge of pharmaceutical
aerosols measured using the modified ELPI has been shown to be comparable to that
measured using the aerosol electrometer. For example, the net fine particle dose charge (184.21 ± 40.02 pC) for Ventolin CFC® determined by the modified ELPI has been found to
be in good agreement with that determined using the aerosol electrometer (-171.00 ± 8.63
pC) (Orban and Peart 2004). In addition, the ELPI was able to discern that Ventolin CFC
produced bipolar aerosol clouds; particles smaller than 0.96 μm were net electronegative
while particles larger than 0.96 μm were net electropositively charged (Orban and Peart
2004).
The modified ELPI has been used to screen the electrostatic properties of
Flixotide® and Ventolin HFA®, as a function of particle size (Glover and Chan 2004a).
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Kwok et al extended the study and investigated a series of commercially available pMDI
suspensions as well as QVAR®, which is a solution pMDI (Kwok et al. 2005). It was found
that suspension pMDIs, e.g., Ventolin HFA and Flixotide, produced bipolar charged
aerosol clouds (mean net charge: -1100 ± 220 pC for Ventolin HFA and +450 ± 30 pC for
Flixotide). The testing protocol was shown to influence the electrostatic charge profiles.
For example, Ventolin HFA produced a bipolar charge distribution profile when a single
shot was actuated into the ELPI, whereas an aerosol produced after a series of continuous
actuations of Ventolin HFA pMDI was electronegatively charged (Kwok et al. 2005).
In contrast, QVAR, a solution pMDI, was found to produce unipolar positively
charged aerosol clouds (mean net charge: +290 ± 230 pC) (Kwok et al. 2005). The charge
distribution from QVAR appeared to follow the drug mass distribution and the authors
hypothesized that for a solution pMDI, a constant mass ratio of drug to excipients would
be present in each of the aerosol droplets and therefore charge and drug mass would likely
exhibit similar distribution profiles (Kwok et al. 2005). However, a systematic study
investigating the apparent difference in the charge distribution profiles between suspension
and solution pMDIs has not been investigated.
A comparison of the charge distribution profiles of Ventolin HFA and Flixotide
revealed that net electronegative charge was measured on stages 1 - 7 for Ventolin HFA
while particles depositing on stages 1 - 7 of the ELPI (corresponding to the manufacturerreported aerodynamic cut-off diameter range: 0.03 - 0.62 μm) were net electropositively
charged in the case of Flixotide (Kwok et al. 2005). Interestingly, chemical analysis
showed that negligible amounts of drug were detected on these stages for both Ventolin
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HFA and Flixotide aerosols (Kwok et al. 2005). The authors suggested that since
negligible amount of drug was present on stages 1 - 7, the electrical charges detected on
these stages might be due to propellant droplets or trace impurities, e.g., moisture;
however, this hypothesis was not tested further.
A well-controlled investigation of the electrostatic properties of albuterol sulfate
suspension HFA pMDIs containing a blend of propellant, cosolvent and surfactant using a
modified ELPI showed that aerosol clouds from non-drug containing pMDIs were
negligibly charged while albuterol sulfate suspension pMDIs produced net bipolar aerosol
clouds (Keil 2005). Interestingly, particles on stages 1 - 5 (particles smaller than approx.
0.27 μm) were electronegatively charged and chemical analysis showed that no drug was
present on these stages. The presence of albuterol sulfate particles in the propellant mixture
appeared to modify the charging properties of non-drug aerosol droplets (Keil 2005).
However, these aerosol droplets existed in multiple forms due to the presence of surfactant
and cosolvent thereby confounding the effect of drug particles on aerosol charge. To
understand the effect of drug on aerosol charge, it is necessary to investigate the
electrostatic properties of a simple suspension comprising of albuterol sulfate and
propellant HFA 134a in the absence of a surfactant and / or cosolvent.
The ELPI has also been used to study the use of spacers such as the Aerochamber
Plus VHC in conjunction with commercially available pMDIs on the electrostatic charge
and particle size distribution of Ventolin HFA pMDI aerosols (Kwok et al. 2006). The
polarity of the aerosol charge distribution remained unchanged in the presence of a VHC,
however, the magnitude of total charge on each of the ELPI stages decreased due to a
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decrease in drug deposition in the impactor (Kwok et al. 2006). For example, the mean
fine particle dose (FPD; particles smaller than 6.67 μm, i.e., the manufacturer reported cutoff diameter of ELPI Stage 12) of Ventolin HFA aerosols decreased from 60.08 ± 1.74 μg
without the VHC to 11.61 ± 1.74 μg in the presence of a new untreated VHC. The mean
total net FPD charge for Ventolin HFA aerosols decreased from -815.81 ± 135.73 pC when
tested without a spacer to -81.50 ± 33.32 pC with an untreated spacer (Kwok et al. 2006).
The modified ELPI has only recently been used to characterize the electrostatic
properties of dry powder inhalers (Telko et al. 2007, Young et al. 2007, Kwok and Chan
2008). The ELPI has been designed to operate at a flow rate of either 10 or 30 L/min and
hence cannot be readily adapted to testing dry powder inhalers since higher flow rates are
required to sample DPI aerosols (Kwok and Chan 2008). The effect of storage relative
humidity ranging from 0 - 85% RH on aerosol performance as well as electrostatic charge
of carrier-based dry powder inhalers (DPIs), e.g., albuterol and lactose powder blend filled
capsules delivered from a Cyclohaler device, has been investigated using an ELPI (Young

et al. 2007). However, their testing protocol was not in accordance with current
compendial specifications for in-vitro testing of DPIs since the DPIs were aerosolized and
sampled at 30 L/min from the ELPI. It has been recommended that DPIs be tested at a flow
rate equivalent to a 4 kPa pressure drop across the device (USP 29 / NF 24 First
Supplement 2006). For a Cyclohaler (ISF inhaler), this flow rate has been determined to be
in the range of 100 - 120 L/min (Clark and Hollingworth 1993).
Further studies have attempted to modify the experimental set-up and aerosolize
DPI aerosols at 60 L/min and sample the aerosols into the ELPI at 30 L/min (Telko et al.
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2007, Kwok and Chan 2008). Telko et al. investigated the effect of various formulation
and packaging factors on the electrostatic charge of experimental albuterol sulfate / lactose
DPI aerosols (Telko et al. 2007). Briefly, the DPI was aerosolized at 60 L/min and
sampled into a preseparator to remove the larger lactose particles, the aerosol flow was
then split and simultaneously sampled into a modified ELPI and an Andersen Cascade
Impactor (ACI) at 30 L/min. Both the magnitude and polarity of the electrostatic charge on
the DPI aerosols were found to be influenced by the grade of lactose used (presence of
lactose fines), capsule material as well as the type of inhaler used (Telko et al. 2007).
Kwok and Chan characterized the electrostatic charging properties of commercially
available drug only dry powder inhalers, Pulmicort® and Bricanyl® Turbohalers (Kwok
and Chan 2008). This enabled the authors to investigate the effect of drug, e.g.,
budesonide, terbutaline sulfate, on the tribocharging properties of the DPI aerosols. The
DPIs were sampled into a USP induction port at 60 L/min and the experimental set-up
utilized a Y-piece to divide the aerosol flow from the USP induction port such that the
ELPI sampled the aerosol at 30 L/min while the remainder of the aerosol was drawn into a
unit dose sampler at 30 L/min (Kwok and Chan 2008). Both the inhalers produced bipolar
charged aerosols; particles depositing on stages 1 - 8 and stages 1 - 7 were
electronegatively charged while particles depositing on stages 9 - 12 and stages 8 - 12 were
electropositively charged for Pulmicort® and Bricanyl® aerosols, respectively. (Kwok and
Chan 2008). Although the mass deposition within the ELPI was not affected, the authors
found that relative humidity influenced the electrostatic charging characteristics of the two
commercial DPIs. The authors found that the electrostatic properties of Pulmicort DPI
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aerosols determined using the ELPI were found to correlate with that measured using the
aerosol electrometer (Byron et al. 1997). Bricanyl Turbohalers were found to produce FPD
charge in the same magnitude as that measured by Byron et al. using the aerosol
electrometer; the specific charge and the number of elementary charges / particle reported
by both the studies were also in the same order of magnitude (Byron et al. 1997, Kwok and
Chan 2008).

I.E.2. Particle Size Characterization of Pharmaceutical Aerosols using the Electrical
Low Pressure Impactor (ELPI)

Few studies have evaluated the sizing ability of the ELPI for pharmaceutical
aerosols (Crampton et al. 2004, Keil 2005, Telko et al. 2007). Crampton et al. have
employed the ELPI in its standard mode of operation to measure the particle size based on
the number distribution of commercially available pMDI aerosols using electrical
detection. The authors reported that HFA propelled pMDIs, e.g., QVAR, Ventolin HFA,
Flixotide produced a higher sub-micron aerosol fraction compared to their CFC
counterparts, e.g., Becotide® and Atrovent Forte® based on their measurements using
electrical detection of charged aerosol particles in the ELPI and the Scanning Mobility
Particle Sizer (SMPS). The authors suggested that although sub-micron (particles smaller
than 1 μm) and ultrafine (particles smaller than 0.1 μm) particles do not have appreciable
mass, it might be relevant to measure the particle number or surface area to understand
their physiological impact (Crampton et al. 2004).
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Telko et al. have employed the ELPI in its standard mode of operation (with the
corona charger switched on) to determine the particle size distribution (PSD) of
experimental albuterol sulfate - lactose blend DPIs via electrical detection (Telko et al.
2007). The PSD of the experimental DPIs determined by electrical detection was found to
compare well with that obtained subsequently by gravimetric analysis; discrepancy in
particle size was observed on the lower stages where the use of the gravimetric sizing
technique was found to be limited by the sensitivity of the analytical balance used (Telko

et al. 2007). Both electrical and gravimetric detection measured particle size distribution of
aerosols that were subjected to a high corona voltage of approximately +5 kV before being
sampled into the ELPI. The particle size distribution obtained by both these techniques was
not specific to drug mass and the results obtained therefore may be of limited use for the
characterization of pharmaceutical aerosols.
Telko et al. also found that when aerosols produced by experimental DPIs
containing micronized albuterol sulfate alone and those containing 1% albuterol sulfate in
lactose were simultaneously sampled into a modified ELPI (without switching on the
charger) and an ACI, the particle size distributions (PSDs) obtained were comparable
(Telko et al. 2007). However the experimental set up used in the study was not comparable
to that used with the standard compendial apparatus. Moreover, the authors have not
compared the PSDs of these experimental albuterol sulfate - lactose blend DPIs determined
using the non-standard experimental set-up to those determined using the ACI under
standard compendial conditions to establish confidence in the PSD data thus obtained.
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Keil has compared the PSD of Ventolin CFC® pMDI aerosols determined using the
ELPI in its standard mode of operation (in the presence of the corona charger) via
electrical detection to that obtained using the modified ELPI (charger-free) by chemical
detection of drug deposited on the ELPI stages (Keil 2005). The mass median aerodynamic
diameter (MMAD) of Ventolin CFC (3.36 ± 2.03 μm) obtained using the electrical
detection technique was not comparable to that determined using chemical detection of
albuterol (1.40 ± 0.06 μm); the overestimated particle size determined by the ELPI via
electrical detection was attributed to the presence of larger excipient-containing particles
such as oleic acid coated albuterol particles in the aerosol cloud (Keil 2005).
The modified ELPI appeared to undersize Ventolin CFC aerosols when particle
size was determined by chemical analysis in comparison to that measured using the ACI, a
compendial sizing apparatus (MMAD of Ventolin CFC: 2.10 ± 0.08 μm) (Keil 2005). It
was speculated that the undersizing of Ventolin CFC aerosols by the modified ELPI might
be due to the higher sub-micron fraction (particles smaller than 1.0 μm) detected by the
ELPI (ELPI: 2.05 ± 0.41 μg, ACI: 0.02 ± 0.03 μg) (Keil 2005).
Although the ELPI was originally designed to measure near real time particle size
of aerosols by electrical detection, the modified ELPI has offered the advantage of
simultaneously determining inherent electrostatic charge and the particle size distribution
of pharmaceutical aerosols. However, there does not appear to be a consensus on the
efficiency of the modified ELPI in terms of its particle sizing ability for pharmaceutical
aerosols in comparison to compendial sizing techniques. In order to have confidence in the
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sizing ability of the modified ELPI, it is essential to compare the size distribution from the
ELPI with that obtained using accepted industry standards.

I.F. Overview

This dissertation is organized to address the charging mechanisms and the particle
interactions within HFA based solution and suspension formulations as well as the
electrostatic properties of aerosols produced by these HFA based pMDI formulations.
Chapter II states the individual hypotheses and the specific aims that will be addressed in
the succeeding chapters. Chapter III describes the general experimental materials and
methods together with an explanation of the operational principles of some of the
instruments used in this research. Each of the chapters consists of a brief introduction, a
materials and methods section, followed by a results and discussion section. Chapter IV
describes the determination of the resistivity and the zeta potential of HFA based solution
and suspension formulations. Chapter V discusses the construction of molecular models
for albuterol sulfate HFA suspension pMDIs and subsequent analysis of interactions
between the formulation components on a molecular level. Chapter VI investigates the
influence of formulation as well as packaging components on the electrostatic charge and
mass distribution of HFA propelled BDP solution and albuterol sulfate suspension pMDI
aerosols using the modified ELPI. Chapter VII describes the recalibration of the modified
ELPI using commercially available polydisperse pMDIs as calibration aerosols with the
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ACI as the reference cascade impactor. Finally, Chapter VIII summarizes the results from
each chapter as it relates to the original hypotheses.

II. HYPOTHESES AND RESEARCH PLAN

II.A. Hypothesis 1

The electrical properties of hydrofluoroalkane (HFA) based solution and
suspension formulations are hypothesized to be a function of their electrical resistivity,
which, in turn, will be influenced by the formulation components. It is also hypothesized
that particles suspended in non-aqueous pressurized solvents including HFA propellants
will acquire a surface charge, which will be a function of the formulation components.
The electrical resistivity of experimental HFA 134a based solutions and
suspensions will be determined using a custom-built high-pressure resistivity cell in order
to characterize any soluble ionic species present in these systems. In addition, zeta
potential of albuterol suspensions in non-aqueous, non-pressurized and pressurized
solvents including chloroform, CFC propellants and HFA 134a will be determined using
an electrophoretic mobility technique. The influence of surfactant, cosolvent (ethanol) and
moisture content of the formulations on the electrical resistivity and the zeta potential will
be investigated.
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II.B. Hypothesis 2

Molecular modeling can be used to characterize particle interactions at the
molecular level within pressurized metered dose inhaler formulations.
In order to test this hypothesis, molecular models of simple pMDI formulations
including albuterol sulfate in HFA 134a will be constructed and optimized and interactions
between the drug and propellant molecules will be investigated using Hydropathic
INTerations (HINT®) software. Interactions within albuterol sulfate suspensions in the
presence of oleic acid (an anionic surfactant) and ethanol (a polar cosolvent) will also be
studied.

II.C. Hypothesis 3

It is hypothesized that the electrical properties of experimental HFA-propelled
solution and suspension pMDIs will be a function of the formulation type (solution or
suspension) and the formulation components, as well as the particle size. The magnitude
and polarity of aerosol clouds produced by experimental HFA-propelled pMDIs will be
influenced by propellant, cosolvent, surfactant, and active drug. Differently sized particles
within the aerosol cloud will be electrically charged to a different magnitude and polarity.
The influence of formulation components on the electrostatic charging
characteristics of solution and suspension HFA pMDIs will be investigated using model
HFA propelled beclomethasone dipropionate (BDP) solution pMDIs and albuterol sulfate
suspension pMDIs. The mass distributions of the aerosols produced by drug containing
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pMDIs will be simultaneously characterized by chemical analysis using the modified
ELPI.

II.D. Hypothesis 4

It is hypothesized that the calibration of the ELPI, determined following electrical
detection of corona-charged particles, cannot be extended to the modified ELPI (chargerfree), where the particle size distribution is determined following chemical analysis of the
drug deposited on each ELPI stage, since the electrical charge acquired by aerosol particles
via the ELPI corona-charger will influence particle deposition within the ELPI.
The aerodynamic particle size distributions (aPSDs) of four independent,
polydisperse,

commercially

available

pMDIs

with

different

median

diameters

characterized using an Andersen Cascade Impactor (ACI) and a modified ELPI will be
compared. The modified ELPI will then be recalibrated based on the aPSDs of the four
‘calibration’ pMDIs obtained using the reference ACI and the new ELPI cut-off diameters
will be validated using a previously untested commercially available pMDI.

III. EXPERIMENTAL MATERIALS AND METHODS

III.A. Preparation of Pressurized Solution and Suspension Formulations
III.A.1. Materials

Beclomethasone dipropionate (BDP) and albuterol sulfate were provided by Dura
Pharmaceuticals (San Diego, CA); albuterol base was donated by Armstrong Laboratories
(West Roxbury, MA). Oleic acid was obtained from Fisher Scientific Company (Swannee,
GA). Absolute ethanol was obtained from AAPER (Alcohol and Chemical Company,
Shelbyville, KY). CFC 11 (monofluorotrichloromethane), CFC 12 (dichlorodifluoromethane) and HFA 134a (1,1,1,2-tetrafluoroethane) were donated by Dupont (Wilmington,
DE).
19-mL aluminum cut-edge canisters and 120 mL plastic coated glass bottles were
obtained from Presspart (Blackburn, UK) and Wheaton Glass Company (Mays Landing,
NJ), respectively. DF10/50 RCU/PBT 50 μL inverted metering valves and DF10/50
RCU/PBT modified continuous (non-metered) valves composed of a polybutylene
terepthalate (PBT) metering chamber and valve stem and fitted with EPDM (ethylenepropylene-diene-terpolymer) elastomers were donated by Valois (Le Vaudreuil, France).
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III.A.2. Methods
III.A.2.1. Experimental HFA Based Solution Formulations

Experimental HFA 134a based solutions including propellant alone, an ethanol and
propellant blend and BDP solutions were prepared by weight and packaged in clean, dry
19 mL aluminum cut-edge canisters. A Valois DF10/50 RCU/PBT 50μL metered valve or
a continuous valve was crimped onto the canister (Model 2005/10, Pamasol Willi Mader
AG, Pfaffikon, Switzerland).
Crimping parameters were in accordance with the valve suppliers’ specifications
for packaging in aluminum canisters (Valois DF10/50 crimp height = 5.7 ± 0.05 mm and
crimp collet closing diameter = 17.70 mm). Propellant HFA 134a was added to the canister
through the metering valve via a pressure burette (Aerosol Laboratory Equipment Model
35B, Walton, NY) overpressured with dry nitrogen. For preparation of an
ethanol/propellant blend, an appropriate quantity of ethanol was weighed into an aluminum
canister, a Valois DF10/50 valve (metered or continuous) was crimped on to the can and
HFA 134a was pressure-filled through the valve to the target fill weight. BDP solution
pMDIs were prepared by weighing an appropriate amount of a BDP solution in ethanol
into an aluminum canister, followed by crimping the valve and pressure-filling HFA 134a
to the target fill weight.
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III.A.2.2. Experimental HFA and CFC Based Suspension Formulations

Albuterol sulfate suspensions in 100% HFA 134a were prepared by weight and
packaged in clean, dry 19 mL aluminum cut-edge canisters fitted with metered or
continuous valves as described in Section III.A.2.1. Albuterol sulfate was micronized using
a jet mill (Model 00 Jet-O-Mizer, Fluid Energy Processing Equipment Co., Hatfield, PA)
and the volume median diameter of albuterol sulfate was determined to be 0.79 ± 0.01 μm
(Mastersizer 2000, Malvern Instruments, Inc., Southborough, MA). Albuterol sulfate
suspension pMDIs were prepared by weighing a fixed amount of albuterol sulfate into an
aluminum canister, a metered or continuous Valois DF10/50 valve was crimped onto the
canister, and propellant HFA 134a was pressure-filled through the valve. To prepare a
suspension of albuterol sulfate in HFA 134a containing oleic acid and ethanol, appropriate
amounts of albuterol sulfate and a stock solution of oleic acid in ethanol were weighed into
the canister followed by pressure-filling HFA 134a to the target fill weight. After the
addition of propellant, the inhalers were shaken on a wrist-action shaker (Burrell
Corporation Model 75, Pittsburgh, PA) for 30 minutes.
Albuterol base suspensions in a CFC propellant blend (70% CFC 12: 30% CFC 11)
were prepared and packaged in 120 mL plastic-coated glass bottles fitted with continuous
valves. The volume median diameter of albuterol particles was determined to be 0.71 ±
0.19 μm (Mastersizer 2000, Malvern Instruments, Inc., Southborough, MA). Crimping
parameters were in accordance with the valve suppliers’ specifications for packaging in
plastic-coated glass bottles (Valois DF 10 crimp height = 5.3 ± 0.05 mm and crimp collet
closing diameter = 17.8 mm).
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All the formulations were stored for 24 hours following preparation before
measurements were performed.

III.B. Determination of Electrostatic Charge and Mass Distribution of pMDIs using
the Modified ELPI

The inherent electrostatic charge and subsequent mass distribution of aerosols
produced by commercially available and experimental HFA 134a pMDIs were determined
using a modified ELPI (Dekati Limited, Tampere, Finland). Table III.1 shows the
manufacturer supplied aerodynamic cut-off diameters for the ELPI.
Table III.1. Manufacturer-Supplied Aerodynamic Cut-off Diameters of the ELPI Stages 1
- 13 at a Flow Rate of 29 L/min (Corrected to Two Decimal Places).
Appendix A.I shows the ELPI Charger Efficiency Curve and the ELPI
Datasheet with the Cut-Off Diameters for the ELPI used in these
Experiments.
Stage Number

Cut-off Diameter (μm)

13
12
11
10
9
8
7
6
5
4
3
2
1

10.08
6.67
4.05
2.42
1.62
0.96
0.62
0.39
0.27
0.16
0.10
0.06
0.03
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The commercially available ELPI consists of a 13-stage low-pressure impactor
with the lower 12 stages connected to a multichannel electrometer and a corona charger
situated atop the impactor. Figure III.1 illustrates the modified ELPI utilized in these
studies.
Figure III.1.

Photograph of the Charger-Free ELPI Cascade Impactor and the Standard
ELPI Inlet (the Modified ELPI), with the USP Induction Port Attached.
Schematic of the Modified ELPI (Adapted from Dekati Manual, Dekati,
Finland) is also Shown.

40
The original ELPI configuration was modified by removing the corona charger as
well as the charger frame from the instrument in order to shorten the aerosol flow path into
the ELPI and to make the aerosol entry conditions comparable to those in the ACI, a
compendial sizing apparatus. The USP induction port was fixed atop the ELPI inlet port
using a purpose-built, airtight stainless steel connector (Figure III.2).

Figure III.2.

Cross Sectional View of the ELPI Inlet (as Supplied by Dekati with the
Instrument), the Connector (Shown Cross-Hatched) and the Down Tube of
the USP Induction Port in their Experimental Configuration. The Connector
is shown in Greater Detail in the Figure Inset. All Dimensions are in
Millimeters and the Diagram is Drawn to Scale. For Complete Dimensions
for the USP Inlet see USP 29 / NF 24 First Supplement 2006.

DOWNTUBE OF
USP INLET
PORT

O RING SEAL

CONNECTOR
O RING SEAL

ELPI INLET

O RING SEAL

CONNECTOR
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The ELPI was allowed to stabilize for an hour prior to operation while set-up
requirements such as air leakage testing were performed in accord with the manufacturer’s
instructions and specifications. The current range setting was 40,000 fA. Silicone-coated
(DS-515 grease spray; Dekati Ltd., Tampere, Finland) aluminum substrates were used on
the impaction plates to collect drug particles for chemical analysis.
Inherent electrostatic properties of pMDIs were determined by actuating a single
shot of the pMDI through a USP induction port into the modified ELPI (Figure III.1). The
ELPI was operated at 100 mbar (below the lowest stage, i.e., Stage 1) to produce a flow
rate of approximately 29 L/min, verified using an external flowmeter (Sierra Instruments,
Inc., Monterey, CA). The electrical current induced by the charged aerosol particles, on
each of the ELPI stages 1 - 12, was measured as a function of time (20 sec). Background
current measurements were performed to ensure zeroing of the electrometer current
readings before and after each experiment. An aerosol current (pA) vs. time (sec) profile
was generated for each impactor stage. The area under each aerosol current vs. time profile
represented the net inherent aerosol charge in picocoulombs (pC) for that stage (1 coulomb
is equivalent to 1 ampere second). The net inherent charge of the aerosol cloud was
calculated as the sum of the net charge on each of the impactor stages. Subsequently, the
mass distribution of drug within the impactor was determined using chemical analysis.

III.C. High Pressure Liquid Chromatography Analyses

Validated high-pressure liquid chromatography (HPLC) methods were employed
for detection of BDP, fluticasone propionate (FP) and albuterol in the samples obtained
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from cascade impaction experiments. Mass of albuterol sulfate deposited on the lower
stages (stages 1 - 4) of the ELPI was also determined using Liquid Chromatography-Mass
Spectrometry (LC-MS).

III.C.1. Materials

BDP and albuterol base were donated by Dura Pharmaceuticals (San Diego, CA)
and Armstrong Laboratories (West Roxbury, MA), respectively. FP was purchased from
Sigma Aldrich (St. Louis, MO). HPLC grade acetonitrile, methanol, ammonium acetate
and ammonium formate were obtained from Fisher Scientific (Swannee, GA). Deionized
water was freshly distilled in the laboratory.

III.C.2. Methods
III.C.2.1. Analysis of BDP and FP using HPLC with UV Detection

For the HPLC assay of BDP and FP, a C-18 Spherisorb ODS-2 column (5 μm, 4.6
x 250 mm, Alltech Associates Inc., Deerfield, IL) was used. Both assays employed 60%
acetonitrile / 40% water (flow rate: 1 mL/min) as mobile phase with UV detection at 238
and 236 nm for BDP and FP, respectively (2996 Photodiode Array Detector, 1515 Isocratic
HPLC Pump, 717 plus Autosampler, Waters, Milford, MA). The sample injection volume
used was 100 μL. Calibration curves of peak area vs. concentration were linear in the range
of 0.05 - 2 µg/mL (r2 = 0.999) for BDP and 0.05 - 2 µg/mL (r2 = 1) for FP. The limit of
detection (LOD), determined to be the smallest detectable peak on the HPLC
chromatogram, was 0.04 µg/mL for both compounds. Typical values for precision (RSD)
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and accuracy (%DFN) were less than 0.6% and 3.9% for BDP and less than 2.1% and
1.1% for FP, respectively.

III.C.2.2. Analysis of Albuterol using HPLC with Fluorescence Detection

HPLC analysis of albuterol employed a C-18 Spherisorb ODS-2 column (5 μm; 4.6
x 150 mm, Alltech Associates, Deerfield, IL). The mobile phase (225 mL of 0.1%
ammonium acetate solution and 800 mL methanol) was pumped at a flow rate of 0.8
mL/min. The sample injection volume used was 40 μL. Fluorescence detection was used
with excitation and emission wavelengths of 276 and 609 nm, respectively (2475 Multi λ
Fluorescence Detector, 1515 Isocratic HPLC Pump, 717 plus Autosampler, Waters,
Milford, MA). Calibration curves of peak area versus concentration of drug were linear in
the range of 0.05 - 1 µg/mL (r2 > 0.999). The limit of detection (LOD), determined to be
the smallest detectable peak on the HPLC chromatogram, was 0.04 µg/mL; typical values
for precision (RSD) and accuracy (%DFN) were less than 0.6% and 0.8%, respectively.

III.C.2.3. Analysis of Albuterol using LC-MS

A Waters Alliance 2695 separations module and a Micromass ZMD4000 single
quadrupole mass spectrometer with ESI ionization probe (Waters Corp., Milford, MA) was
used for analysis of albuterol. The mobile phase, 80% methanol / 20% water solution with
2 mM ammonium formate (used to adjust pH to 3.4) was pumped into an Allure PFP
propyl column (5 μm, 3.2 x 150 mm, Restek Corporation, Bellefonte, PA) at a flow rate of
1 mL/min. A flow splitter (Upchurch Scientific Inc., Oak Harbor, WA) was used after the
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HPLC column to introduce approximately 0.10 mL/min of the eluent into the mass
spectrometer. Ionization conditions for MS were optimized with the source block and
desolvation temperatures of 150 and 140 °C, respectively; the desolvation nitrogen flow
was 700 L/hr. Samples were analyzed and the protonated molecular ion of albuterol was
monitored at m/z = 240. The calibration curve of peak area of the single ion chromatogram
vs. albuterol concentration was linear, r2 = 0.997 over the concentration range of 1 - 50
ng/mL. The limit of detection (LOD), determined to be the smallest detectable peak on the
chromatogram, was 0.5 ng/mL; typical values for precision (RSD) and accuracy (%DFN)
were less than 5.2% and 4.5%, respectively.

IV. INVESTIGATION OF CHARGE MECHANISMS OF NON-AQUEOUS
LIQUEFIED PROPELLANT CONTAINING SOLUTIONS AND SUSPENSIONS

IV.A. Introduction

In order to fully explain the effect of pMDI formulation components on the
triboelectric charging properties of the aerosol clouds, it is important to determine the
electrical charges within the pMDI formulation itself. However, electrical properties inside
pMDIs have not been well characterized due to a lack of consensus on charge generation
mechanisms and the experimental difficulties associated with the measurement of electrical
properties in non-aqueous liquefied propellants (Sidhu et al. 1993, Rogueda 2002,
Rogueda 2005a). Electrical measurements in CFC and HFA containing formulations are
challenging due to the need to maintain the liquids under pressure.
The resistivity of a liquid is a measure of its electrical insulating properties; high
resistivity would indicate low content of free ions and ion-forming particles and possibly a
low concentration of conducting impurities (ASTM Standard D1169-02 2002). Electrical
properties of CFC and HFA refrigerants have been measured in terms of their electrical
resistivity (Meurer et al. 2001). For example, the resistivity of CFC 12 was determined to
be 0.51x106 MΩ.cm while that of HFA 134a was 108.9 MΩ.cm (Meurer et al. 2001). Zeta
potential measurements using an electrophoretic mobility technique can provide a measure
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of the surface charge within suspensions; electrophoretic mobility measurements have
demonstrated formation of charged species in non-polar, non-aqueous dispersions
(Kitahara and Watanabe 1984). A limited number of studies have also reported zeta
potential measurements for drug suspensions in a model non-pressurized HFA solvent e.g.
HPFP; however, the role of electrostatics in HFA based suspension pMDIs remains poorly
understood (Rogueda 2002).
In the present study, the electrical resistivity of experimental HFA 134a based BDP
solutions and albuterol sulfate suspensions was determined in order to obtain an indication
of the soluble ionic species present in these systems. In addition, zeta potential of albuterol
suspensions in non-aqueous, non-pressurized and pressurized solvents including
chloroform, CFC propellants and HFA 134a was determined using an electrophoretic
mobility technique. The influence of surfactant, cosolvent, e.g., ethanol and moisture
content of the formulations on electrical resistivity and zeta potential was investigated.

IV.B. Electrical Resistivity of HFA Based Solution and Suspensions
IV.B.1. Methods
IV.B.1.1. Preparation of HFA Based Solution and Suspensions

Resistivity measurements were performed using experimental HFA solutions and
albuterol sulfate HFA suspensions. Table IV.1 summarizes the experimental HFA based
solutions prepared and packaged using continuous valves as described in Chapter III.A.2.1.
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Table IV.2 summarizes the experimental albuterol sulfate suspensions in HFA 134a
containing increasing concentrations of oleic acid and ethanol, which were formulated and
packaged using continuous valves as described in Chapter III.A.2.2.
Table IV.1. Experimental HFA 134a Based Solutions
Beclomethasone Dipropionate
Ethanol (%w/w)
(%w/w)
0
0
0
7
0.08
7

HFA 134a (%w/w)
100
93
93

Table IV.2. Experimental HFA 134a Based Albuterol Sulfate Suspensions
Albuterol Sulfate
Oleic Acid (%w/w) Ethanol (%w/w) HFA 134a (%w/w)
(%w/w)
0.2
100
0.2
0.02
5
95
0.2
0.03
5
95
0.2
0.04
5
95
0.2
0.02
10
90
0.2
0.02
15
85

IV.B.1.2. Determination of Electrical Resistivity of Experimental HFA Based Solution
and Suspensions
IV.B.1.2.a. Design and Validation of the Resistivity Cell

The electrical resistivity of HFA based solution and suspension formulations was
determined by measuring the resistance of the formulation to an applied voltage. A unit
volume resistivity cell was constructed from PTFE with two parallel stainless steel circular
electrodes of cross-sectional area of 1 cm2 and placed at a gap of 1 cm from each other
(Figure IV.1).
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Figure IV.1. Schematic Diagram of the Non-Pressurized Unit Volume Resistivity Cell

Teflon Screw Cap
Sample volume: 1 cm3
PTFE cell
Cross-sectional area of
electrodes: 1 cm2

Electrode gap: 1 cm

This unit volume cell was used to measure the resistivity of a model nonpressurized organic liquid, methyl ethyl ketone (MEK; Fisher Scientific, Swannee, GA).
MEK was dried over 0.3 nm molecular sieve (Metrohm AG, Switzerland) for 24 hours
before measuring the resistivity. Resistivity was calculated using the Equation IV.1:

ρ = RK

Equation IV.1

where ρ is the resistivity in Ω.cm, R is the measured resistance (Ω) = V/I where V is the
applied voltage (volts), I is the measured current (amperes) and K is the cell constant (cm1

). The cell constant is a function of the area of the electrodes (A), the electrode gap (d) and

the electric field pattern between the electrodes in the cell. Theoretically, the cell constant
may be calculated as the ratio of the electrode gap to the area of the electrodes (d/A). Since
the cell constant was 1 cm-1 for the unit volume resistivity cell, the value of the measured
resistance would be identical to the resistivity.
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In order to measure the electrical resistivity of HFA based solutions and
suspensions, the resistivity cell was modified to hold pressurized samples. A custom-made
PTFE high-pressure resistivity cell with 2 stainless steel electrodes, fitted with a
continuous valve to enable direct transfer of pressurized formulations, was constructed for
the resistance measurements (Figure IV.2).
Figure IV.2. Schematic Diagram of the High-Pressure Resistivity Cell
Continuous Valve

Teflon Screw
Cap

Sample

2.64 cm

0.21 cm diameter
stainless steel
electrode

0.21 cm diameter
stainless steel
electrode
Electrode gap: 0.57 cm

Teflon Base

The cross-sectional area of the electrodes was 0.069 cm2 and the electrode gap was 0.57
cm. Due to the design of the resistivity cell, it was difficult to determine the cell constant;
the high-pressure cell was therefore calibrated using the non-pressurized unit volume cell
(Figure IV.1). The cell constant (K) of the high-pressure resistivity cell was calculated
using Equation IV.1 from the resistivity (ρ) of MEK measured with the non-pressurized
unit volume resistivity cell and the resistance (R) measured with the high-pressure
resistivity cell.
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A 1920 Precision LCR meter (QuadTech Inc, Maynard, MA) was used to apply an
AC voltage in order to prevent electrode polarization that may occur in the presence of
polar cosolvents e.g. ethanol. The LCR meter uses a reference resistor whose resistance is
accurately known; the voltages measured across the sample and across the reference
resistor simultaneously, at a given AC frequency, are compared to obtain the final value of
unknown (sample) resistance. The range of resistance measured by this instrument is 10
mΩ - 100 MΩ. The resistivity of MEK was measured using the one cubic centimeter
resistivity cell and the high pressure cell using the Precision LCR meter by applying an
electric voltage in the range of 20 - 100 mV with frequency ranging from 20 - 100 Hz; 20
readings were averaged per sample and 3 replicate samples were tested.

IV.B.1.2.b. Measurement of Electrical Resistivity of HFA Based Solutions and
Suspensions

For determining the electrical resistivity of HFA based solutions and suspensions,
the formulations were filled into the high-pressure resistivity cell (Figure IV.2) through a
continuous valve via a PTFE coupler. The cell was weighed before and after sample
transfer to fill approximately 2 g of the formulation into the cell each time. In order to
ensure that the high-pressure cell was being filled with liquid formulation, both the
resistivity cell and the canister containing the HFA based formulation were cooled in dry
ice for about 5 minutes and the formulation then transferred into the cell through a
continuous valve. The cell was allowed to stand for approximately 15 - 20 minutes and
equilibrate to room temperature (21 °C) measured using thermocouples attached to the
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electrodes. The cell was reweighed to check for leakage of the pressurized formulations.
The cell was carefully cleaned five times between samples with acetone, and air dried.
Preliminary experiments with MEK showed that the resistance values remained
unchanged at an applied voltage ranging from 20 mV to 1 V with a frequency range of 20
Hz to 1 kHz. Hence, lower voltages were used for further experiments to prevent any
undesirable heating of the pressurized samples. The applied voltage was varied in the range
20 - 100 mV while the frequency was varied from 20 - 100 Hz. Twenty measurements
were averaged per can, and 3 cans of each formulation were tested. All the measurements
were performed at 21 - 22.5 °C and 18 - 40 % RH. Water content of the formulations was
determined using Karl Fischer titration (Kulphaisal 2003).

IV.B.2. Results and Discussion
IV.B.2.1. Determination of the Cell Constant of the High Pressure Resistivity Cell

In the present study, MEK, a non-aqueous, non-pressurized solvent was used for
calibrating the high-pressure resistivity cell using the unit volume reference cell. The
measured water content of MEK determined by Karl Fischer titration was 162 ± 11 ppm.
The equation for resistance, R = V/I does not take into account the frequency at which the
voltage is applied and for all practical purposes, the resistance would not be expected to
change with the frequency of the applied AC voltage. Table IV.3 shows that the mean
resistivity values for MEK remained statistically similar (p > 0.05, one way ANOVA) over
the range of the applied voltage (20 - 100 mV) and the frequency (20 - 100 Hz) tested
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suggesting that there was a finite increase in the flow of current through the sample with an
increase in the applied voltage.

Table IV.3. Electrical Resistivity (MΩ.cm) of Methyl Ethyl Ketone as a Function of
Applied Voltage and Frequency (n = 3 Samples, 20 Readings Averaged per
Sample)
Applied
Applied Frequency
Voltage (mV)
20 Hz
50 Hz
100 Hz
20
0.48 ± 0.08
0.48 ± 0.08
0.48 ± 0.08
50
0.48 ± 0.08
0.48 ± 0.08
0.48 ± 0.08
100
0.48 ± 0.08
0.48 ± 0.08
0.49 ± 0.08
In order to compare the electrical properties of MEK measured in the present study
using the unit volume resistivity cell with that reported in literature, the electrical
conductivity (reciprocal of electrical resistivity) was calculated. The mean resistivity of
MEK was 0.48 ± 0.08 MΩ.cm and the corresponding calculated electrical conductivity of
MEK was 2.12 ± 0.34 μS/cm. This value was a magnitude higher than the reported
electrical conductivity of MEK (0.2 μS/cm) measured using a DC test method (ASTM
Standard D4308-95 2005) at 20 ºC, although the test voltage has not been reported (Shell
Chemicals 2005). In the present study, AC resistivity measurements were employed since
the presence of ethanol in HFA based formulations was considered likely to cause
polarization of the electrodes. Electrical resistivity measurements are known to be
influenced by water content, other impurities in the test sample and the applied voltage.
MEK used in the present study was dried to minimize the moisture content but further
purification of MEK by distillation to remove low-volatility impurities was not performed.
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The presence of trace impurities may be a possible factor responsible for the decrease in
the resistivity of MEK. The resistivity cell was cleaned thoroughly with acetone to remove
water soluble impurities, if any, between measurements.
In order to calculate the cell constant for the high pressure cell, the electrical
resistance was measured for MEK using the high pressure cell. The applied electric voltage
and the frequency varied in the range 20 - 100 mV and 20 - 100 Hz, respectively. The cell
constant of the high pressure cell was calculated as the ratio of the electrical resistance
measured using the high pressure cell to the resistivity measured using the unit volume
resistivity cell. Table IV.4 shows the resistivity (ρ) values obtained for MEK using the unit
volume resistivity cell and the resistance (R) values measured using the high-pressure cell.
Table IV.4. Resistivity and Resistance Measurements for MEK as a Function of Applied
Voltage and Frequency (n = 3 Samples, 20 Readings Averaged per Sample).
The Cell Constants Determined for the High-Pressure Cell are also Included.
Cell
Resistance (R) in
Applied
Frequency
Resitivity (ρ) in
Constant in
MΩ (using high
Voltage (mV)
(Hz)
MΩ.cm (using
cm-1 (R/ρ)
pressure cell)
unit volume cell)
20
0.48 ± 0.08
2.06 ± 0.52
4.28
20
50
0.48 ± 0.08
2.12 ± 0.63
4.40
100
0.48 ± 0.08
2.13 ± 0.67
4.43
50
20
0.48 ± 0.08
2.18 ± 0.70
4.51
50
0.48 ± 0.08
2.19 ± 0.73
4.53
100
0.48 ± 0.08
2.19 ± 0.74
4.54
100
20
0.48 ± 0.08
2.24 ± 0.76
4.61
50
0.48 ± 0.08
2.23 ± 0.77
4.60
100
0.49 ± 0.08
2.23 ± 0.78
4.54
Table IV.4 also includes the cell constant for the high resistivity cell derived from
the Equation IV.1. The mean cell constant for the high pressure cell was calculated to be
4.5 cm-1. In contrast, the theoretical cell constant obtained from the ratio of the electrode
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gap to the cross-sectional area of the electrodes of the high pressure cell was 8.2 cm-1. The
experimental method of determining the cell constant involved standardization of the highpressure cell based on the comparison of the electrical resistance of a stable non-aqueous
solvent, MEK, in the unit volume reference resistivity cell with that measured in the highpressure cell using the same device, 1920 Precision LCR meter and similar electrical
connections. The mean cell constant for the high pressure cell was calculated to be 4.5 cm1

. In contrast, the theoretical cell constant obtained from the ratio of the electrode gap to

the cross-sectional area of the electrodes of the high pressure cell was 8.2 cm-1. The
experimental method of determining the cell constant involved standardization of the highpressure cell based on the comparison of the electrical resistance of a stable non-aqueous
solvent, MEK, in the unit volume reference resistivity cell with that measured in the highpressure cell using the same device, 1920 Precision LCR meter and similar electrical
connections. The experimentally calculated cell constant would therefore be expected to be
valid for the measurements performed in similar conditions for the HFA based
formulations and was used for further determination of resistivity for all the HFA based
formulations.

IV.B.2.2. Electrical Resistivity of HFA Based Solutions

The electrical resistance of 100% HFA 134a was measured using the high pressure
cell at an applied electrical voltage ranging from 20 - 100 mV and frequency ranging from
20 - 100 Hz. The measured resistance values varied from 59 - 402 MΩ while the
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corresponding resistivity values ranged between 13 - 90 MΩ.cm. However, as the
resistance meter used in the present study could only measure resistances in the range of 10
mΩ - 100 MΩ, the results should be viewed with caution. The electrical resistivity of
pharmaceutical grade HFA 134a has been reported to be 180 MΩ.cm (Solvay Fluor
Product Bulletin 2001). Although the measurements obtained for HFA 134a were highly
variable, the resistivity of HFA 134a was found to be in the same order of magnitude as
that reported in the literature. However, a resistance meter capable of measuring
resistances greater than 100 MΩ would be required to obtain reliable resistivity
measurements for HFA 134a.
The electrical resistivity of HFA based solution formulations including 7% ethanol
/ 93% HFA 134a and BDP solutions in 7% ethanol / 93% HFA 134a blend was
determined. Table IV.5 summarizes the results for an applied electric voltage ranging from
20 - 100 mV with a frequency ranging from 20 - 100 Hz.
Table IV.5.

Electrical Resistivity Measurements for HFA Based Solutions as a Function
of Applied Voltage and Frequency
Applied
Frequency
Resistivity (MΩ.cm)a
Voltage (mV)
(Hz)
7% Ethanol /
0.08% BDP / 7% Ethanol /
93% HFA 134a
93% HFA 134a
20
0.84, 0.81
2.38 ± 1.31
20
50
0.84, 0.81
2.41 ± 1.36
100
0.84, 0.81
2.39 ± 1.34
50
20
0.85, 0.78
2.42 ± 1.37
50
0.85, 0.82
2.43 ± 1.38
100
0.85, 0.80
2.42 ± 1.37
100
20
0.86, 0.82
2.46 ± 1.41
50
0.86, 0.82
2.46 ± 1.41
100
0.86, 0.83
2.47 ± 1.43
a
20 measurements averaged / can, n = 2 cans for 7% ethanol / 93% HFA 134a, n = 3 cans
for 0.08% BDP / 7% ethanol / 93% HFA 134a.
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The electrical resistivities determined for 7% ethanol / 93% HFA 134a blend as
well as 0.08% BDP / 7% ethanol / 93% HFA 134a solutions were found to remain
consistent with the applied voltage (20 - 100 mV) and frequency (20 - 100 Hz) tested. The
mean electrical resistivity of the ethanol-HFA 134a blend (0.83 ± 0.02 MΩ.cm) was
significantly lower (p < 0.05) in magnitude than that reported for HFA 134a in the
literature (180 MΩ.cm). The mean resistivity of BDP solutions in 7% ethanol / 93% HFA
134a blend (2.4 ± 1.14 MΩ.cm) was found to be slightly higher in comparison to that
determined for the ethanol-HFA blend alone. It was observed that the resistivity values for
the BDP HFA solutions showed variability between cans.
The addition of ethanol to HFA 134a would be predicted to lower the resistivity of
the formulation since the polarity of the blend would be higher than that of HFA 134a
alone. Delgado et al. classified non-aqueous liquids on the basis of their dielectric constant
(ε) as weakly polar liquids (5 < ε ≤ 12) and moderately polar liquids (12 < ε ≤ 40)
(Delgado et al. 2005). The dielectric constant of 100% HFA 134a is 9.5 (Purewal 1998)
while that of ethanol is 25.3 (Wohlfarth 2007). Assuming that the blend of ethanol and
HFA 134a forms an ideal mixture, the dielectric constant of the 7% ethanol / 93% HFA
134a blend can be approximated to be 10.61 (Appendix A.II), which is higher than that of
100% HFA 134a. The water content of 7% ethanol / 93% HFA 134a and the BDP HFA
solutions was determined to be 654 ± 166 ppm and 567 ± 184 ppm, respectively. The high
water content is not unexpected since these HFA based solutions containing ethanol have
an increased tendency for water ingress through the valve during storage. The presence of
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water may possibly confound the results of the electrical resistivity measurements for the
ethanol / HFA blend.

IV.B.2.3. Electrical Resistivity of HFA Based Suspensions

Commercially available albuterol sulfate suspensions in HFA 134a have been
developed using two different formulation strategies; Ventolin HFA is a simple suspension
of albuterol sulfate in 100% HFA 134a, while Proventil HFA is a more complex
suspension of albuterol sulfate in HFA 134a since it contains oleic acid as a surfactant and
a polar cosolvent, ethanol. In the present study, the electrical resistivity of simple
suspensions of albuterol sulfate in 100% HFA 134a was not measured, since the resistance
offered by 100% HFA 134a was found to be greater than the measurable range of
resistance (10 mΩ - 100 MΩ) for the resistance meter used in the present study, making the
results unreliable.
However, the electrical resistivities of albuterol sulfate suspensions in HFA 134a in
the presence of oleic acid and ethanol, as shown in Table IV.2, were measured after
diluting these suspensions. The resistivity values for albuterol sulfate suspensions in HFA
134a containing 0.02% oleic acid and different ethanol concentrations determined at an
applied voltage of 20 - 100 mV and a frequency of 20 - 100 Hz are shown in Table IV.6.
There was a marked decrease in the resistivity of HFA 134a with the addition of ethanol as
observed earlier in Section IV.B.2.2. The resistivity values did not vary at the applied
voltage and frequency range tested, however, variability existed in resistivity between
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canisters. The difference in the mean resistivity of albuterol sulfate suspensions in HFA
134a containing 0.02% oleic acid with increasing ethanol concentrations was statistically
significant (p < 0.05, one way ANOVA).
Table IV.6.

Electrical Resistivity of 0.003% Albuterol Sulfate HFA 134a Suspensions
Containing 0.02% Oleic acid as a Function of Ethanol Concentration,
Applied Voltage and Frequency (20 Readings / Can, 3 Cans)
Applied
Frequency
Resistivity (MΩ.cm)
Voltage (mV)
(Hz)
a
10% Ethanolb
15% Ethanolc
5% Ethanol
20
1.71 ± 0.92
0.38 ± 0.05
0.30 ± 0.11
20
50
1.72 ± 0.93
0.37 ± 0.05
0.29 ± 0.11
100
1.71 ± 0.93
0.37 ± 0.05
0.29 ± 0.11
50
20
1.73 ± 0.95
0.38 ± 0.05
0.30 ± 0.11
50
1.74 ± 0.96
0.37 ± 0.05
0.29 ± 0.11
100
1.74 ± 0.96
0.37 ± 0.05
0.29 ± 0.11
100
20
1.76 ± 0.98
0.38 ± 0.05
0.30 ± 0.11
50
1.76 ± 0.98
0.37 ± 0.05
0.29 ± 0.11
100
1.77 ± 0.99
0.37 ± 0.05
0.29 ± 0.11
Water content of albuterol sulfate suspensions containing varying ethanol concentrations:
a
275 ± 42 ppm, b375 ± 28 ppm, c567 ± 85 ppm.
Dielectric Constant of formulations containing varying ethanol concentrations in HFA
134a: a10.29, b11.08, c11.87 (Appendix A.II).
The mean resistivity decreased by almost one-fifth when the ethanol concentration in
albuterol sulfate suspensions containing 0.02% oleic acid in HFA 134a was increased from
5% to 10% w/w. However, further increase in ethanol concentration to 15% did not cause a
corresponding decrease in resistivity of the suspensions.
The resistivity would be expected to decrease with the addition of ethanol to the
HFA formulations, as shown by the increase in the calculated dielectric constants. For
example, the dielectric constant of formulations containing a 5% ethanol / 95% HFA 134a
blend was calculated to be 10.29, while those determined for 10% ethanol / 90% HFA
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134a and 15% ethanol / 85% HFA 134a blends were 11.08 and 11.87, respectively
(Appendix A.II). The water content of these formulations also increased significantly (p <
0.05, one-way ANOVA) with increase in ethanol concentration (Table IV.6), the presence
of water may infleunce polarity of these formulations. The water content for albuterol
sulfate suspensions in a 10% ethanol / 90% HFA 134a blend (375 ± 28 ppm) was lower
than the HFA based solutions in a 7% ethanol / 93% HFA 134a blend (567 ± 184 ppm).
The increased water content for the solution based formulations was considered to be
related to the storage time of the formulations. Solution formulations were prepared
approximately 2 weeks before the suspension formulations, and as a consequence, water
ingress in the HFA based solutions on storage would be expected to be higher.
Table IV.7 shows the influence of oleic acid concentration on the electrical
resistivity of albuterol sulfate suspensions at an applied voltage ranging from 20 - 100 mV
with a frequency ranging from 20 - 100 Hz.
Table IV.7.

Electrical Resistivity of 0.003 %w/w Albuterol Sulfate Suspensions in 5%
Ethanol / 95% HFA 134a as a Function of Oleic Acid Concentration,
Applied Voltage and Frequency (20 Readings Averaged / Can, 3 Cans)
Applied
Frequency
Resistivity (MΩ.cm)
a
Voltage (mV)
(Hz)
0.03% oleic acidb 0.04% leic acidc
0.02% oleic acid
20
1.71 ± 0.92
1.21 ± 0.36
0.88 ± 0.15
20
50
1.72 ± 0.93
1.21 ± 0.36
0.88 ± 0.15
100
1.71 ± 0.93
1.21 ± 0.36
0.88 ± 0.15
50
20
1.73 ± 0.95
1.23 ± 0.36
0.89 ± 0.15
50
1.74 ± 0.96
1.23 ± 0.36
0.89 ± 0.15
100
1.74 ± 0.96
1.24 ± 0.35
0.88 ± 0.15
100
20
1.76 ± 0.98
1.24 ± 0.36
0.90 ± 0.15
50
1.76 ± 0.98
1.24 ± 0.36
0.90 ± 0.15
100
1.77 ± 0.99
1.24 ± 0.35
0.90 ± 0.15
Water content of albuterol sulfate suspensions containing varying oleic acid
concentrations: a275 ± 42 ppm, b198 ± 17 ppm, c256 ± 28 ppm.
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The mean resistivity of albuterol sulfate suspensions in HFA 134a containing oleic acid
and ethanol decreased with increase in oleic acid concentration, however the decrease was
not statistically significant (p > 0.05, one-way ANOVA) due to considerable variation in
the resistivity values between canisters. Table IV.7 shows that the resistivity values were
consistent at the applied voltage and frequency range tested.
Although increasing the oleic acid concentration caused a decrease in the resistivity
of the ethanol containing albuterol sulfate HFA suspensions, this decrease was not
statistically significant. The water content of albuterol sulfate suspensions in a 5% ethanol
/ 95% HFA 134a blend containing varying concentrations of oleic acid (275 ± 42 ppm, 198
± 17 ppm and 256 ± 28 ppm for suspensions containing 0.02, 0.03 and 0.04 %w/w oleic
acid, respectively) differed significantly (p < 0.05, one-way ANOVA). The presence of
moisture in these formulations may possibly confound the electrical resistivity
measurements.
In summary, the resistivity measurements have provided an indication that ionic
species are present in HFA based solutions. Although HFA 134a has high resistivity,
which could not be measured reliably in the present study, the presence of ethanol in the
control HFA solutions tested increased the polar nature of the formulation and
subsequently decreased the resistivity. The presence of trace quantities of water may
possibly influence the formation of charged ionic species in ethanol-HFA based
formulations and confound the results obtained for the resistivity measurements. The use
of ethanol dried over molecular sieves may be able to distinguish the influence of water on
the resistivity measurements. The variability in the resistivity measurements of these
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pressurized formulations made it difficult to discern subtle changes in the resistivity due to
the addition of excipients. For albuterol sulfate suspensions in HFA 134a containing
ethanol and oleic acid, the resistivity measurements decreased with increase in the ethanol
concentration, however, no significant effect of oleic acid concentration on resistivity was
observed for the concentrations studied. The resistivity measurements suggested that
ethanol containing HFA formulations are relatively polar and may likely produce charged
species in these systems.

IV.C. Zeta Potential of Albuterol Suspensions in Non-Aqueous Solvents
IV.C.1. Methods
IV.C.1.1. Preparation of Albuterol Suspensions in Non-Aqueous Solvents

The electrophoretic mobility technique used in the present study was validated for
measurements in non-aqueous suspensions using model albuterol suspensions in nonpressurized and pressurized chlorinated solvents. 0.001 - 0.004 %w/v albuterol sulfate
suspensions in chloroform (Fisher Scientific, Swannee, GA) were prepared as model
suspensions in a non-aqueous, non-pressurized chlorinated solvent and tested in order to
compare the zeta potential values obtained to that reported in the literature. In addition,
albuterol base suspensions in a CFC 11: CFC 12 blend containing oleic acid were prepared
as outlined in Chapter III.A.2.2 as model suspensions in non-aqueous pressurized
chlorinated solvents. A 0.09 % w/w albuterol base suspension in a mixture of CFC 11:
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CFC 12 with 0.015% w/w oleic acid (drug-surfactant ratio of 6:1) was prepared and tested
in order to compare the zeta potential with that reported in the literature for a similar
concentration. Further, in order to study the effect of albuterol base and oleic acid
concentration on the zeta potential, a series of albuterol base suspensions in a mixture of
CFC 11: CFC 12, with oleic acid as the surfactant were prepared (Table IV.8 and IV.9).
Table IV.8.

Albuterol Base Suspensions in Chlorofluorocarbon (CFC) 11 and 12 Blend
with a Fixed Drug-Surfactant Ratio of 6:1
Albuterol base (%w/w)
Oleic acid (%w/w) CFC 11 (%w/w)
CFC 12 (%w/w)
0.001
0.00016
30
70
0.005
0.0008
30
70
0.03
0.005
30
70
0.06
0.01
30
70
0.09
0.015
30
70

Table IV.9. Albuterol Base Suspensions in Chlorofluorocarbon (CFC) 11 and 12 Blend
with varying Oleic Acid Concentration
Albuterol base (%w/w) Oleic acid (%w/w) CFC 11 (%w/w)
CFC 12 (%w/w)
0.03
0.002
30
70
0.03
0.003
30
70
0.03
0.005
30
70
0.03
0.0075
30
70
0.03
0.01
30
70
After validation of the electrophoretic mobility technique, the zeta potential of
HFA based albuterol sulfate suspensions was determined. In order to prepare samples for
electrophoretic measurements for concentrated suspensions, careful dilution preserving the
existing state of the particle surface is recommended (Delgado et al. 2005). Table IV.2
summarizes the dilute albuterol sulfate HFA suspensions (approximately 0.003 %w/w
albuterol sulfate) used for the zeta potential measurements.
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IV.C.1.2. Determination of Zeta Potential of Albuterol Suspensions in Non-Aqueous
Solvents

Zeta potential was determined by measuring the electrophoretic mobility of charged
particles in suspension. Electrophoretic measurements were performed using Laser
Doppler Electrophoresis with a Malvern Zetasizer 2000 (Malvern Instruments, Inc.,
Southborough, MA) and a custom-built pressurized non-aqueous electrophoresis cell
(Figure IV.3).
Figure IV.3. Schematic Diagram of the High-Pressure Electrophoresis Cell
Electrode
contacts
Pressurized formulation
Polycarbonate coupler
Continuous valve
Electrophoresis cell
Electrode

The electrophoresis cell was designed to hold pressurized samples and incorporated
with a continuous valve to enable direct transfer; low voltages could be applied to
minimize sample heating since the electrode gap in the cell was only 2 mm. The Zetasizer
2000 uses heterodyne detection; one of the laser beams was modulated at 250 Hz to detect
the direction of movement and hence the sign of the charge on the particles. The applied
electric field was reversed at a frequency of 2 Hz to prevent electrode polarization. The
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Zetasizer 2000 measures the electrophoretic mobility of particles suspended in the
dispersion medium. In order to determine zeta potential values from the measured
electrophoretic mobility, the Zetasizer 2000 software uses the Henry’s formula as given by
Equation IV.2.

ζ =

3ημ
2 f (κa)ε rsε 0

Equation IV.2

where ζ is the zeta potential, η is the viscosity, μ is the electrophoretic mobility, κa is the
ratio of the electrical double layer (κ-1) and the particle radius (a) and εrs is the electrical
permittivity of the medium and ε0 is the electrical permittivity of the vacuum. The values
of dielectric constant (εrs/ε0) and viscosity of the formulations tested (Table IV.10) were
entered into the Zetasizer software.
Table IV.10. Summary of the Dielectric Constants and Viscosity of the Dispersion Media
of the Albuterol Suspensions
Dispersion Medium
Dielectric Constant
Viscosity (cP)
a
100% Chloroform
4.8
0.54a
30% CFC 11 / 70% CFC 12
2.17a
0.30a
b
100% HFA 134a
9.5
0.21d
c
5% ethanol / 95% HFA 134a
10.29
0.23e
10% ethanol / 90% HFA 134a
11.08c
0.30e
c
15% ethanol / 85% HFA 134a
11.87
0.33e
a
Sandstrom et al. 1994, bPurewal, 1998, cAppendix A.II, dSolvay Fluor HFA 227 and HFA
134a Datasheet 2003, eDeStefano and McNamara 1996.
In order to estimate the surface charge of albuterol sulfate particles in these HFA
based suspensions, f(κa) was assigned a value of 1.0 in the Zetasizer software. This
corresponds to the Hückel approximation. In the case of HFA based suspensions, the
presence of a polar cosolvent, ethanol, makes these formulations more polar, as suggested
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by the resistivity measurements. For these HFA formulations, it may be possible that the
value of f(κa) lies between 1.0 and 1.5, which are generally used for non-aqueous
formulations and aqueous formulations, respectively. The resistivity measurements for the
HFA based formulations performed in Section IV.B confirmed the presence of charge
ionic species, however, the nature of these species is not known. Hence, κ (reciprocal of
the electrical double layer) could not be calculated for the HFA based suspension
formulations.
Preliminary experiments were performed by applying an electrical field in the
range of 50 - 120 V/cm with the model albuterol suspensions in chloroform and CFC 11:
CFC 12 blend. The zeta potential values remained consistent in the range of the applied
electric field tested. Further experiments with HFA based suspensions were performed
using an electrical field of 100 V/cm. Five measurements were averaged per can, 3 cans
were tested per formulation. The cell was carefully cleaned with methanol five times
between samples.

IV.C.2. Results and Discussion
IV.C.2.1. Zeta Potential of Albuterol Suspensions in Non-Pressurized and Pressurized
Chlorinated Solvents

Figure IV.4 summarizes the results of zeta potential measurements of albuterol
sulfate suspensions in chloroform as a function of applied electric field (50 - 120 V/cm)
and albuterol sulfate concentration (0.001 - 0.004 %w/v). Zeta potential was not
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significantly different (p > 0.05, one-way ANOVA) as a function of the applied electric
field for all the concentrations tested. Zeta potential of albuterol sulfate in chloroform did
not differ significantly (p > 0.05, one-way ANOVA) as a function of the albuterol sulfate
concentrations measured at an applied electric field in the range of 50 - 120 V/cm.
Figure IV.4.

Zeta Potential of Albuterol Sulfate Suspensions in Chloroform as a
Function of Electric Field Strength and Concentration of Albuterol Sulfate.
Error Bars Represent S.D., n=9 (3 Samples, 3 Replicates / Sample)
50

Zeta potential (mV)

40

30

20

10

0
5 0 V /c m

7 5 V /c m

1 0 0 V /c m

1 2 0 V /c m

A p p lie d e le c tric fie ld
0 .0 0 1 %
0 .0 0 2 %
0 .0 0 3 %
0 .0 0 4 %

w /v
w /v
w /v
w /v

a lb u te r o l
a lb u te r o l
a lb u te r o l
a lb u te r o l

su lfa te
su lfa te
su lfa te
su lfa te

in
in
in
in

c h lo r o fo r m
c h lo r o fo r m
c h lo r o fo r m
c h lo r o fo r m

Albuterol sulfate suspensions in chloroform were tested in order to compare the
zeta potential values obtained to that reported in literature. However, the concentration of
albuterol sulfate used in these studies was not reported (Sidhu et al. 1993). Low
concentrations of albuterol sulfate suspensions in chloroform (0.001 - 0.004% w/v) have
been suggested for the determination of zeta potential using laser Doppler electrophoresis
(Rogueda 2005b). The mean zeta potential for albuterol sulfate suspensions in chloroform,
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in the concentration range of 0.001 - 0.004 %w/v, determined at an applied electric field of
100 V/cm was +28.6 ± 4.3 mV, which was comparable to +34 ± 5 mV as reported in the
literature (Sidhu et al. 1993). The results suggested that albuterol sulfate particles possibly
acquired a positive surface charge in chloroform.
Table IV.11 summarizes the electrophoretic mobility and zeta potential data for
albuterol base suspensions containing 0.09 %w/w albuterol base and 0.015 %w/w oleic
acid at an applied electric field in the range of 50 - 120 V/cm, which was found to have an
insignificant effect on the zeta potential (p = 0.90).
Table IV.11. Zeta Potential and Electrophoretic Mobility for 0.09 %w/w Albuterol Base /
0.015 %w/w Oleic Acid / CFC 11:12 (30:70) Suspensions as a Function of
Applied Electrical Field (n = 6; 2 Samples, 3 Replicates/ Sample)
Zeta Potential (mV)
Applied Electrical Electrophoretic Mobility (10-8 m2V-1s-1)
Field (V/cm)
50
0.30 ± 0.09
72.9 ± 21.3
75
0.30 ± 0.11
74.9 ± 27.2
100
0.35 ± 0.08
82.3 ± 23.3
120
0.36 ± 0.09
88.7 ± 22.8
Electrophoretic mobility for albuterol base CFC suspensions containing 0.09 %w/w
albuterol base and 0.015 %w/w oleic acid was 0.35 ± 0.08 (10-8) m2V-1s-1, which was
comparable to that reported in the literature (0.43 x 10-8 m2V-1s-1; Sandstrom et al. 1994)
for albuterol base suspensions of equivalent composition. The corresponding zeta potential
for the same formulation (82.3 ± 24.1 mV) obtained in this study was also similar to that
reported by Sandstrom et al. (80mV; Sandstrom et al. 1994). However, in the present
study, the suspensions tested were found to be too concentrated for electrophoretic
mobility measurements using light scattering. The signals obtained during the
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electrophoretic mobility measurements were influenced by the sample particle
concentration.
An indication of sample concentration is obtained from the number of photons
counted per second expressed as kilo counts per second (kcps). The reference beam
contributes between 2000 - 2500 kcps to the photon count rate used in the measurement
sequence. Ideally, the scattering beam or the light beam from the sample should contribute
between 100 and 1000 kcps. A kcps value of 2400 - 3000 during the measurement
sequence indicates an acceptable suspension concentration. A count rate above 4000 kcps
suggests a concentrated suspension. The sample data extracted from the corellogram after
processing the signal is displayed as a fringe model. An acceptable fringe model will have
a symmetric decay about zero and a large depth of modulation of the signal, which is
indicative of an appropriately prepared sample. A sample with too high or too low particle
concentration will yield a signal, which does not display a good depth of modulation as
seen from Figure IV.5. It is difficult to dilute pressurized suspensions; hence in order to
keep the dispersed phase in an acceptable concentration range for the technique used,
suspensions containing lower concentrations of albuterol were prepared. Suspensions
containing a fixed drug-surfactant ratio of 6:1 and albuterol base concentration in the range
of 0.001 - 0.09% w/w were prepared to investigate the effect of particle concentration on
the measured electrophoretic mobility and the zeta potential tested at an applied electric
field of 100 V/cm (Table IV.12).
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Figure IV.5.

Example of an Acceptable and Poor Fringe Model from Electrophoretic
Mobility Measurements of 0.001 %w/w and 0.09 %w/w Albuterol Base
Suspensions in CFC 11: CFC 12 blend, respectively.

0.001% albuterol CFC suspension
Good Depth of Modulation

0.09% albuterol CFC suspension
Poor Depth of Modulation

Table IV.12. Electrophoretic Mobility and Zeta Potential of CFC Based Suspensions at an
Electrical Field of 100 V/cm (n = 9; 3 Samples, 3 Replicates / Sample)
Zeta Potential Photon Count Rate
Albuterol base Oleic Acid
Electrophoretic
(mV)
(kcps)
%w/w
%w/w
Mobility
-8 2 -1 -1
(10 m V s )
0.001
0.00016
0.67±0.03
164±9
5724 ± 230
0.005
0.0008
0.52±0.07
128±17
8630 ± 620
0.03
0.005
0.41±0.01
111±23
5929 ± 1032
0.06
0.01
0.47±0.04
116±11
7404 ± 908
0.09a
0.015
0.35±0.08
82±23
8828 ± 697
a
n = 6; 2 samples, 3 replicates/ sample
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There was a statistically significant difference in the measured zeta potential across
the particle concentration range studied (p < 0.0001, one way ANOVA). Post-hoc analysis
using Tukey’s HSD showed that the difference in the mean zeta potential was significant
between the highest concentration of 0.09 %w/w albuterol and the lower concentrations of
0.005 and 0.001 %w/w albuterol base suspensions. The mean zeta potential for
suspensions with albuterol concentration 0.005%, 0.03%, 0.06 %w/w was not significantly
different. The photon count rate decreased with decrease in albuterol base concentration in
the suspensions but still remained above 4000 kcps even for the lowest albuterol base
concentration studied. However, the fringe pattern of the data improved as observed in
Figure IV.5. Unfortunately, the low albuterol base concentrations used for zeta potential
measurements are not reflective of the concentration of albuterol base in the marketed CFC
formulation, for example, Ventolin CFC, which contains 0.12 %w/w albuterol base
suspended in a CFC 11: CFC 12 propellant blend with oleic acid as a surfactant. Hence,
application of the zeta potential data to commercially available suspensions with higher
drug concentrations is considered to be limited.
Further, keeping the particle concentration unchanged, the effect of surfactant
concentration on the particle mobility and the zeta potential was investigated using 0.03%
w/w albuterol base suspensions in CFC 11: CFC 12 blends containing varying
concentrations of oleic acid. The mean zeta potential measured for albuterol suspensions in
CFC 11: CFC 12 in the absence of oleic acid was +58.1 ± 18.1 mV and became more
positive on the addition of oleic acid (Table IV.13). Variability in the measurements was
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found to be high, probably due to the high particle concentration (photon count rates in the
range of 6000 kcps).
Table IV.13. Effect of Oleic Acid Concentration on Electrophoretic Mobility and Zeta
Potential of Albuterol Suspensions in CFC 11:12 Blend (n = 9, 3 Samples, 3
Replicates / Sample)
Zeta Potential
Albuterol Base
Oleic Acid
Electrophoretic Mobility
(mV)
% w/w
% w/w
(10-8 m2V-1s-1)
0.03
0.03
0.03
0.03
0.03
0.03

0.0015
0.003
0.005
0.0075
0.01

0.26±0.10
0.43±0.04
0.37±0.16
0.41±0.01
0.55±0.03
0.55±0.07

58±18
106±10
90±39
111±23
136±10
135±18

The zeta potential of albuterol base suspensions was observed to increase with
increasing oleic acid concentration from 0.003 - 0.0075 %w/w. The mean zeta potential did
not increase further at an oleic acid concentration of 0.01 %w/w. The effect of oleic acid
concentrations above 0.01% w/w on the zeta potential of albuterol base CFC suspensions
was not tested. These studies have indicated that the addition of oleic acid increased the
positive charge on the albuterol particle surface. In comparison, Sandstrom et al reported
that the zeta potential of 0.09 %w/w albuterol base in a CFC 11: CFC 12 (30:70) blend
increased until a maximum value of +80 mV at an oleic acid concentration range of 0.01 0.02 %w/w and further increase in oleic acid concentration caused a decrease in the zeta
potential values (Sandstrom et al. 1994).
The present study showed that the electrophoretic mobility of albuterol suspensions
in non-aqueous pressurized solvents can be measured and was in good agreement with the
data reported in the literature. Although, the experiments have indicated that albuterol
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suspensions in chloroform and CFC propellant blend exhibit positive zeta potentials, low
particle concentrations were required to obtain acceptable measurements for the
electrophoretic mobility technique employed in this study. Unfortunately, these
concentrations do not reflect the concentration of drug present in commercially available
suspension pMDIs and hence the results obtained are difficult to extrapolate to commercial
products.

IV.C.2.2. Zeta Potential of Albuterol Sulfate Suspensions in HFA 134a

The electrophoretic mobility of albuterol sulfate suspensions in HFA 134a
determined at an alternating electric field of 100 V/cm was 2.20 ± 0.70 (10-8) m2V-1s-1,
while the corresponding zeta potential was 76 ± 26 mV. There was variability in the
measurements both within can and between cans, which was also observed with
measurements within pressurized albuterol base CFC suspensions. A simple suspension of
albuterol sulfate in 100% HFA 134a was tested to investigate the presence of surface
charge on albuterol sulfate particles in the absence of excipients, e.g., surfactants and
cosolvents.
The electrophoretic mobility determined for albuterol sulfate suspensions in HFA
134a was higher than that achieved by albuterol base suspensions in CFC 11: CFC 12
propellants. For example, the electrophoretic mobility for 0.09 %w/w albuterol base /
0.015 %w/w oleic acid / CFC 11: CFC 12 suspensions measured at 100 V/cm was 0.35 ±
0.08 (10-8) m2V-1s-1. HFA 134a has a higher dielectric constant (ε = 9.5) than a 30:70 blend
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of CFC 11: CFC 12 (ε = 2.2). Zeta potential is directly proportional to electrophoretic
mobility and viscosity, while it is inversely proportional to the dielectric constant. By
virtue of the higher dielectric constant of HFA 134a, albuterol sulfate particles in HFA
134a would be predicted to have a higher electrophoretic mobility compared with albuterol
base particles suspended in CFC 11: CFC 12 propellant blends for similar zeta potential
values.
For albuterol sulfate suspensions in HFA 134a in the absence of surfactant, it is
difficult to explain the formation of surface charge due to the absence of any ionic species.
The electrical resistivity of 100% HFA 134a could not be reliably measured since the
resistance meter used was not capable of measuring resistances above 100 MΩ.cm. This
suggested that the conductivity of the propellant HFA 134a by itself is very low. Sidhu et
al showed that presence of trace water can influence surface charge. Lactose suspensions in
dry chloroform produced a zeta potential of –5 ± 2 mV as compared to –23 ± 5 mV when
dispersed in non-dry chloroform (water content approximately 100 ppm; (Sidhu et al.
1993). Surface potentials in HFA 134a may possibly be influenced by the presence of
soluble impurities from both the formulation components e.g. albuterol sulfate, HFA 134a
as well as the packaging components e.g. extractables and leachables from valve
elastomers or the presence of moisture. Valois DF10/50 continuous valves with EPDM
elastomers were used in this study. EPDM elastomers do not contain carbon fillers, have
low tendency for water ingress as well as limited swelling on contact with HFA 134a
(Williams and Tcherevatchenkoff 1998, Cummings 1999, Pischtiak 2000b). HFA 134a
may contain trace quantities of processing impurities including hydrogen fluoride (HF) as
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well as water (Solvay Fluor HFA 227 and HFA 134a Datasheet 2003). In the present study,
the water content of albuterol sulfate suspensions in HFA 134a was 59 ± 7 ppm. It is
difficult to remove traces of water from non-aqueous systems, especially in pressurized
dispersion media e.g. HFA 134a.
The effect of ethanol concentration on the zeta potential of albuterol sulfate
suspensions in HFA 134a containing 0.02 % oleic acid was investigated. Table IV.14
summarizes the electrophoretic mobility, zeta potential, resistivity and water content of
albuterol sulfate suspensions in HFA 134a containing 0.02% oleic acid and increasing
concentration of ethanol.
Table IV.14. Electrophoretic Mobility and Zeta Potential of Albuterol Sulfate in HFA
134a Containing 0.02% Oleic Acid as a Function of Ethanol Concentration
(n = 30; 5 Readings / Sample, 2 Samples / Can, 3 Cans)
Resistivity
Water
Zeta
Ethanol
Electrophoretic
Albuterol
(MΩ.cm)
Content
Potential
%w/w
Mobility
sulfate
(ppm)
(mV)
(10-8 m2V-1s-1)
%w/w
0.003
5
1.07±0.22
40±8
1.74±0.02 275 ± 42
0.003
10
0.48±0.31
24±13
0.37±0.00 375 ± 28
0.003
15
0.38±0.23
15±10
0.29±0.00 567 ± 85
The mean electrophoretic mobility and the corresponding zeta potential of albuterol
sulfate particles decreased significantly (p < 0.0001, one way ANOVA) with an increase in
the ethanol concentration from 5 - 15 % w/w. Table IV.14 also summarizes the resistivity
of these formulations, which also decreased with an increase in the ethanol concentration.
The water content of albuterol sulfate HFA suspensions increased significantly (p < 0.05,
one way ANOVA) with increasing ethanol concentration as shown in Table IV.14. The
presence of ethanol in these albuterol sulfate HFA suspensions may possibly contribute to
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formation of ionic species as implied by the decrease in electrical resistivity, which may
have a role in decreasing the overall surface charge in suspensions containing increasing
concentrations of ethanol.
Table IV.15 shows the effect of oleic acid concentration on the electrophoretic
mobility and the zeta potential of albuterol sulfate suspensions in a 5% ethanol / 95% HFA
134a blend. The mean zeta potential of albuterol sulfate suspensions in a 5% ethanol / 95%
HFA 134a blend containing 0.02 % oleic acid was 40 ± 8 mV, while that for suspensions
containing 0.03 % w/w oleic acid was 47 ± 16 mV. Variability in the measurements was
high.
Table IV.15
Albuterol
sulfate
(%w/w)
0.003
0.003
0.003

Electrophoretic Mobility and Zeta Potential of Albuterol Sulfate in 5%
Ethanol / 95% HFA 134a Blend as a Function of Oleic Acid Concentration
(n = 30; 5 Readings / Sample, 2 Samples / Can, 3 Cans)
Resistivity
Water
Zeta
Oleic acid
Electrophoretic
(MΩ.cm)
Content
Potential
(%w/w)
Mobility
(ppm)
(mV)
(10-8 m2V-1s-1)
0.02%
1.07±0.22
40±8
1.74±0.02
275 ± 42
0.03%
1.27±0.43
47±16
1.23±0.01
198 ± 17
0.04%
0.70±0.45
30±14
0.89±0.01
256 ± 28

Table IV.15 also shows the resistivity of the formulations, which slightly decreased
with increase in the oleic acid concentration. On further increase in the oleic acid
concentration to 0.04 % w/w, the mean zeta potential decreased to 30 ± 14 mV. There was
a statistically significant difference (p < 0.0001, one-way ANOVA) in the zeta potential
values between the formulations with three different oleic acid concentrations. Due to high
variability in the measurements, the effect of increasing the oleic acid concentration on the
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zeta potential was not clear. In addition, the presence of water may have had an adverse
effect on the surface charge of albuterol sulfate in these suspensions as well.
The typical concentration range of surfactants used in suspension pMDIs is usually
0.01 - 1 %w/w depending upon the concentration of drug; higher surfactant concentrations
are used for high drug concentration suspensions (Dalby 1990). In this study, oleic acid
concentrations were varied between 0.02 - 0.04 %w/w of the formulation, which was 10 20 % of the initial concentration of albuterol sulfate in the suspensions. In general, the
electrophoretic mobility and the corresponding zeta potential values for albuterol sulfate
suspensions in HFA containing oleic acid and ethanol were lower than those obtained for
albuterol sulfate HFA suspensions without surfactant. In contrast, the electrophoretic
mobilities of albuterol sulfate particles suspended in HFA 134a containing oleic acid and
ethanol were higher than those determined for albuterol particles suspended in a CFC 11:
CFC 12 blend containing oleic acid.
In summary, electrophoretic mobility studies in a simple albuterol sulfate
suspension in 100% HFA 134a showed that albuterol sulfate acquired a positive zeta
potential although there was variability in the measurements. Albuterol sulfate
concentrations in these suspensions (approximately 0.003 %w/w) were significantly lower
than that present in commercially available albuterol sulfate HFA suspension pMDIs e.g.
Ventolin HFA, which contains 0.14 %w/w albuterol sulfate in 100 % HFA 134a. It may be
speculated that surface charge formation in such formulations may be due to the presence
of trace water or impurities, however, these studies are difficult to undertake. The
electrophoretic mobility of albuterol sulfate decreased in the presence of oleic acid and
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ethanol; increasing the concentration of ethanol decreased the mobility and the
corresponding zeta potential of albuterol sulfate HFA suspensions. However, the limitation
of these techniques used to measure electrical charge is that dilute particle concentrations
are required. Other techniques such as electroacoustic techniques could possibly be used to
measure charge in high particle concentration suspensions, however, electroacoustics has
not been adapted for pressurized formulations.
Both the resistivity and electrophoretic mobility measurements have confirmed the
presence of charged species within HFA based solutions and suspensions. However,
whether these species have a role in the overall suspension stability of HFA suspensions
would depend on the type of soluble species present and their interactions within these
formulations. Chapter V describes a theoretical approach to study the particle interactions
within model albuterol sulfate HFA suspension pMDIs.

V. MODELING PARTICLE INTERACTIONS IN SUSPENSION BASED
METERED DOSE INHALERS

V.A. Introduction

Most pMDIs are formulated as suspensions of micronized drug in liquefied
propellant blends (Farr et al. 1994). Surfactants such as lecithin, oleic acid and sorbitan
trioleate have been traditionally used to stabilize these inherently unstable systems (Farr et
al. 1994). Although traditional DLVO theory has been used to explain suspension stability
within aqueous systems on the basis of van der Waals attractive forces and electrostatic
repulsion, its application to non-aqueous systems including pMDI suspensions has not
been validated (Vervaet and Byron 1999). The extent to which the above-mentioned forces
influence particle interactions within the pMDI suspension is considered to vary depending
on surface chemistry and surface morphology of drug, excipients and packaging
components like the canister coating material (Parsons et al. 1992, Clarke et al. 1993).
The pMDI formulation and device components have undergone major
modifications due to the transition from the ozone-depleting CFCs to the ozone-friendly
HFA propellants (Thiel 1996, Leach 2005). The difference in physicochemical properties
of HFA and CFC propellants, particularly the solvent characteristics, has necessitated the
use of different salt forms of drugs and the inclusion of polar cosolvents like ethanol to
78
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dissolve surfactants traditionally used in CFC based pMDIs (Byron et al. 1994, Tzou et al.
1997, Jannick 2006). For example, Proventil HFA® is a suspension of albuterol sulfate in
HFA 134a containing oleic acid as a surfactant and a polar cosolvent, ethanol. In contrast,
Ventolin HFA is a simple suspension of albuterol sulfate in 100% HFA 134a. HFA based
suspension pMDIs also have a greater propensity for drug adhesion to the canister inner
surface than CFC based suspensions (Ashurst et al. 2000a). Recent studies have employed
atomic force microscopy and surface tension measurements to explain particle interactions
between drug, excipients and canister material (Traini et al. 2005). However, a theoretical
understanding of the interactions within pressurized suspension formulations on a
molecular level is still lacking.
In this pilot study, molecular models of simple pMDI formulations including
albuterol sulfate in HFA 134a were constructed and optimized to investigate interactions
between the drug and propellant molecules. Interactions within albuterol sulfate
suspensions in the presence of oleic acid (an anionic surfactant) and ethanol (a polar
cosolvent) were also studied.

V.B. Molecular Modeling
V.B.1. Construction and Optimization of the Molecular Models

Molecular modeling was undertaken using Sybyl software (Version 7.3, Tripos,
Inc., St. Louis, MO), which employs molecular mechanics or the force field method to
calculate the molecular geometry, energies and various other properties of the compound
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of interest (Tripos Bookshelf Force Field Manual 2006). A molecule is considered to be a
mechanical system in which particles (atoms) are connected by springs (bonds) and the
elasticities of the springs are the force constants. A force field is used to calculate the
interaction forces for both bonding (covalent) and non-bonding (van der Waals and
electrostatic) interactions for all the atoms in the molecule. The molecule can rotate,
vibrate and translate in response to the inter- and intramolecular forces acting upon it, to
attain its most favored conformation in space (Schlick 2002).
Electrostatic point charges on the atoms in a molecule drawn in Sybyl can be
calculated using various empirical methods. The Gasteiger-Huckel method is one
commonly used method, where the calculation of charges on the molecule is based on the
relationship between the orbital electronegativity and the atomic charge given by Equation
V.1 (Tripos Bookshelf Force Field Manual 2006):
XA=aA+bA.Q+cA.Q2

Equation V.1

where XA = orbital electronegativity and is represented as a function of the total charge (Q)
on an atom (A), and aA, bA and cA are the coefficients of the quadratic equation based on
the ionization potential and electron affinity of the atom.
The energy associated with a molecular model of a compound is a function of its
atomic coordinates. After constructing a molecular model in Sybyl, the energy is
minimized by changing the atomic coordinates of the molecular model iteratively until a
minimum energy value relative to the energy associated with the inital set of atomic
coordinates is obtained. The resulting atomic coordinates corresponding to the local energy
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minimum correspond to the favored structural conformation of the molecule in space
(Tripos Bookshelf Force Field Manual 2006).
Sybyl can be used to study properties of the molecule in a vacuum. However, since
almost all chemical interactions occur in a solvent medium, the software offers three
options to take into account the solvent effects in the study of molecular interactions.
These include using a distance dependent dielectric screening term in the force field to
simulate solvent screening effects on electrostatic charges, implicit solvation of molecules
by adding a new term/terms to the force field to account for solvent effects or explicitly
including solvent molecules in the calculation of intermolecular forces (Tripos Bookshelf
Force Field Manual 2006).

V.B.2. Estimation of Molecular Interactions Using the Hydropathic INTeractions
(HINT®) Scores

The HINT program in Sybyl has been designed to classify and quantitatively score
non-covalent interactions e.g. hydrogen bonding, acid-base, Coulombic attractions and
hydrophobic interactions (Kellogg and Abraham 2000). Experimental data from solvent
partition experiments between water and 1-octanol (logPo/w) have been used to develop the
HINT program. The HINT model scores each atom-atom interaction, within or between
molecules, with the following equation:
bij= aiSi ajSj TijRij + rij

Equation V.2
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where bij is the interaction score between atoms i and j, a is the hydrophobic atom constant,
S is the solvent accessible surface area (H2O probe), Tij is a logic function which returns a
value of 1 or –1; depending on the character of the interacting polar atoms (a < 0 for polar
atoms), there are three possibilities: acid-acid, base-base and acid-base of which only acidbase interactions are scored favorably. Tij also flags hydrogen bonds, which are considered
a special case of acid-base interactions. Rij is the exponential e-r (r is the distance between
the two atoms i and j) and rij is an implementation of the Lennard-Jones potential function
(Levitt 1983, Levitt and Perutz 1988). The rij term serves as a penalty function to flag van
der Waals violations. The total HINT interaction score for the system is given by the sum
of all the individual interaction scores (ΣΣbij). The HINT convention is that favorable
interactions are scored positively (bij > 0) and unfavorable interactions are scored
negatively (bij < 0) (Kellogg and Abraham 2000). HINT has typically been used to
calculate an empirical hydropathic field in or around a protein or small molecule, and
displaying contours to qualitatively visualize hydrophobic and polar regions of the
molecules; to determine the effects of site-directed mutagenesis on substrate-binding or
protein subunit-subunit interactions; to calculate a predicted binding interaction constant
that is the sum of all atom-atom interactions between two species and to calculate LogP
and hydropathic maps for use with conventional and 3D QSAR (quantitative structureactivity relationship) (Tripos Bookshelf HINT Manual 2006).
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V.C. Methods

Molecular models of albuterol sulfate suspensions in HFA 134a were constructed
and optimized in Sybyl. Figure V.1 shows the molecular structures of all the formulation
components studied in the present study.
Figure V.1. Chemical Structures of the Formulation Components of Albuterol Sulfate
HFA Suspension pMDIs studied
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The molecular structure of albuterol sulfate was downloaded directly from the
Cambridge small molecule crystallographic database. The crystal structure of a compound
can be described in terms of a unit cell, which is the smallest arrangement of molecules,
having the same symmetry and properties as that of the crystal; the unit cell repeats itself
in a regular pattern to form a crystal lattice. The terms a, b, and c are the lengths of the
edges of the unit cell while α, β and γ are the inclination angles of the edges of the unit
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cell. The space group is a mathematical description of the symmetry inherent to a crystal
structure. Albuterol sulfate consists of a monoclinic crystal structure and has the following
parameters: a = 28.069, b = 6.183, c = 16.914 Å, α= γ=90˚, β = 81.9˚, Cc space group
(Leger et al. 1978).
The chemical structures of HFA 134a, ethanol and oleic acid were drawn in Sybyl
and energy minimization was performed. In the present study, energy minimization was
performed until the difference in the energy values between two consecutive iterations was
0.005 kcal/mol Å or a maximum number of 1000 iterations (Tripos Bookshelf Force Field
Manual 2006). The Gasteiger-Huckel method was employed to calculate the atomic
charges for the molecule.
In order to study the interactions between albuterol sulfate (solvate) and the
propellant (HFA 134a) molecules surrounding it, the explicit solvation technique available
in Sybyl was used. The ‘Precomputed Box’ option in the ‘Solvent’ algorithm in Sybyl was
used to create a three-dimensional periodic box lattice for the optimized molecular model
of HFA 134a. The 3-D solvent lattice was generated and optimized; the density of HFA
134a at room temperature (1.21 g/cm3 at 20 °C; Purewal 1998) was specified in the
algorithm in order to simulate the pressurized liquid within the pMDI canister. The
molecule of interest was solvated in the solvent box, i.e., it was placed in the solvent box
and the energy of this solvate-solvent system was minimized. The process of energy
minimization was used to optimize the conformation of solvent molecules in the vicinity of
the solvate molecule in the periodic box. Energy minimization was performed with
Gasteiger-Huckel charges and the dielectric constant of HFA 134a (ε = 9.5).
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Using the above technique, an initial prototype molecular model of a single
albuterol sulfate molecule in HFA 134a was built and energy minimized. Following
preliminary investigation of the intermolecular interactions between albuterol sulfate and
HFA 134a molecules, a unit cell of an albuterol sulfate crystal (consisting of eight
molecules of albuterol and 4 sulfate groups; Leger et al. 1978) was used to create the
remaining molecular models for albuterol sulfate suspensions in a propellant medium.
Since non-covalently bonded interaction forces decrease exponentially with distance,
interactions of albuterol sulfate with propellant molecules beyond a distance of 5 Å were
not considered.
In order to study the interactions of oleic acid and ethanol with albuterol sulfate and
HFA 134a, an approximate number of molecules of oleic acid and ethanol were calculated
based on the number of HFA 134a molecules within a 5 Å radius around the albuterol
sulfate unit cell. In the molecular models of the albuterol sulfate unit cell in a HFA 134a
solvent box, an average of 84 molecules of HFA 134a were present within a 5 Å radius of
the unit cell. The concentration of oleic acid and ethanol was assumed to be 0.02% and
15% w/w, corresponding to 0.03% and 19 %v/v, respectively. The approximate number of
oleic acid and ethanol molecules that would occupy 0.03% and 19%, respectively, of the
total volume occupied by an average of 84 molecules of HFA 134a was calculated. 20
molecules of ethanol were placed together with a unit cell of an albuterol sulfate crystal.
Since the number of molecules of oleic acid (0.03% v/v) was less than 1, two oleic acid
molecules were randomly placed near the albuterol sulfate unit cell such as to expose
different regions of the unit cell to the surfactant molecule. The albuterol sulfate unit cell,
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along with the ethanol and oleic acid molecules, was then solvated in a HFA 134a solvent
lattice and energy minimization of this entire system was performed. The density of the
HFA 134a solvent box was maintained constant at 1.21 g/cm3 for all the molecular models
constructed and hence the volume of the box and the number of HFA 134a molecules
included increased in comparison to the model containing only the unit cell in the HFA
solvent box.
For all the molecular models containing unit cell structures of albuterol sulfate, the
positions of the solvated molecules were modified and energy minimization of the system
was performed (n = 3). Following energy minimization, the molecular interactions within
these systems were investigated using the HINT program within Sybyl. The total HINT
score was the sum of individual contributions from the favorable interactions such as
hydrophobic, acid-base and hydrogen bonds, as well as unfavorable interactions, e.g.,
hydrophobic-polar, base-base and acid-acid interactions. HINT also reported the individual
contributions, in addition to the total HINT score, if the absolute value of the scores for the
unfavorable or favorable interactions was greater than 10. Interaction scores lower than 10
would indicate weak interactions possibly due to the increasing distance between the
interacting atoms. Nevertheless, the total HINT score for the interacting molecules
included all those weak interactions. The interactions of the solvated molecule with solvent
molecules beyond a radius of 5 Å around it were not considered since non-covalently
bonded interaction forces decrease exponentially with distance.
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V. D. Results and Discussion
V.D.1. Molecular Models of Albuterol Sulfate Suspensions in HFA 134a

Figure V.2.a shows the molecular model of a single albuterol sulfate molecule in a
HFA 134a solvent box. A single molecule of albuterol sulfate was used to build a
prototype of a simple suspension of albuterol sulfate in HFA 134a in order to study the
interactions between the drug and the propellant molecules. Figure V.2.b shows the
molecular model of albuterol sulfate in HFA 134a, which was used for determining the
interactions between the drug and propellant molecules; only interactions within a 5 Å
radius around the albuterol sulfate molecule were considered.
Figure V.2.a. Model of a Single Albuterol Sulfate Molecule Solvated in HFA 134a
Solvent Lattice
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Figure V.2.b. Molecular Model of Albuterol Sulfate with HFA 134a Molecules Within a 5
Å Radius

Molecular modeling software such as Sybyl is not adapted to study particle
interactions (approximate particle size range 3 - 5 μm). Hence, in order to determine the
feasibility of using Sybyl to build a model of a suspension pMDI, a preliminary prototype
of an albuterol sulfate suspension in HFA 134a was first modeled by solvating a single
albuterol sulfate molecule in a HFA 134a solvent lattice. Although HFA 134a could not be
modeled as a pressurized liquid, the solvent lattice of HFA 134a was created so as to take
the density of the propellant at room temperature (20 °C) into account. In addition, the
dielectric constant used during the energy minimization was specified to be equal to that of
the propellant. In order to obtain a practical model of albuterol sulfate particles suspended
in HFA 134a, a unit cell of an albuterol sulfate crystal (consisting of eight albuterol
molecules and four sulfate groups; Figure V.3) was solvated in HFA 134a using the same
parameters as those set for the initial prototype model of albuterol sulfate molecule in HFA
134a.
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Figure V.3. Model of an Albuterol Sulfate Unit Cell

Two approaches have been employed to formulate commercial albuterol sulfate
HFA suspension pMDIs. Ventolin HFA is a simple suspension of albuterol sulfate in 100%
HFA 134a without any surfactant. Another marketed albuterol sulfate HFA suspension
pMDI, Proventil HFA, is a more complex suspension of albuterol sulfate suspension in
HFA 134a containing oleic acid as a surfactant and ethanol as a cosolvent. In order to
study the interactions of oleic acid and ethanol with albuterol sulfate and HFA 134a,
molecular models containing an albuterol sulfate unit cell, 2 molecules of oleic acid and 20
molecules of ethanol solvated in a HFA 134a solvent box were created. Figure V.4 shows
the albuterol sulfate unit cell as a space-filling model with ethanol and oleic acid molecules
placed in the vicinity of the unit cell. Figure V.5 shows the three solvated components
surrounded by HFA 134a molecules within a 5 Å radius.

90
Figure V.4.

Representative Model of the Albuterol Sulfate Unit Cell (Space-filling
Model) Along with Ethanol and Oleic Acid Molecules in the Vicinity of the
Unit Cell

Figure V.5.

Molecular Model of Albuterol Sulfate Unit Cell, Oleic Acid and Ethanol
Molecules Surrounded by HFA 134a Molecules Within a 5 Å Radius

The molecular interactions within these optimized molecular models of albuterol
sulfate HFA suspensions were analyzed using the HINT program.
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V.D.2. Interactions within Albuterol Sulfate HFA Suspensions
V.D.2.1. Interactions Between Albuterol Sulfate and HFA 134a Molecules

The HINT program accounted for the interactions between a single molecule of
albuterol sulfate and each individual HFA 134a molecule within the 5 Å radius around it.
For the molecular model containing a single albuterol sulfate molecule, 31 molecules of
HFA 134a were within this range. The composite logP value calculated by the HINT
program for the 31 molecules of HFA 134a was 36.51. Therefore, the logP for a single
molecule of HFA 134a could be approximated to be 1.17, which was in good agreement
with that reported in literature (logPo/w: 1.06; Solvay Chemicals Solkane 134a MSDS
2003). The logP value for the albuterol sulfate molecule determined by HINT was -15.82.
The HINT program calculates the logP based on the hydrophobic atom constants (a) for
each atom in the molecule and denotes the hydrophobic nature of the molecule. The logP
value can be positive or negative depending on the hydrophobic or polar nature of the
atoms present in the molecule since a < 0 for polar atoms e.g. oxygen and halogen atoms
and positive for hydrophobic atoms e.g. carbon. The logP values suggested that HFA 134a
molecule was hydrophobic in comparison to albuterol sulfate.
Figure V.6 shows the chemical structure of HFA 134a, which contains two small
asymmetrically placed hydrogen atoms along with the electronegative fluorine atoms
together forming the mantel (surface atoms) of the molecule. The presence of
electronegative fluorine atoms creates distinct dipoles in the carbon-hydrogen bonds in
HFA 134a.
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Figure V.6.

Chemical Structure of HFA 134a and the Hydrophobic Atom Constants for
the Carbon and Fluorine Atoms in HFA 134a
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The fluorine atom (F5) attached to C2 (which also has the two asymmetric hydrogen atoms
(H3 and H4) attached to it) has a negative hydrophobic atom constant of –0.428. Due to the
dipole created between the C-H bonds in HFA 134a, C2 also has a negative hydrophobic
atom constant of –0.472. The hydrophobic atom constant calculated by HINT for all three
fluorine atoms (F6, F7, F8) attached to C1 was +0.255, while that for C1 was 0.984 implying
that these atoms are hydrophobic relative to C2 and F5. Thus the fluorine atoms in HFA
134a show both hydrophobic as well as polar (electronegative) characteristics.
The total HINT interaction score was calculated as the sum of the individual HINT
scores for interactions between albuterol sulfate and each of the 31 molecules of HFA
134a. Table V.1 summarizes the individual contributions from the various non-covalent
interactions including hydrophobic, hydrogen bonding, acid-base, hydrophobic-polar and
base-base, to the total HINT score.
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Table V.1. HINT Score Analysis for the Contributing Interactions Within a Molecular
Model of a Single Albuterol Sulfate Molecule in HFA 134a

Hydrophobic

H-Bond

960

469

Type of Interaction
Acid-Base Hydrophobic/
Polar
150
-3402

Base-Base

Total

-720

-2543

The total HINT score was predominantly negative (HINT score: -2543) signifying
unfavorable interactions between the albuterol sulfate molecule and the surrounding HFA
134a molecules. Hydrophobic interactions, hydrogen bonds and acid-base interactions
contributed to favorable or positive interaction scores between albuterol sulfate and HFA
134a molecules while hydrophobic-polar and base-base interactions accounted for the
unfavorable or negative HINT scores. Table V.1 shows that negative or unfavorable
interactions were predominantly contributed by hydrophobic-polar interactions in the
albuterol sulfate / HFA 134a system. Hydrophobic-polar interactions arise when polar
atoms or groups, either acidic or basic, are either trapped in a hydrophobic pocket or come
in close proximity to the hydrophobic groups of the neighboring molecule). These
interactions represent the energy required to desolvate the polar groups and place them in
an unfavorable (hydrophobic) environment and hence are negatively scored by HINT
(Kellogg and Abraham 2000).
Figure V.7.a summarizes the likely interactions between atoms, which could
contribute to favorable interactions between albuterol sulfate and HFA 134a molecules as
determined by HINT analysis. Hydrophobic interactions included those between carbon
atoms on the side chain of albuterol sulfate and the two carbon atoms present in HFA 134a.
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Interactions between the sulfur (sulfate group) of albuterol sulfate and carbon atoms of
HFA 134a have also been classified as favorable hydrophobic type, however, this
interaction is unlikely to occur and may therefore be an artefact. Interactions between
fluorine atoms of HFA 134a connected to C1 and carbon atoms on the albuterol sulfate side
chain were also hydrophobic in nature which would be expected since fluorine atoms in the
-CF3 group of HFA 134a were classified as having hydrophobic character (a = +0.255).
Figure V.7.a. Examples of Favorable Non-covalent Interactions Between Albuterol
Sulfate and HFA 134a Molecules
Hydrophobic interactions between CH3 of
albuterol sulfate and CF3 of HFA 134a

Hydrophobic interactions between C1 and S1

Acid-base or H-bond interactions between N and F, O and F

In addition to its hydrophobic character in HFA 134a, since fluorine atom needs
only one electron to completely fill its valence shell, the atom is very electronegative and
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may therefore also contribute to acid-base type interactions with polar groups in albuterol
sulfate. Figure V.7.a displays possible acid-base interactions including those between
fluorine atoms of HFA 134a and the -OH or -NH group of the albuterol sulfate molecule.
When the distance between the interacting atoms is less than 3.65 Å, acid-base interactions
were classified as hydrogen bonds. The hydrogen bond length between fluorine atoms of
HFA 134a and the oxygen (hydroxyl group) or nitrogen (amine group) atoms of albuterol
sulfate ranged from 2.67 - 3.65 Å. Figure V.7.a displays hydrogen bonds (shown as -----)
between albuterol sulfate and HFA 134a molecules. Figure V.7.b illustrates the likely
atoms involved in unfavorable interactions between albuterol sulfate and HFA 134a
molecules.
Figure V.7.b. Examples of Unfavorable Non-covalent Interactions Between Albuterol
Sulfate and HFA 134a Molecules
Hydrophobic-polar interactions between C1 and O

Base-Base Interactions between C1 and N

Base-Base Interactions between F7 and O10

96
Negative HINT scores were contributed by unfavorable interactions between the
hydrophobic carbon atoms of the HFA 134a molecule and the polar oxygen (hydroxyl) or
nitrogen (amine) atoms of the albuterol base molecule. Unfavorable base-base type
interactions included those between the fluorine atoms of HFA 134a and the oxygen atoms
attached to the sulfate group of the albuterol sulfate molecule.
Placing the solvate (albuterol sulfate) molecule in the solvent (HFA 134a) box
involves removal of solvent molecules to fit in the solvate molecule, and this may
sometimes result in either empty spaces between the solvate and the surrounding solvent
molecules or the solvate and some of the solvent molecules being placed too close
together. Minimization of energies will prevent any unreasonable interactions between
closely placed molecules by optimizing the conformation of the molecules. However, a
visual check was performed to ensure that the negative interactions were not due to the
solute and solvent molecules placed too close to each other.
Since albuterol sulfate consists of polar hydroxyl groups on its surface (Figure
V.1), formation of hydrogen bonds with the mantel fluorine atoms would be expected,
while interactions between the sulfate group and fluorine atoms would be repulsive.
Solubility of albuterol sulfate in 100% HFA 134a has been reported to be negligible (lower
than 0.0005 µg/mg using a UV-Visible detection technique; Tzou et al. 1997), which
would be predictable since the interactions between the two molecules were observed to be
predominantly unfavorable.
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V.D.2.2.

Interactions between the Albuterol Sulfate Unit Cell and HFA 134a
Molecules

For the molecular model containing an albuterol sulfate unit cell in HFA 134a, the
interaction of the unit cell with an average of 84 molecules of HFA 134a within a 5 Å
radius was considered. The HINT calculated logP values for the albuterol sulfate unit cell
and the surrounding HFA 134a molecules were –63.65 and 143, respectively. Since four
units of the albuterol sulfate molecule are present in the unit cell of the crystal, the
calculated LogP for the unit cell was approximately four times that of a single albuterol
sulfate molecule. Table V.2 summarizes the individual contributions to the total HINT
score for the interactions of the albuterol sulfate unit cell with each of the surrounding
HFA 134a molecules.
Table V.2. HINT Score Analysis with the Contributing Interactions for the Albuterol
Sulfate Unit Cell Solvated in HFA 134a
Albuterol
Type of Interaction
sulfate unit
Hydrophobic/
cell in HFA Hydrophobic H-Bond Acid/Base
Base/Base Total
Polar
134a
1
4158
1412
1918
-10108
-6503
-9122
2
4284
2582
2067
-9958
-7395
-8420
3
3373
1531
1706
-6920
-4940
-5249
Mean
3939
1842
1897
-8995
-6280
-7597
SD
494
644
182
1799
1243
2063
The mean total HINT score was negative (-7597 ± 2063) and small changes in the
position of the unit cell of albuterol sulfate within the HFA 134a solvent box did not cause
a marked change in the total HINT interaction score. The interactions remained similar to
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those observed for the albuterol sulfate molecule-HFA 134a model but the scores were
higher since both the number of albuterol sulfate molecules and the HFA 134a molecules
surrounding the unit cell were higher. In order to obtain a better understanding of all the
possible interactions between the unit cell and HFA 134a molecules and to have
confidence in the HINT scores for these interactions, a large number of replicates
(approximately 20 replicates) would be required. Nevertheless, this pilot study provided a
theoretical understanding of intermolecular interactions possible within an albuterol sulfate
- HFA 134a suspension pMDI.
Further analysis of the individual HINT scores for interactions between the
albuterol sulfate unit cell and each individual HFA 134a molecule revealed that the HINT
interaction scores could be either positive or negative depending upon the relative position
of the molecules (Appendices A.III.1 and A.III.2). The majority of the HFA 134a
molecules (an average of 73% of HFA 134a molecules) surrounding the albuterol sulfate
unit cell exhibited a net negative HINT score. Fewer hydrophobic-polar and base-base
interactions were found for HFA 134a molecules with net positive interactions with the
albuterol sulfate unit cell as compared to those with a net negative HINT interaction score.
The range of net negative HINT scores obtained for interactions between the albuterol
sulfate unit cell and a single molecule of HFA 134a was –1 to –1080, while the net positive
HINT scores for albuterol sulfate unit cell interacting with individual HFA 134a molecules
was +1 to +239 over the three models studied. The average HINT score calculated for net
positive and negative interactions between albuterol sulfate and a single HFA 134a
molecule were +35 ± 18 and –136 ± 32, respectively.
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The present study showed that interactions between albuterol sulfate and HFA 134a
molecules are a composite of hydrophobic and polar interactions. Since most of the
interactions between the two molecules are accounted for by unfavorable hydrophobicpolar interactions, it would not be unexpected to observe drug adhesion to canister walls
and/or the valve-metering chamber in pMDIs. Recent studies employing AFM and surface
energy measurements have demonstrated that adhesion of drug particles such as albuterol
sulfate to canister material such as aluminum or PTFE was dependent on both the
dispersive and polar components of particle interactions in a model HFA propellant
(HPFP) (Traini et al. 2006). In the present study, interactions between albuterol sulfate and
HFA 134a were observed to be a function of both unfavorable hydrophobic-polar and
base-base interactions as well as favorable hydrophobic and polar acid-base interactions.
Future studies using molecular modeling of albuterol sulfate in HFA 134a in the presence
of different canister coating materials may provide an improved understanding of these
experimentally derived results.

V.D.2.3. Interactions within Albuterol Sulfate Suspensions in HFA 134a containing
Oleic Acid and Ethanol

Table V.3 displays the HINT calculated logP values for the formulation
components of the molecular model of albuterol sulfate HFA suspension pMDI containing
ethanol and oleic acid. The logP values for albuterol sulfate and HFA 134a were similar to
those obtained for the albuterol sulfate unit cell-HFA 134a model. Oleic acid has a high
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logP value (7.61) indicating its hydrophobic nature. A negative logP of –0.32 signifies the
polar nature of ethanol.

Table V.3. LogP of Formulation Components of Albuterol Sulfate Suspension pMDI
Calculated by HINT
Formulation Components
Total number of
Total logP
LogP/Molecule
molecules
Albuterol Sulfate Unit Cell
4
-63.65
-15.91
Oleic Acid
2
15.22
7.61
Ethanol
20
-6.48
-0.32
HFA 134a (Average)
169
142
0.84

In order to determine the interactions within this complex albuterol sulfate HFA
formulation, interactions between each of the following components: albuterol sulfate,
oleic acid and ethanol with the surrounding HFA 134a molecules were individually
analyzed using HINT. Interactions between albuterol sulfate, oleic acid and ethanol
molecules were also analyzed. The HINT scores for the three molecular models built and
optimized by changing the positions of the solvated molecules within the HFA 134a
solvent box have been summarized in Table V.4. These scores are the sum of the
interactions between individual molecules within the model. It was observed that the total
HINT interaction score for all the molecules studied was net negative with the exception of
interactions between oleic acid and HFA 134a molecules suggesting that the net
interactions between oleic acid and HFA 134a were favorable.
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Table V.4

Summary of the Mean HINT Scores for Interactions Between the Albuterol
Sulfate Unit Cell, Oleic Acid, Ethanol and HFA 134a Molecules. Values in
Parentheses are Standard Deviation (n=3 models)

Interacting Molecules
Molecule
1

HFA 134a

Albuterol
Sulfate
Unit Cell

Oleic
Acid

Ethanol

Type of Interaction
Hydrophobic

H-bond

Acid/
Base

Hydrophobic/
Polar

Base/
Base

Total

2641
(491)

1435
(87)

1443
(167)

-6850
(208)

-5200
(582)

-6531
(1366)

Oleic
Acid

2619
(1263)

344
(102)

537
(159)

-1878
(553)

-1148
(401)

474
(1266)

Ethanol

6774
(564)

2685
(24)

1426
(42)

-8321
(341)

-4605
(214)

-2041
(486)

HFA
134a

2641
(491)

1435
(87)

1443
(167)

-6850
(208)

-5200
(582)

-6531
(1366)

378
(269)

305
(239)

328
(127)

-1326
(889)

-426
(306)

-846
(581)

Ethanol

936
(190)

3025
(307)

1565
(189)

-4686
(819)

-2940
(396)

-3584
(810)

HFA
134a

2619
(1263)

344
(102)

537
(159)

-1878
(553)

-1148
(401)

474
(1266)

Albuterol
sulfate
unit cell

378
(269)

305
(239)

328
(127)

-1326
(889)

-426
(306)

-846
(581)

Ethanol

212
(90)

161
(280)

223
(223)

-547
(206)

-211
(271)

-229
(113)

HFA
134a

6774
(564)

2685
(24)

1426
(42)

-8321
(341)

-4605
(214)

-2041
(486)

Albuterol
sulfate
unit cell

936
(190)

3025
(307)

1565
(189)

-4686
(819)

-2940
(396)

-3584
(810)

Oleic
Acid

212
(90)

161
(280)

223
(223)

-547
(206)

-211
(271)

-229
(113)

Molecule
2
Albuterol
sulfate
unit cell

Oleic
acid
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The interactions within the molecular model of albuterol sulfate molecule and the
unit cell in HFA 134a alone were simpler to analyze since the models contained only two
components. However, the analysis of the interactions within a complicated formulation of
albuterol sulfate in HFA 134a containing ethanol and oleic acid becomes challenging. Due
to the nature of the HINT program, the interactions between all four components could not
be analyzed simultaneously. Instead, the interactions between two components were
analyzed individually and the results are summarized in Table V.4. The individual
interactions summarized in Table V.4 will be discussed separately in the following
sections.

V.D.2.3.a. Interactions Between the Albuterol Sulfate Unit Cell and HFA 134a in the
Presence of Oleic Acid and Ethanol

Table V.5 summarizes the total HINT scores and the contribution of the favorable
and unfavorable interactions of albuterol sulfate with HFA 134a molecules in the presence
of oleic acid and ethanol. Table V.5 shows that the interactions between the albuterol
sulfate unit cell and the surrounding HFA 134a molecules were predominantly unfavorable
(-6531 ± 1336) as observed in Section V.D.2. The types of atoms involved in the
interactions characterized by HINT were similar to those described in Section V.D.2. Table
V.5 shows that the mean total HINT score was similar to that obtained for albuterol sulfate
unit cell in HFA 134a alone (-7597 ± 2063).
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Table V.5. HINT Score Analysis with the Contributing Interactions for Albuterol Sulfate
Unit Cell Solvated in HFA 134a Containing Oleic Acid and Ethanol
Albuterol sulfate
Type of Interaction
unit cell/ HFA
Hydrophobic/
134a
Hydrophobic H-bond Acid/Base
Polar
Base/Base Total
1
3199
1387
1621
-6636
-4529
-4959
2
2448
1536
1417
-7051
-5557
-7206
3
2276
1383
1291
-6865
-5515
-7429
Mean
2641
1435
1443
-6850
-5200
-6531
SD
491
87
167
208
582
1366
An average of 107 molecules of HFA 134a showed significant interactions with the
unit cell of albuterol sulfate with 68% of the HFA 134a molecules exhibiting net negative
interactions. Appendices A.III.3 and A.III.4 show the summary of net positive and
negative interactions for the albuterol sulfate unit cell with HFA 134a molecules in the
presence of oleic acid and ethanol. The maximum net negative HINT score for interactions
between the albuterol sulfate unit cell and individual HFA 134a molecules was –1119
while that for net positive interactions between albuterol sulfate unit cell and a single HFA
134a molecule was +249. The average net negative and positive HINT scores calculated
for interactions between the unit cell and a single HFA 134a molecule were –97 ± 1 and
+14 ± 11, respectively. Unfavorable interactions were predominant similar to that observed
for the albuterol sulfate unit cell-HFA 134a model.
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V.D.2.3.b.

Interactions between Oleic Acid and HFA 134a molecules in the
Presence of Albuterol Sulfate and Ethanol

Table V.6 shows that the average total HINT score for interactions between oleic
acid and HFA 134a molecules was +474 ± 1266. The variability in the total HINT scores
was high as shown in Table V.6. For the first model, the HINT score was net negative (632) while it was positive for the other two models (199 and 1855). Changing the position
of oleic acid molecules with respect to the albuterol sulfate unit cell in the molecular model
resulted in favorable interactions between oleic acid and the surrounding HFA 134a
molecules. The hydrophobic interactions between oleic acid and HFA 134a molecules
were predominantly responsible for the favorable interactions.
Table V.6. HINT Score Analysis with the Contributing Interactions for 2 Oleic Acid
Molecules Solvated in HFA 134a in the Presence of Albuterol Sulfate Unit
Cell and Ethanol
Type of Interaction
Oleic acid/
Hydrophobic/
HFA 134a Hydrophobic H-bond
Acid/Base
Polar
Base/Base Total
1
2172
444
643
-2448
-1443
-632
2
1640
240
354
-1344
-691
199
3
4044
348
613
-1842
-1309
1855
Mean
2619
344
537
-1878
-1148
474
SD
1263
102
159
553
401
1266
Since the two oleic acid molecules in the molecular model were arbitrarily placed
in the vicinity of the albuterol sulfate unit cell, not all HFA 134a molecules present in the
molecular model interacted with the two oleic acid molecules since the interactions
between the molecules decrease exponentially as a function of distance. An average of 59
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molecules of HFA 134a exhibited significant interactions with the oleic acid molecules. It
was observed that an average of 40 HFA 134a molecules exhibited favorable interactions
with the oleic acid molecules while an average of 18 HFA 134a molecules exhibited net
unfavorable interactions (Appendices A.III.5 and A.III.6). The average net positive HINT
score for interactions between oleic acid and a single HFA 134a molecule was estimated to
be 39 ± 11, which was lower than the average net negative HINT score (-63 ± 11). The
maximum net positive score for interactions between oleic acid molecules and a single
molecule of HFA 134a was +170, while that for net negative HINT score was –296.
Unfavorable hydrophobic-polar and base-base interactions were predominant for the
molecules with a net negative HINT interaction score.
Figures V.8.a summarizes the atoms involved in the favorable interactions between
oleic acid and HFA 134a molecules as determined by HINT. Interactions between any of
the three fluorine atoms attached to C1 of HFA 134a with the non-polar carbon atoms on
oleic acid was classified as a favorable hydrophobic interaction (Figure V.8.a). Favorable
acid-base interactions included those between –COOH group of oleic acid and the fluorine
atoms in the HFA 134a molecule. Hydrophobic interactions also involved the non-polar
carbon atoms, for example, as shown in Figure V.8.a, interactions between C6 on the oleic
acid and C1 on the HFA 134a molecule.
Figure V.8.b shows some of the possible unfavorable interactions, which included
hydrophobic-polar as well as base-base interactions. Hydrophobic-polar interactions
included interactions between the polar –COOH group of oleic acid and the carbon atoms
in HFA 134a as well as interactions with any of the fluorine atoms attached to C1. Base-

106
base interactions included those between –COO- of oleic acid and the fluorine atoms of
HFA 134a.
Figure V.8.a. Examples of Favorable Interactions Between Oleic Acid and HFA 134a
Molecules
Hydrophobic interactions between C4 and F8

Acid-Base interactions between F5 and –COOH

Hydrophobic interactions between C6 and C1

Figure V.8.b. Examples of Unfavorable Interactions Between Oleic Acid and HFA 134a
Molecules
Hydrophobic-Polar Interactions between C1 and O

Base-Base Interactions Between F6 and O
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Oleic acid is insoluble in HFA 134a and hence cannot be used as a suspending
agent in suspensions containing HFA 134a alone. Ethanol is used as a cosolvent for oleic
acid in HFA suspension pMDIs. It has been suggested that the reason for the poor
performance of oleic acid as a surfactant in suspensions containing HFA 134a alone may
possibly be the unfavorable interactions between the polar HFA 134a molecules and the
hydrophobic portion of oleic acid (Byron et al. 1994). However, the same study has shown
that precoating micronized albuterol with oleic acid before formulating a suspension in
HFA 134a alone increased the time required for the drug to flocculate indicating that
restricting the surface interactions of oleic acid molecules may improve its surfactant
behavior in HFA 134a in the absence of a cosolvent. Analysis of molecular interactions
between oleic acid and HFA 134a in the models of albuterol sulfate suspension in HFA
134a containing oleic acid and ethanol indicated that in addition to the unfavorable
interactions between oleic acid and HFA 134a due to hydrophobic-polar interactions,
favorable interactions between oleic acid and HFA 134a molecules were also likely due to
both hydrophobic and acid-base type interactions.

V.D.2.3.c.

Interactions between Ethanol and HFA 134a molecules in the presence
of Albuterol Sulfate and Oleic Acid

Table V.7 summarizes the HINT scores for interactions between ethanol molecules
and the surrounding HFA 134a molecules along with the individual contributions to the
total HINT score.
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Table V.7. HINT Score Analysis with the Contributing Interactions for 20 Ethanol
Molecules Solvated in HFA 134a in the Presence of Albuterol Sulfate Unit
Cell and Oleic Acid
Type of Interaction
Ethanol/
HFA
Hydrophobic/
134a
Hydrophobic H-bond
Acid/Base Polar
Base/Base Total
1
6123
2710
1396
-8244
-4384
-2399
2
7112
2684
1473
-8694
-4811
-2235
3
7087
2662
1408
-8025
-4620
-1488
Mean
6774
2685
1426
-8321
-4605
-2041
SD
564
24
42
341
214
486
The mean total HINT score was negative (-2041 ± 486) for interactions between 20
ethanol molecules and an average of 143 molecules of HFA 134a. The contribution of
hydrophobic interactions to the favorable interactions was higher than that of hydrogen
bonds and acid-base interactions. Most of the unfavorable interactions were contributed by
the hydrophobic-polar interactions between the cosolvent and propellant molecules. Basebase interactions also contributed to the unfavorable interactions.
Appendices A.III.7 and A.III.8 provides a summary of the net positive and negative
HINT scores for interactions between ethanol and HFA 134a molecules. The average
number of HFA 134a molecules in the model exhibiting positive interactions (74 ± 7) with
ethanol molecules was not significantly different (p < 0.05) than those exhibiting negative
interactions (69 ± 11). The average net positive and negative HINT scores for interactions
between ethanol molecules with an individual HFA 134a molecule were 26 ± 5 and –59 ±
11, respectively. The maximum net positive HINT score for interactions between ethanol
and a single HFA 134a molecule for the three molecular models tested was +128 while that
for the net negative score was –326. It was observed that hydrophobic interactions between
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ethanol and HFA 134a molecules were predominantly responsible for the net positive
interaction scores while hydrophobic-polar interactions were predominantly responsible for
the net negative HINT score.
Figure V.9.a illustrates examples of favorable interactions between ethanol and
HFA 134a molecules. Interactions between the carbon atoms of ethanol and HFA 134a
molecules would be hydrophobic while acid-base or H-bonds would be contributed by
interactions between the hydroxyl group of ethanol and fluorine atoms of HFA 134a.
Figure V.9.a. Examples of Favorable Interactions Between Ethanol and HFA 134a
Molecules
Hydrophobic Interactions between C1 of HFA
and C2 of ethanol

Acid-base Interactions between F8 of HFA and
-OH of ethanol

Figure V.9.b shows some of the possible unfavorable interactions between ethanol
and HFA 134a molecules. Interactions between the carbon atoms (e.g. C1) of the HFA
134a molecule and the hydroxyl group of ethanol as well as those between carbon atoms of
ethanol (e.g. C1) and the fluorine atom (F5) attached to the C1 atom of HFA 134a were
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classified as hydrophobic-polar. Base-base interactions would possibly involve interactions
between the hydroxyl group of ethanol and fluorine atoms of HFA 134a.
Figure V.9.b. Examples of Unfavorable Interactions Between Ethanol and HFA 134a
Molecules

Hydrophobic-polar interactions between C1 of HFA
and –OH of ethanol

Base-base interactions between F7 of HFA and –OH
of ethanol

Hydrophobic-polar interactions between F5 of HFA
and C1 of ethanol

Conventional wisdom suggests that interactions between ethanol and HFA 134a
would be favorable owing to the polar nature of ethanol as well as due to the possibility of
strong dipole formation in HFA 134a molecule (Vervaet and Byron 1999). In the present
study, ethanol molecules were placed arbitrarily around the albuterol sulfate unit cell,
hence interactions between HFA 134a molecules and the ethanol molecules within such a
molecular model will depend on both the distance and the orientation of the molecules.
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Although, the interactions were predominantly unfavorable, there was evidence of
favorable polar interactions, e.g., acid-base and hydrogen bonding between ethanol and
HFA 134a molecules.

V.D.2.3.d.

Interactions Between Albuterol Sulfate, Oleic Acid and Ethanol
Molecules in the presence of HFA 134a

Interactions between the solvate components of the molecular model containing
albuterol sulfate, oleic acid and ethanol in HFA 134a were analyzed using HINT and the
results are shown in Tables V.8 - V.10. Each set of interactions will be discussed
separately.

Molecular Interactions between the Albuterol Sulfate Unit cell and Oleic Acid

Table V.8 summarize the total HINT scores for interactions between the albuterol
sulfate unit cell and oleic acid molecules in the presence of ethanol and HFA 134a.
Table V.8. HINT Score Analysis with the Contributing Interactions for Albuterol Sulfate
Unit Cell with Oleic Acid in the Presence of Ethanol and HFA 134a
Albuterol
Type of Interaction
Sulfate Unit
Cell/ Oleic
Hydrophobic/
Acid
Hydrophobic H-bond Acid/Base
Polar
Base/Base Total
1
473
40
184
-1228
-109
-659
2
586
371
372
-2260
-451
-1497
3
74
504
427
-491
-718
-381
Mean
378
305
328
-1326
-426
-846
SD
269
239
127
889
306
581

112
The HINT scores suggested that interactions between albuterol sulfate and oleic
acid were unfavorable (-846 ± 581), which were predominantly due to hydrophobic-polar
interactions. Changes in the position of oleic acid molecules resulted in a decrease in
hydrophobic interactions while the number of H-bond and acid-base interactions increased
as shown in Table V.8. It was observed that the unfavorable hydrophobic-polar
interactions decreased from –1228 for molecular model 1 to –491 for model 3. However,
the total unfavorable base-base interactions increased from –108 to -718.
Figure V.10.a shows some of the possible interactions between albuterol sulfate
and oleic acid molecules contributing to favorable interactions.
Figure V.10.a. Examples of Favorable Interactions Between Albuterol Sulfate and Oleic
Acid Molecules
Favorable Acid-Base Interaction between N and O

Favorable Hydrophobic Interactions between carbon
atoms

Favorable hydrophobic interaction between C2 of oleic acid and S of albuterol sulfate
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Favorable acid-base interactions included those between the oxygen atoms of the –COOH
group of oleic acid and nitrogen from the amine group in albuterol sulfate. Figure V.10.a
illustrates the favorable interactions contributed by hydrophobic interactions between
carbon atoms of oleic acid and either carbon or sulfur atoms of albuterol sulfate.
Figure V.10.b shows examples of unfavorable interactions between albuterol sulfate and
oleic acid. Interactions between the hydrophobic carbon atoms of oleic acid and polar amine
or hydroxyl groups of the albuterol sulfate molecule were classified as unfavorable
interactions.

Figure V.10.b. Examples of Unfavorable Interactions Between Albuterol Sulfate and Oleic
Acid Molecules

Unfavorable hydrophobic-polar interaction
between carbon atoms of oleic acid and amine
group of albuterol sulfate

Unfavorable hydrophobic-polar interaction
between C18 and hydroxyl group
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The interactions between oleic acid and the albuterol sulfate unit cell determined by
HINT were dependent on the placement of the surfactant molecules around the unit cell in
the model. The oleic acid molecules were arbitrarily placed near the albuterol sulfate unit
cell and small changes in the orientation of the molecules with respect to the unit cell were
made for the three molecular models. It may be possible to obtain a more representative
value for the HINT scores for interactions between albuterol sulfate and oleic acid by
repeating the above procedure multiple times, however, this would result in increased
computational time for optimizing the models generated.
Molecular Interactions between Albuterol Sulfate unit cell and Ethanol molecules

Table V.9 shows that interactions between albuterol sulfate and ethanol were found
to be predominantly negative (-3584 ± 810). The individual interaction scores contributing
to the total HINT score were in the same order of magnitude between the three molecular
models.
Table V.9. HINT Score Analysis with the Contributing Interactions for Albuterol Sulfate
Unit Cell with Ethanol Molecules Solvated in HFA 134a
Albuterol
Type of Interaction
Sulfate
Unit Cell/
Hydrophobic/
Ethanol Hydrophobic H-bond
Acid/Base Polar
Base/Base Total
1
1155
2875
1711
-5624
-3201
-4512
2
839
3378
1633
-4322
-3134
-3216
3
814
2823
1352
-4112
-2484
-3024
Mean
936
3025
1565
-4686
-2940
-3584
SD
190
307
189
819
396
810
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Figure V.11.a shows some of the possible interactions between albuterol sulfate
and ethanol molecules contributing to favorable interactions. Favorable hydrophobic
interactions included those between the carbon atoms of albuterol sulfate and ethanol
molecules.

Figure V.11.a also illustrates the favorable acid-base or hydrogen bond

interactions between the hydroxyl groups of the two molecules. Figure V.11.b illustrates
examples of possible unfavorable interactions between atoms of albuterol sulfate and
ethanol. For example, as shown in Figure V.11.b, hydrophobic-polar interactions would
include those between C1 of ethanol and O3 of albuterol sulfate. Hydrophobic-polar
interactions can also be contributed by interactions between the sulfur group of albuterol
sulfate and hydroxyl group of ethanol while base-base interactions can involve interactions
between the hydroxyl group of ethanol and oxygen atom from the sulfate group of
albuterol sulfate.
Figure V.11.a. Examples of Favorable Interactions Between Albuterol Sulfate and Ethanol
Molecules
Favorable Hydrophobic Interactions between
C25 and C1

Favorable H-bond between the oxygen atoms
attached to C2 of ethanol and C13 of albuterol sulfate
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Figure V.11.b Examples of Unfavorable Interactions Between Albuterol Sulfate and
Ethanol Molecules
Unfavorable hydrophobic-polar
interactions between C1 and O3

Unfavorable hydrophobic-polar interactions
between S1 and O3 and base-base interactions
between O3 and O10

Ethanol is a polar molecule capable of forming hydrogen bonds with polar
molecules such as albuterol sulfate within these formulations (Tzou et al. 1997), hence the
interactions between the two molecules would be expected to be net positive or favorable.
However, molecular modeling results showed that interactions between the two molecules
were made up of both negative hydrophobic-polar and positive acid-base interactions. The
orientation of the ethanol molecules as well as the distance between the respective atoms
involved in the interactions would influence the interactions determined by HINT. In order
to obtain a more reliable HINT score, all the likely interactions between ethanol and the
albuterol sulfate unit cell arising from possible conformation of ethanol molecules with
respect to albuterol sulfate would have to be considered. Although the three molecular
models tested may not completely represent the possible particle interactions within an
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albuterol sulfate suspension pMDI, an indication of the likely types of interactions could
be obtained from the analysis of these models.
Molecular Interactions between Oleic Acid and Ethanol Molecules

Interactions between oleic acid and ethanol molecules are summarized in Table
V.10. The average net HINT score for interactions between oleic acid and ethanol was
negative (-229 ± 113). As observed in the Table V.10, the individual contributions e.g.
hydrogen-bonding, acid-base and base-base interaction scores to the total HINT score
increased from model 1 to model 3 due to the change in the positions of oleic acid and
ethanol molecules. Since the oleic acid and ethanol molecules were randomly placed
within the solvent box, it may be possible that some of the ethanol molecules do not
interact with the oleic acid molecules or may exhibit weak interactions.
Table V.10. HINT Score Analysis with the Contributing Interactions Between Oleic Acid
and Ethanol Molecules Solvated in HFA 134a
Oleic
Type of Interaction
Acid/
Hydrophobic/
Ethanol Hydrophobic H-bond
Acid/Base Polar
Base/Base Total
1
316
0
58
-662
-38
-340
2
167
0
135
-308
-72
-114
3
153
484
476
-669
-523
-232
Mean
212
161
223
-547
-211
-229
SD
90
280
223
206
271
113

Figure V.12 shows examples of possible unfavorable and favorable interactions
between oleic acid and ethanol molecules. Hydrophobic interactions between the carbon
atoms of oleic acid and ethanol molecules contribute to the favorable interactions. Acid-
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base interactions between the hydroxyl group of ethanol and –COOH group of the oleic
acid molecules were also classified as favorable interactions. Unfavorable interactions
were contributed by hydrophobic-polar interactions. For example, Figure V.12 illustrates
an example of an unfavorable interaction between hydrophobic carbon atom (C1) of oleic
acid and the polar hydroxyl group of ethanol.
Figure V.12. Examples of Favorable and Unfavorable Interactions between oleic acid and
ethanol molecules
Favorable hydrophobic interactions between
carbon atoms of the two molecules

Favorable acid-base interactions between –OH of
ethanol and oxygen atom of –COOH of oleic acid

Unfavorable hydrophobic-polar interactions between
–OH of ethanol and carbon atom of oleic acid

Not all interactions between the two oleic acid molecules and the ethanol molecules
were significant since the oleic acid and ethanol molecules were placed such that selected
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sections of the albuterol sulfate unit cell were exposed to the surfactant and solvent
molecules. As a result, only those ethanol molecules in the vicinity of oleic acid such that
the interacting atoms were at a distance of about 5 Å exhibited significant interactions with
the oleic acid molecules.
In summary, this pilot study involving molecular modeling of albuterol sulfate
HFA suspension pMDIs provided an improved understanding of the possible interactions
between the various components within the formulation. Analysis of interactions in twocomponent models, for example, the interactions between a single albuterol sulfate
molecule and those of the albuterol sulfate unit cell with the surrounding HFA 134a
molecules is possible with HINT. However, the study of interactions within a complex
formulation, e.g., interactions within a molecular model containing albuterol sulfate unit
cell, oleic acid and ethanol molecules solvated in a HFA 134a solvent box are significantly
more challenging compared to the two-component system.
The molecular models were created such that the oleic acid and ethanol molecules
were arbitrarily placed around the albuterol sulfate unit cell and finally placed inside the
solvent box. It was therefore not possible to take into consideration the interactions
between the solvated components within the model for every possible conformation with
respect to the interacting molecules. Also, further analysis of the net negative and positive
HINT scores for interactions per molecule between the solvated molecules, albuterol
sulfate unit cell, oleic acid and ethanol, was not performed. Although, it was possible to
obtain an overall understanding of interactions within a complex albuterol sulfate HFA
suspension pMDI in this pilot study, further studies (large number of replicates) appear
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warranted to better optimize the molecular models and to have increased confidence in the
prediction of the possible interactions within these models.
The use of molecular dynamics could possibly provide improved molecular models
of the albuterol sulfate HFA suspension pMDIs. However, the analysis of the interactions
would still be extensive due to the number of interactions possible between these
components. Nevertheless, molecular modeling in conjunction with the analysis of
interactions using HINT may serve as a useful tool to provide a better understanding of
interactions between pMDI formulation components. Studies could also usefully be
extended to the investigation of canister coating materials used in pMDI canisters.

VI. ELECTROSTATIC CHARGE AND SIZE DISTRIBUTION OF
HYDROFLUOROALKANE (HFA) SOLUTION AND SUSPENSION
PRESSURIZED METERED DOSE INHALERS (pMDIs)

VI.A. Introduction

Aerosol clouds produced by pressurized metered dose inhalers (pMDIs) are highly
charged and these charges may influence particle deposition behavior in the respiratory
tract and valved holding chambers (VHCs) (Melandri et al. 1983, Peart et al. 1998,
Bisgaard et al. 2002). Although, aerodynamic particle size is the major parameter
influencing deposition in pMDIs, studies have also demonstrated that charge can influence
particle deposition from aerosols (Melandri et al. 1983, Balachandran et al. 1991,
Balachandran et al. 1997). In order to understand the impact of pMDI aerosol electrostatics
on drug deposition, in-vitro measurement of aerosol electrostatic properties in relation to
the particle size distribution is important. The modified Electrical Low Pressure Impactor
(ELPI) enables measurement of the charge distribution of aerosol clouds as a function of
particle size, and the simultaneous determination of the mass distribution using chemical
analysis. Electrostatic charge characterization of commercial HFA based solution and
suspension pMDIs using a modified ELPI has been reported (Kwok et al. 2005). QVAR, a
solution HFA pMDI, was found to produce unipolar positively charged aerosol clouds
121
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(mean net charge: +290 ± 230 pC) while suspension pMDIs such as Ventolin HFA and
Flixotide produced bipolar charged aerosol clouds (mean net charge: -1100 ± 220 pC for
Ventolin HFA and +450 ± 30 pC for Flixotide; (Kwok et al. 2005). However, a systematic
study investigating the differences in the electrostatic charging characteristics of solution
and suspension HFA pMDIs is lacking.
The objective of this study was to investigate the influence of formulation
components on the electrostatic charging characteristics of solution and suspension HFA
pMDIs. HFA propelled beclomethasone dipropionate (BDP) solution pMDIs and albuterol
sulfate suspension pMDIs were chosen as the model pMDIs. The mass distributions of the
aerosols produced by drug containing pMDIs were simultaneously characterized by
chemical analysis using the modified ELPI.

VI.B. Materials and Methods
VI.B.1. HFA Propelled Solution pMDIs
VI.B.1.1. Commercially Available HFA Propelled BDP Solution pMDIs

QVAR 40 and 80 µg (Ivax Laboratories Inc., Miami, FL, USA; Lot # ED037A and
Lot # 060086, respectively), BDP solutions in HFA 134a and ethanol, were obtained
commercially and tested prior to their expiry dates.
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VI.B.1.2. Experimental HFA Propelled Solution pMDIs

QVAR pMDI is packaged using 3M Spraymiser valves. However, the experimental
HFA solution pMDIs used in the present study were packaged in canisters crimped with
Valois metered valves. Hence, the contents of QVAR 40 were repackaged into aluminum
canisters fitted with 50 μL Valois metering valves, to allow the comparison of results
which would not be confounded by changes in the particle charge and size distribution due
to different packaging components between commercial and experimental HFA solution
pMDI formulations.
HFA experimental solution pMDIs (lot size: 3 pMDIs for each formulation)
including 100% HFA 134a, an ethanol and propellant blend (7% ethanol / 93% HFA
134a), and a BDP solution (0.08% BDP in 7% ethanol / 93% HFA 134a) were prepared by
weight based on a targeted 10 g fill and packaged in 19 mL aluminum cut-edge canisters
and fitted with Valois DF10/50 RCU/PBT 50 μL metered valves using the technique
described in Chapter III.A.2.1. The BDP solution formulation provided a theoretical exvalve dose of BDP equal to 50 μg / 50 μL.
VI.B.2. HFA Propelled Suspension pMDIs
VI.B.2.1. Commercially Available HFA Propelled Albuterol Sulfate Suspension
pMDIs

Ventolin HFA 100 μg (GlaxoSmithKline, Raleigh, NC, USA; Lot 4ZP3714), an
albuterol sulfate suspension in HFA 134a, was obtained commercially and tested prior to
its expiry date.

124
VI.B.2.2. Experimental HFA Propelled Suspension pMDIs

HFA experimental suspension pMDIs (lot size: 3 pMDIs for each formulation)
including 100% HFA 134a and an albuterol sulfate suspension (0.2% albuterol sulfate in
100% HFA 134a) were prepared by weight based on a targeted 15 g fill and packaged in
19 mL aluminum cut-edge canisters fitted with Valois DF10/50 RCU/PBT 50 μL metered
valves as described in Chapter III.A.2.2. The metering valves used were similar to those
used for packaging Ventolin HFA pMDIs. Each canister of the albuterol sulfate suspension
pMDIs provided a theoretical ex-valve dose of albuterol sulfate equal to 120 μg / 50 μL
(equivalent to 100 μg albuterol base).
In order to test the influence of any soluble impurities on the electrostatic charging
properties of the experimental albuterol sulfate suspension pMDIs, removal of the
suspended drug from the formulations was necessary. The contents of the experimental
0.2% albuterol sulfate / 100% HFA 134a suspension pMDIs were transferred to aluminum
canisters fitted with Valois continuous valves by the cold-filling technique. Briefly, the
pMDI containing the formulation as well as the aluminum canister into which the
formulation was to be transferred were cooled using a mixture of methanol and dry ice,
following which the valve on top of the pMDI was removed, the formulation was quickly
transferred to the chilled empty canister and a continuous valve was crimped in place.
After transfer into canisters with continuous valves, albuterol sulfate suspensions in
HFA 134a (n = 3) were filtered through a filtration assembly (Dalby et al. 1991) into
canisters fitted with Valois continuous valves. The filtration assembly comprised of a
stainless steel microsyringe filter housing containing a 25 mm diameter Type A/E glass
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fiber filter (Pall Corp., Ann Arbor, MI) sandwiched between stainless steel support screens
(Millipore, Bedford, MA). Figure VI.1 is a schematic representation of the filtration
technique used.

Figure VI.1.

Schematic Diagram of the Filtration Assembly used for Filtration of
Albuterol Sulfate Suspensions in HFA 134a

Suspension

Filter

Filtrate

The filtrate obtained was then transferred into canisters fitted with Valois
RCU/PBT DF 10/50 50 μL metered valves using the cold-filling technique described
earlier. These pMDIs were stored overnight in a desiccator before testing to allow for any
electrostatic charge acquired during the filtration process to be discharged through the
conductive aluminum canister. Experimental 100% HFA 134a pMDIs subjected to the
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same treatment, as described for the suspension pMDIs, served as the control pMDIs for
the experiment.
All the experimental solution pMDIs were actuated using polypropylene actuators
with an orifice diameter of 0.7 mm (Valois, Le Vaudreuil, France). The experimental
pMDIs were stored in a desiccator immediately after manufacture and tested within 2
weeks.

VI.B.3.

Determination

of

Electrostatic

Charge

and

Mass

Distribution

of

Commercially Available and Experimental HFA 134a Solution and
Suspension pMDIs using the Modified ELPI

The inherent electrostatic charge and subsequent mass distribution of aerosols
produced by commercially available and experimental HFA 134a pMDIs were determined
using a modified ELPI (Dekati Limited, Tampere, Finland) as described in Chapter III.B.
Single shots of the pMDIs were actuated, n = 5 (5 shots / can, 1 can) for commercial
pMDIs and n = 9 (3 shots / can, 3 cans) for experimental pMDIs, using a randomized block
design, through a USP induction port into a modified ELPI (Figure III.1) operated at
approximately 29 L/min. The canister was shaken for 5 sec and primed by firing either 2 or
4 shots to waste for HFA based solution and suspension pMDIs, respectively. The canister,
fitted with a clean actuator, was then weighed, shaken for 5 sec, and actuated into the
ELPI. The mass of each inhaler was recorded prior to, and following, each actuation into
the ELPI as a procedural check to ensure accurate valve function, by checking to assess
that the shot weight was within 5% of the target weight for that product.
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The electrical current induced on each stage of the impactor by the tribocharged
aerosol particles was measured as a function of time (20 sec); the net charge on each
impactor stage was calculated as the area under the current vs. time curve. Background
current measurements were performed. The correction algorithm employed by the ELPI
software to account for diffusion losses of smaller particles was not used in these
experiments (Dekati Ltd. Technical Note 2002). The net inherent charge of the aerosol
cloud was calculated as the sum of the net charge on each of the impactor stages.
Subsequently, the ELPI was disassembled and the actuator, USP induction port and
thirteen impactor stages were washed with appropriate washing solvents, 60% acetonitrile /
40% water solution for BDP samples and 75% methanol / 25% water solution for albuterol
sulfate samples. Drug deposition in the impactor for BDP and albuterol containing pMDI
aerosols was quantified using validated HPLC analytical methods as described in Chapter
III.C.2.1 and III.C.2.2, respectively. Trace quantities of albuterol deposited on stages 1-4
were determined using LC-MS (Chapter III.C.2.3). The mass of drug depositing on all
stages below stage 11 of the ELPI (particles smaller than 4.05 μm, manufacturer-reported
cut-off diameter of stage 11) was defined as the fine particle dose (FPD). The sum of the
electrical charge of particles depositing below stage 11 was defined as the FPD charge.
All pMDIs were tested at temperatures between 23 - 24 ºC and relative humidity
ranging from 20 - 43 %. The water content of the experimental pMDIs was also
determined using Karl Fischer titration (Kulphaisal 2003). Precautions were taken to
ensure that all inhalers and actuators were subjected to the same procedures throughout the
study.
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VI.C. Results and Discussion
VI.C.1. Electrostatic Charge and Mass Distribution of HFA Propelled Solution
pMDIs
VI.C.1.1. Effect of BDP Concentration in HFA Based BDP Solution pMDIs on
Electrostatic Charge

Figure VI.2 summarizes the mean net inherent charge of aerosols produced by
QVAR 40 and QVAR 80 pMDIs on stages 1 - 12 of the ELPI.
Figure VI.2.

Electrostatic Charge Distribution of Aerosols Produced by QVAR 40 and
QVAR 80 pMDIs (n = 5 Shots / Can, 1 Can). Appendices A.IV.1.1 A.IV.1.4 List the Electrostatic Charge Data for Background Measurements
and Individual Shots.

Both strengths of QVAR pMDIs produced unipolar predominantly electropositive
aerosol clouds with a mean total net electrostatic charge of +449 ± 254 pC and +1314 ±
364 pC. Background measurements for QVAR 40 and QVAR 80 were negligible (+0.13 ±
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0.17 pC and –0.05 ± 0.16 pC, respectively), corresponding to less than 0.04 % of the total
net inherent charge (Appendices A.IV.1.1 and A.IV.1.2).
The electrostatic charging properties of QVAR 40 obtained in the present study
were in good agreement with results previously obtained in our laboratory (mean total net
charge for QVAR 40 determined using a modified ELPI: +563 ± 314 pC; Keil 2005).
Kwok et al. have determined the electrostatic charge characteristics of QVAR 80 aerosols;
the aerosols produced from QVAR 80 were found to be unipolar electropositively charged
as well, although the mean total net charge (300 ± 240 pC; Kwok et al. 2005) was lower
than that observed in the present study.
Table VI.1 summarizes the mass distribution data for aerosols from QVAR 40 and
QVAR 80 pMDIs. The delivered mass (shot weight) of the formulation for QVAR 40 and
QVAR 80 was 57 ± 2 and 60 ± 1 mg, respectively, which suggested that QVAR 80
contains a more concentrated solution of BDP compared to QVAR 40.

Table VI.1.

Actuator Dose, Emitted Dose, Throat Deposition, Impactor Dose, and Fine
Particle Dose of QVAR 40 and QVAR 80 pMDIs. Results Represent Mean
(S.D.) (n = 5; 5 shots / can, 1 can)
Fine Particle
Impactor
Throat
Emitted
Actuator
Dose*
Dose*
Deposition*
Dose*
Formulation Deposition*
(μg)
(μg)
(μg)
(μg)
(μg)
QVAR 40

11.1 (1.5)

34.8 (4.5)

10.6 (3.6)

24.2 (1.3)

24.0 (1.2)

QVAR 80

26.6 (5.3)

70.3 (5.6)

31.2 (2.5)

39.1 (7.0)

39.0 (7.1)

*Difference between QVAR 40 and QVAR 80 was significant.
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Table VI.1 shows that the actuator deposition from QVAR 80 was significantly
higher (p < 0.05) than that from QVAR 40 aerosols, which would be expected since
QVAR 80 consists of a higher concentration of BDP in solution. The ballistic fraction of
QVAR 80 aerosols collected in the USP induction port was also greater (47.0 ± 7.5 % of
the emitted dose) than that of QVAR 40 aerosols (29.8 ± 7.6 % of the emitted dose). As
would be expected, the mass of drug recovered in the impactor for QVAR 80 (39.1 ± 7.0
µg) was significantly higher (p < 0.05) than that recovered for QVAR 40 (24.2 ± 1.3 µg).
Since a larger fraction of the emitted QVAR 80 aerosols deposited on the USP throat than
that for QVAR 40 aerosols, the impactor dose for QVAR 80 was not proportionately
higher than that for QVAR 40 aerosols. Figure VI.3 illustrates the BDP mass distribution
for both strengths of QVAR pMDIs. BDP predominantly deposited on stages 1 - 10 of the
ELPI for both QVAR 40 and QVAR 80.
Figure VI.3.

Mass Distribution of BDP Determined Using the Modified ELPI for QVAR
40 and QVAR 80 pMDI Aerosols (n = 5; 5 shots / can, 1 can)
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The fine particle doses (FPD) for QVAR 40 and QVAR 80 were 24.0 ± 1.2 and
39.0 ± 7.1 μg, respectively, which were not significantly different (p > 0.05) from the
impactor doses since drug deposition on stages 11 - 13 was negligible. In order to
normalize the electrostatic charge data for each stage with respect to the mass of BDP
deposited on the corresponding stage, the net charge for each stage was divided by the
mass of BDP deposited on that stage to obtain the charge to mass ratio for QVAR 40 and
QVAR 80 and the results are shown in Table VI.2. The charge to mass ratio for stages 4 10 was higher for QVAR 80 than that for QVAR 40, i.e., more electrostatic charge was
associated with QVAR 80 pMDI aerosols on each stage when compared with QVAR 40
pMDI aerosols. However, due to high variability, the charge to mass ratios for stages 4 - 10
were not statistically different (p > 0.05) between the two strengths of QVAR pMDIs.
Charge to mass ratios were not obtained for stages 1 - 3 and 11 - 12 for both the aerosols;
stages 1 - 3 were combined for washings in order to determine the mass of BDP deposited
while there was no drug detected on stages 11 - 12.
Table VI.2. Mean Charge to Mass Ratio (pC/μg) of QVAR 40 and 80 pMDIs (Values in
Parentheses are Standard Deviation, n = 5; 5 shots / can, 1 can).
Stage
4
5
6
7
8
9
10
19.85
18.03
15.81
14.00
13.55
17.27
51.32
QVAR 40
(11.77)
(7.71)
(7.43)
(6.42)
(6.09)
(8.00)
(26.80)
QVAR 80

47.83
(26.61)

36.02
(17.04)

24.31
(6.96)

22.02
(6.87)

24.74
(9.11)

42.22
(22.02)

192.30
(172.68)

Results for individual shots are listed in Appendices A.IV.1.5 and A.IV.1.6.
QVAR pMDI contains a solution of BDP in ethanol and HFA 134a, and it should
be noted that the electrostatic charge on the ELPI stages would be due to all of the
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formulation components while the mass is only due to BDP. However, for a solution based
pMDI aerosol, it can be assumed that each droplet formed has a uniform distribution of the
drug and the excipients (Stein and Myrdal 2004). Therefore, it is reasonable to assume that
the electrostatic charge on the aerosol droplets of QVAR solution pMDI depositing on
stages 1 - 12 will be proportional to the corresponding mass of the drug on those stages.
The effect of the mass of BDP on the aerosol charge was studied by comparing the
charge to mass ratios for stages 4 - 10 of the ELPI for QVAR 40 and QVAR 80, which are
the same BDP HFA solution formulations with different BDP concentrations. The mass of
drug in each droplet of the aerosol for QVAR 80 would therefore be greater as compared to
that in QVAR 40 aerosol droplets. The charge to mass ratios for QVAR 80 were not
statistically different from those obtained for QVAR 40 suggesting that the electrostatic
charge developed in aerosol droplets produced by QVAR solution pMDIs was proportional
to the mass of BDP present in the aerosol.

VI.C.1.2. Effect of Packaging Components of HFA Based BDP Solution pMDIs

Figure VI.4 compares the electrostatic charge distribution of QVAR 40 pMDIs, as
obtained, and the repackaged formulations. Repackaged QVAR pMDIs produced net
positively charged aerosols similar to those produced by QVAR pMDIs; however, the
magnitude of charge was significantly lower (p = 0.0079) when compared to that produced
by QVAR pMDIs (repackaged pMDIs: +175 ± 56 pC, QVAR pMDIs: +449 ± 254 pC).
Background measurements were found to be less than 0.07% of the total net charge of
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repackaged QVAR aerosols (0.12 ± 0.28 pC). Appendix A.IV.1.7 summarizes the net
charge for background measurements.
Figure VI.4. Electrostatic Charge Distribution of QVAR 40 pMDIs (n=5; 5 shots / can, 1
Can) and Repackaged QVAR 40 pMDIs (n = 9; 3 Shots / Can, 3 Cans).
Electrostatic Charge Data for Individual Shots of Repackaged pMDIs are
listed in Appendix A.IV.1.8.

The net charge on stages 1 - 3 was negligible but electronegative which may
possibly be an effect of changing the valve and the actuator combination in the repackaged
QVAR pMDIs. 3M Spraymiser valves consist of a stainless steel valve stem and metering
chamber while Valois valves used with the experimental pMDIs were comprised of a PBT
valve stem and metering chamber. A Valois actuator was used with the experimental
solution pMDIs in order to fit the Valois valves.
Table VI.3 summarizes the mass distribution data for aerosols from QVAR pMDIs
as obtained and the repackaged QVAR pMDIs. Emitted doses for the pMDIs were not
significantly different (p = 0.2794). However, deposition within the USP induction port
from the repackaged pMDIs was significantly higher (p < 0.0001) in comparison with
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marketed QVAR 40 pMDIs. Not unexpectedly, the mean impactor dose (10.6 ± 2.7 µg)
from the repackaged QVAR 40 pMDIs was found to be approximately half of the impactor
dose obtained from the commercially available QVAR 40 pMDIs (24.2 ± 1.3 µg). Previous
studies have illustrated the effect of the actuator orifice diameter on the FPD (particles
smaller than 4.7 μm) characterized using an ACI; the FPD was found to decrease with
increase in the actuator orifice diameter (Lewis et al. 1998). The Valois actuator has a
large orifice diameter (0.7 mm) intended for use with suspension pMDIs; in comparison,
the QVAR actuator has a smaller orifice diameter (0.25 mm; Nithyanandan et al. 2007). It
would therefore be predictable to observe a higher ballistic fraction and a lower impactor
dose for the repackaged pMDI aerosols in comparison to those for QVAR 40 pMDIs.
Table VI.3. Actuator Dose, Emitted Dose, Throat Dose, Impactor Dose and FPD of QVAR
40 (n = 5; 5 shots / can, 1 can) and Repackaged QVAR pMDIs (n = 9; 3 Shots
/ Can, 3 Cans). Results Represent Mean (S.D.)
Impactor
Throat
Emitted
Actuator
Dose*
FPD* (μg)
Deposition*
Dose
Formulation Deposition*
(μg)
(μg)
(μg)
(μg)
QVAR 40

11.1 (1.5)

34.8 (4.5)

10.6 (3.6)

24.2 (1.3)

24.0 (1.2)

Repackaged
8.1 (0.5)
37.4 (2.8)
26.8 (2.4)
10.6 (2.7)
10.2 (2.6)
QVAR 40
*Difference between QVAR 40 and Repackaged QVAR pMDIs was significant.

Figure VI.5 illustrates the BDP mass distributions of QVAR 40, as obtained and
repackaged QVAR pMDIs. It was observed that BDP predominantly deposited on stages 5
- 10 of the ELPI as determined by chemical analysis.
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Figure VI.5. Mass Distribution of BDP for QVAR 40 pMDIs (n = 5; 5 Shots / Can, 1 Can)
and Repackaged QVAR 40 pMDIs (n = 9; 3 Shots / Can, 3 Cans)

Table VI.4. Mean Charge to Mass Ratio (pC/μg) of QVAR 40 pMDIs (as obtained) and
Repackaged QVAR 40 pMDIs (Values in Parentheses are Standard
Deviation, n = 5; 5 Shots / Can, 1 Can for QVAR as is and n = 9; 3 Shots /
Can, 3 Cans for Repackaged QVAR).
Stage
4
5
6
7
8
9
10*
QVAR 40

19.85
(11.77)

18.03
(7.71)

15.81
(7.43)

14.00
(6.42)

13.55
(6.09)

17.27
(8.00)

51.32
(26.80)

Repackaged
QVAR 40

18.47
(10.77)

22.24
(7.24)

19.11
(6.56)

14.79
(4.92)

11.37
(4.12)

14.60
(6.49)

18.71
(9.43)

Results for individual shots are listed in Appendices A.IV.1.5 and A.IV.I.9.
*Difference between QVAR 40 and Repackaged QVAR pMDIs was significant.

To normalize the charge data between the QVAR 40 formulations packaged in the
two different valve and actuator combinations, the mean charge to mass ratio for each of
the ELPI stages was calculated (Table VI.4). The charge to mass ratio was not calculated
for stages 1 - 3 and 11 - 12 since stages 1 - 3 were combined for analysis while deposition
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of BDP on stages 11 and 12 was negligible. There was no significant difference in the
mean charge to mass ratio for stages 4 - 9 (p > 0.05 for each of the stages) between the
QVAR pMDIs in two different packaging configurations. The mean charge to mass ratio
on stage 10 was significantly different (p < 0.05) between QVAR, as is, and repackaged
pMDIs. The similar mean charge to mass ratio data confirmed that the formulations
packaged in different valve and actuator combinations were in effect the same and the
difference in the magnitude of the charge was due to a decrease in the impactor dose.

VI.C.1.3. Effect of Formulation Components of HFA Based BDP Solution pMDIs

Figure VI.6 shows the electrostatic charge distribution of aerosol produced by the
experimental HFA solution pMDIs. The experimental 100% HFA 134a pMDIs produced
primarily net electropositively charged aerosol clouds as shown in Figure VI.6.a (68 ± 100
pC). There was both shot to shot and can to can variability in the net electrostatic charge
distribution of aerosols produced by 100% HFA 134a pMDIs.
Background measurements were less than 0.2% of the total net charge of the
propellant aerosol clouds (0.13 ± 0.43 pC; Appendix A.IV.1.10 provides a summary of the
background measurements). Figure VI.6.b represents the mean net inherent charge for
ethanol/propellant blend aerosol clouds, which was also predominantly electropositive
(108 ± 11 pC).
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Figure VI.6.

Electrostatic Charge Distribution of Control HFA Solution pMDIs and
Repackaged QVAR pMDIs (n = 9; 3 Shots / Can, 3 Cans). Electrostatic
Charge Data for Individual Shots are listed in Appendices A.IV.1.11 A.IV.1.13.

The experimental BDP solution pMDIs produced predominantly electropositive
clouds (Figure VI.6.c) with a mean net electrostatic charge of 160 ± 30 pC, which was
significantly higher (p = 0.0069) than that obtained for ethanol / propellant blend pMDIs
but not significantly different (p < 0.0001) from that obtained for repackaged QVAR
pMDIs (+175 ± 56 pC; Figure VI.6.d). Droplets depositing on stages 4 - 12 were found to
be net positively charged, whereas stages 1 and 2 were negligibly charged. Stage 3 was net
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electronegatively charged which may possibly be a function of the metering valve and
actuator combination used.
Chemical analysis of the drug deposited in the impactor enabled determination of
the mass distribution of the experimental BDP pMDI aerosols. Table VI.5 compares the
actuator dose, emitted dose, throat deposition, impactor dose and FPD of experimental
BDP solution pMDIs and repackaged QVAR 40 pMDIs determined by the ELPI. There
was a small but statistically significant difference (p < 0.0001) in the actuator deposition as
well as the emitted dose from the experimental BDP solution pMDIs and that obtained
from the repackaged pMDIs. The ballistic fraction from the experimental BDP solution
pMDIs was 69.2 ± 1.2 % of the emitted dose, which was comparable (p > 0.05) to that
observed with the repackaged QVAR pMDIs (71.8 ± 5.5 % of the emitted dose). The mean
impactor dose (9.8 ± 0.4 μg) was not significantly different (p = 0.3890) from that obtained
for the repackaged QVAR pMDIs. The FPD (9.6 ± 0.4 μg) accounted for 98 % of the mass
of drug depositing in the impactor since negligible amount of drug deposited on stages 11 13.
Table VI.5. Actuator Dose, Emitted Dose, Throat Deposition, Impactor Dose and FPD of
Experimental BDP Solution pMDIs (n = 9; 3 Cans, 3 Shots / Can) and
Repackaged QVAR pMDIs. Results Represent Mean (S.D.).
Actuator
Emitted
Throat
Impactor
Deposition*
Dose*
Deposition*
Dose
Formulation
FPD (μg)
(μg)
(μg)
(μg)
(μg)
Experimental
6.7 (0.6)
31.8 (1.5)
22.0 (1.3)
9.8 (0.4)
9.6 (0.4)
BDP Solution
pMDIs
Repackaged
QVAR 40
8.1 (0.5)
37.4 (2.8)
26.8 (2.4)
10.6 (2.7)
10.2 (2.6)
*Differences between experimental BDP pMDIs and Repackaged QVAR pMDIs are
significant
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Figure VI.7. Electrostatic Charge and Mass Distribution of BDP for Experimental BDP
Solution pMDIs (n = 9; 3 Shots / Can, 3 Cans)

Figure VI.7 shows the electrostatic charge distribution and the corresponding mass
distribution of the experimental BDP solution pMDIs; BDP predominantly deposited on
stages 1 - 10. Except for stage 3 where net negatively charged particles deposited, the
electrostatic charge measured on stages where BDP deposited was determined to be net
positive.
QVAR 40 was used as the model solution pMDI and the influence of individual
formulation components of BDP solution pMDIs on aerosol charge were investigated by a
systematic study of a series of experimental solution formulations. Since the repackaged
QVAR pMDIs produced aerosols with similar electrostatic charging characteristics
compared to those of QVAR pMDIs (as obtained), the effect of formulation components of
BDP solution pMDIs on the electrostatic charge of the aerosols could be systematically
investigated using experimental HFA solution pMDIs packaged with Valois metering
valves.
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The addition of BDP to an ethanol / propellant HFA 134a blend did not affect the
unipolar charge distribution profile observed for the ethanol - propellant blend alone. The
water content for the control 100% HFA 134a ranged from 36 – 55 ppm, while the water
content was higher for the ethanol containing control pMDIs (water content for ethanolpropellant blend and BDP solution in ethanol-propellant blend: 354 - 361 ppm and 357 362 ppm, respectively). The presence of water in the ethanol-containing pMDIs may
contribute to their relatively polar nature and possibly influence the aerosol charging
properties. It was hypothesized that since BDP solution pMDIs could be considered to be a
homogeneous system, all the aerosol droplets exhibited uniform charging characteristics
similar to the ethanol-propellant blend alone resulting in a unipolar charge distribution.
The predominant effect of ethanol as a polar cosolvent on the electrical properties
of the control HFA based solutions was confirmed from the electrical resistivity
measurements. Propellant HFA 134a has been reported to have a high electrical resistivity
(180 MΩ.cm; Solvay Fluor Product Bulletin 2001). As observed in Chapter IV.B.2.2, the
addition of ethanol decreased the resistivity of pure propellant HFA 134a; for example, the
resistivity of 7% ethanol / 93% HFA 134a blend was 0.8 MΩ.cm suggesting that addition
of ethanol increased the polar nature of the propellant as well as the conductivity of the
solution. Addition of BDP to the ethanol-propellant blend only slightly increased the
electrical resistivity (2.38 ± 1.31 MΩ.cm) in comparison to the ethanol / propellant blend
alone. In summary, the presence of ethanol was shown to have a predominant effect on the
electrical properties of BDP HFA solutions inside the canister as well as the electrostatic
properties of the aerosols produced by these pMDIs.
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VI.C.2. Electrostatic Charge and Mass Distribution of HFA Propelled Albuterol
Sulfate Suspension pMDIs
VI.C.2.1. Electrostatic Charge and Mass Distribution of Ventolin HFA pMDI
Aerosols

The mean electrostatic charge and mass distribution of aerosols produced by
Ventolin HFA are shown in Figure VI.8. Ventolin HFA produced bipolar aerosol clouds
with the particles depositing on stages 1 - 6 net electronegatively charged while particles
depositing on stages 7 - 12 being net electropositively charged similar to that observed in
the literature (Kwok et al. 2005).

Figure VI.8.

Electrostatic Charge and Mass Distribution of Ventolin HFA pMDI
aerosols. Error Bars Represent Standard Deviation (n = 5; 5 Shots / Can, 1
Can). Electrostatic Charge Data for the Individual Shots are Listed in
Appendix A.IV.2.2.
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Background measurements were less than 0.06% of the net FPD charge. Appendix
A.IV.2.1 shows the net charge obtained for background measurements. The mean net FPD
charge was –232 ± 37 pC, which was comparable to the FPD charge (particles smaller than
5 μm) reported in the literature for Ventolin HFA (-231 ± 3 pC) measured using an aerosol
electrometer (Kulphaisal 2003).
In contrast, the magnitude of the electrostatic charge produced by Ventolin HFA
aerosols measured using a modified ELPI reported in literature was almost five fold higher
(-1100 pC) (Glover and Chan 2004a, Kwok et al. 2005). A possible explanation for this
difference in the total net aerosol charge of Ventolin HFA could be the manner in which
the ELPI software analyzes the electrical current data. When the ELPI is used for sizing
aerosol particles via electrical detection, the ELPI software uses a correction algorithm to
account for diffusion losses of smaller particles such that some of the electrical current is
transferred to the upper stages (Dekati Ltd. Technical Note 2002). Keil has illustrated for
Ventolin CFC aerosols that the use of the corrected electrical current data for charge
determination resulted in a higher mean total aerosol charge (–768 ± 136 pC) than that
determined using the raw current data (–154 ± 26 pC) (Keil 2005). However, it is not
possible to confirm from the data published by Kwok et al whether the correction
algorithm was used in their experiments.
The total emitted dose for Ventolin HFA was 78.3 ± 6.0 µg while the impactor dose
was 36.6 ± 2.8 μg. Figure VI.8 shows that albuterol was found to deposit on stages 6 - 13
of the ELPI, but predominantly on stages 7 - 11, which correspond to the stages where
electropositive particles deposited. Negligible amount of drug was detected on stage 5;
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albuterol was not detected on stages 1 - 4 of the ELPI using the HPLC method described in
Chapter III.C.2.2.

VI.C.2.2. Influence of Formulation Components on Electrostatic Properties of
Experimental Albuterol Sulfate HFA Suspension pMDIs

Experimental albuterol sulfate HFA based suspension pMDIs were systematically
tested to evaluate the contribution of individual components of the formulation to the
electrostatic charge. Figure VI.9 shows the electrostatic charge distribution of 100% HFA
134a and 0.2% albuterol sulfate / 100% HFA 134a suspension pMDI aerosols.
Figure VI.9. Electrostatic Charge Distribution of Experimental HFA 134a pMDI Aerosols.
Error Bars Represent Standard Deviations (n = 9; 3 Shots / Can, 3 Cans).
Electrostatic Charge Data for the Individual Shots are Listed in Appendices
A.IV.2.4 and A.IV.2.5.

Propellant HFA 134a pMDIs produced primarily electropositive charge (mean total
net charge: 59 ± 45 pC), although the total net charge varied from -12 pC to +137 pC.
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Background measurements were less than 0.4% of the total net charge of propellant HFA
134a pMDIs (0.21 ± 0.25 pC; Appendix A.IV.2.3 provides a summary of the background
measurements). The mean net charge of the propellant droplets on the individual stages,
stages 1 - 12 of the ELPI, was found to be negligible in comparison to that of the
experimental albuterol sulfate pMDI aerosols, as shown in Figure VI.9.
Albuterol sulfate pMDIs produced bipolar charged aerosol clouds with a mean net
FPD charge of –227 ± 264 pC, similar to those produced by Ventolin HFA pMDI aerosols.
Although the charge distribution profiles of the experimental albuterol sulfate pMDIs were
similar for all the 3 canisters tested, there was can to can and shot to shot variability in the
total net electrostatic charge of the aerosols. For example, aerosols from canister 1
produced a total net electronegative charge ranging from –370 to +546 pC. In contrast,
canister 2 produced a total net aerosol charge ranging from –353 +175 pC; canister 3
produced aerosols with a total net charge ranging from –60 to +10 pC.
The systematic investigation of the electrostatic charging properties of propellant
HFA 134a pMDIs and albuterol sulfate suspension pMDIs showed that the electronegative
charge on the lower stages of the ELPI was not due to propellant droplets (Figure VI.9).
This observation was in contradiction to Kwok et al. who speculated that the highly
electronegative charges on stages 1 - 6 of the ELPI, detected for Ventolin HFA pMDI
aerosols, were due to the propellant droplets since negligible amounts of albuterol sulfate
was found to deposit on these stages (Kwok et al. 2005).
Table VI.6 compares the mass recovery data for the experimental albuterol sulfate
pMDIs and Ventolin HFA aerosols.
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Table VI.6. Actuator Dose, Emitted Dose, Throat Deposition, Impactor Dose, and FPD
for Experimental Albuterol Sulfate HFA pMDIs (n = 9; 3 Shots / can, 3 Cans)
and Ventolin HFA (n = 5; 5 Shots / Can, 1 Can). Results Represent Mean
(S.D.).
Impactor FPD* (μg)
Throat
Emitted
Actuator
Formulation
Deposition* Dose* (μg)
Dose*
Deposition*
(μg)
(μg)
(μg)
Experimental
22.0 (3.0)
28.7 (5.1)
33.8 (6.0)
62.5 (11.0)
18.6 (2.8)
Albuterol
Sulfate pMDIs
Ventolin HFA

13.5 (5.9)

78.3 (6.0)

41.7 (4.6)

36.6 (2.8)

33.3 (2.8)

*Difference between experimental albuterol pMDIs and Ventolin HFA pMDIs was
significant
The mass of albuterol sulfate depositing within the actuator (18.6 ± 2.8 μg) from
the experimental albuterol sulfate suspension pMDIs was significantly greater (p < 0.05)
than that obtained for Ventolin HFA aerosols

(13.5 ± 5.9 μg). The actuator orifice

diameter (0.7 mm) for the experimental pMDIs is larger than that for the actuator used with
Ventolin HFA (0.52 mm; Nithyanandan et al. 2007), which is reflected in the lower drug
mass recovery from the actuator for the experimental pMDIs. It was therefore not
unexpected that the emitted dose obtained for the experimental albuterol sulfate pMDIs
(62.5 ± 11.0 μg) was significantly lower (p < 0.05) in comparison to the emitted dose
obtained from Ventolin HFA aerosols (78.3 ± 6.0 μg). The emitted doses of the
experimental albuterol sulfate suspension pMDIs, however, were found to be statistically
comparable (p = 0.4332; one-way ANOVA) between the three canisters tested.
The difference in the total drug recovery between Ventolin HFA and the
experimental albuterol sulfate suspension pMDIs may be related to the difference in the
amount of drug metered per shot. The mass of Ventolin HFA formulation delivered per
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shot ranged from 75 – 76 mg, which corresponds to a metering volume of 63 μL, while the
shot weight for the experimental albuterol sulfate pMDIs ranged from 55 - 57 mg
(metering volume: 50 μL). Both the formulations were intended to deliver a dose of 120 μg
of albuterol sulfate per shot, thus the experimental albuterol sulfate suspension pMDI was
formulated as a more concentrated suspension compared to Ventolin HFA. In addition,
both the commercially available and the experimental albuterol sulfate HFA suspension
pMDI tested in this study did not contain any surfactant, which would render the
formulations inherently unstable. Owing to the increased drug mass in the experimental
albuterol sulfate suspensions as well as the absence of a suspending agent, there may be an
increased tendency for the suspended albuterol sulfate particles to aggregate and adhere to
the canister inner walls as well as the metering chamber during storage and not be
available for delivery.
Molecular modeling studies described in Chapter V have shown that the
interactions between the molecules of albuterol sulfate and HFA 134a are predominantly
unfavorable as suggested by the HINT scores. It would not be unexpected for albuterol
sulfate particles to aggregate when suspended in HFA 134a in the absence of any
suspending agent. The patent literature has documented the use of fluoropolymer coating
on the canister inner walls as well as the metering chamber to minimize drug adhesion
(Ashurst et al. 2000a, Riebe et al. 2003). The experimental albuterol sulfate pMDIs were
packaged in uncoated aluminum canisters and untreated Valois metering valves, which
may possibly be another factor responsible for the low drug recovery.
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The ballistic fraction of the aerosols emitted from the experimental albuterol sulfate
suspension pMDIs depositing in the USP induction port (54.1 ± 1.3 % of the emitted dose)
was not significantly different from that obtained for Ventolin HFA pMDIs (53.2 ± 3.0 %
of the emitted dose). As a consequence of the lower emitted dose recovery for the
experimental albuterol sulfate pMDIs, the corresponding impactor dose (28.7 ± 5.1 µg)
was significantly lower (p < 0.05) than the impactor dose for Ventolin HFA pMDI aerosols
(36.6 ± 2.8 μg). However, the impactor doses for the experimental albuterol sulfate pMDIs
were not significantly different (p = 0.3644, one-way ANOVA) between the canisters (3
cans) tested. Droplets depositing on stages 1 - 6 were net electronegatively charged while
droplets depositing on stages 7 - 12 were net electropositively charged as shown in Figure
VI.9.
FigureVI.10. Electrostatic Charge and Mass Distribution of Experimental Albuterol
Sulfate pMDIs (n = 9; 3 Shots / Can, 3 Cans)

Chemical analysis using a validated HPLC method (Chapter III.C.2.2) showed that
albuterol sulfate deposited on stages 6 - 13 of the ELPI, but predominantly on stages 7 - 12
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where net electropositive charge was recorded. There was a negligible amount of albuterol
sulfate on stage 5 while no drug was detected on stages 1 - 4 of the ELPI using the HPLC
analysis with fluorescence detection (Figure VI.10). Interestingly, the net electrical charge
recorded on these stages was highly electronegative.
The present study showed that the addition of albuterol sulfate to propellant HFA
134a appeared to modify the triboelectric properties of the non-drug droplets. However, the
causative factors for the highly electronegative charges on stages 1 - 5 for albuterol sulfate
pMDIs were not clearly understood. Trace amounts of albuterol sulfate on the lower stages
1 - 4 of the ELPI were detected using an LC-MS technique as described in Chapter
III.C.2.3. From the analysis of albuterol sulfate recovered on the lower stages (Stages 1 - 4)
of the ELPI, it was observed that the total mass of albuterol depositing on stages 1 - 4 was
0.05 ± 0.01 μg i.e. less than 0.1% of the emitted dose of albuterol sulfate penetrated
beyond stage 5 (manufacturer-reported stage cut-off diameter: 0.27 μm). Further
experiments were needed to address the origin of the electrostatic charge on stages 1 - 4 of
the ELPI.
One possible explanation for the electronegative charge on the lower stages of the
ELPI was considered to be the presence of trace quantities of soluble drug or related
impurities. However the solubility of albuterol sulfate in 100% HFA 134a has been
reported to be lower than 0.0005 μg/mg using a UV-Visible detection technique (Tzou et
al. 1997). The effect of soluble impurities, if any, in the experimental albuterol sulfate
suspension pMDIs was further investigated by filtering the suspensions and analyzing the
electrostatic properties of the filtrates.

149
VI.C.2.3. Influence of Soluble Impurities on Electrostatic Charge Distribution of
Experimental HFA Suspension pMDIs

Figure VI.11 shows the electrostatic charge distribution of aerosols produced by
filtrates of the experimental HFA pMDIs. Metered dose analysis using HPLC with
fluorescence detection confirmed the absence of albuterol sulfate in filtrates of albuterol
sulfate suspensions in HFA 134a. Filtrates of 100% HFA 134a produced aerosols with
predominantly net positive charge (139 ± 110 pC). Background measurements were less
than 0.1 % of the total net charge of the control HFA 134a filtrates (0.11 ± 0.18 pC;
Appendix A.IV.2.6).
Figure VI.11. Electrostatic Charge Distribution of Aerosols Produced by Filtrates of
Experimental HFA pMDIs (n = 9; 3 Shots / Can, 3 Cans). Electrostatic
Charge Data for the Individual Shots are Listed in Appendices A.IV.2.7 and
A.IV.2.8.

The aerosol clouds produced by filtrates from 0.2 % albuterol sulfate suspensions
in 100 % HFA 134a were also net electropositively charged (151 ± 55 pC); the total net
electrostatic charge was not statistically different (p = 0.7790) from that obtained for 100
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% HFA 134a pMDIs post-filtration. In the absence of suspended albuterol sulfate particles
in the formulation, the electrostatic charging characteristics of aerosols produced by the
filtrates of experimental albuterol sulfate pMDIs were similar to those produced by the
filtrates of 100% HFA 134a pMDIs. The mean net electrostatic charge on each stage of the
ELPI for the filtrates of the control propellant pMDIs was higher than that obtained for the
propellant pMDIs before filtration, although for some shots, net electronegative charge was
observed on the ELPI stages.
The process of filtration and transfer of formulations via cold filling could possibly
result in water ingress in the formulations. The water content of the experimental 100%
HFA 134a pMDIs and 0.2% albuterol sulfate suspension pMDIs before filtration of the
formulations measured by Karl Fischer titration was found to be 138 ± 4 ppm and 118 ± 38
ppm, respectively. After filtration, the water content of the filtrates of the experimental
100% HFA 134a and 0.02% albuterol sulfate / 100% HFA 134a pMDIs increased to 238 ±
41 ppm and 246 ± 55 ppm, respectively. The presence of water in the filtrates may have
influenced the charging properties of the aerosols produced by them thus resulting in
higher net electropositive aerosol charge for the HFA 134a filtrates and the formation of
unipolar electropositive aerosol clouds for the filtrates of experimental albuterol sulfate
pMDIs.
However, the absence of highly charged sub-micron particles suggests that the
soluble albuterol impurities or the propellant HFA 134a itself may not be responsible for
the highly electronegative charge on the lower stages of the ELPI in case of the albuterol
sulfate pMDIs. An alternative explanation for the electrostatic charge on stages 1 - 4 may
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be the presence of a very large number of small (particles smaller than 0.39 μm,
manufacturer-reported cut-off diameter for stage 5) aerosol particles present on these
stages. Crampton et al. have reported that HFA propelled pMDIs produce a higher submicron aerosol fraction compared to their CFC counterparts based on their measurements
using electrical detection of charged aerosol particles in the ELPI and the Scanning
Mobility Particle Sizer (SMPS) (Crampton et al. 2004). The authors determined that
0.269% of the labeled dose claim of Ventolin HFA had an aerodynamic size smaller than
0.1 μm. It was suggested that although sub-micron and ultrafine particles do not have
appreciable mass; it might be relevant to measure the particle number or surface area to
understand their physiological impact (Crampton et al. 2004). It was interesting to observe
that the number of albuterol particles depositing on stages 1 - 4 of the ELPI contributed
approximately 75% of the total number concentration calculated from the mass of albuterol
deposited within the cascade impactor (Appendix A.V). It may be possible that this large
number of sub-micron and ultrafine particles of albuterol detected on stages 1 - 4 could be
responsible for the electronegative charge. It was hypothesized that the interactions
between HFA 134a droplets and the valve stem on actuation of the pMDI would be
influenced by albuterol sulfate particles such that the droplets emitted from the actuator
orifice contained both positively and negatively charged species.
HFA 134a can be classified as a weakly polar solvent based on its dielectric
constant (ε = 9.5) (Delgado et al. 2005). Although, the electrical resistivity of 100 % HFA
134a has been reported to be high (180 MΩ.cm; Solvay Fluor Product Bulletin 2001),
albuterol sulfate particles were observed to acquire a positive zeta potential (75.9 ± 26.2
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mV) when dispersed in 100% HFA 134a, which suggests that charge formation can occur
within a weakly polar solvent. This observation compares favorably with the electrostatic
properties of albuterol sulfate HFA pMDI aerosols; albuterol sulfate predominantly
deposited on stages 7 - 12, on which a net electropositive aerosol charge was detected.
In summary, the systematic investigation of the electrical properties of droplets
generated by HFA suspension and solution pMDIs demonstrated that surface
electrification can be influenced by the formulation components. Characterization of these
aerosol clouds from HFA propelled suspension and solution pMDIs using the modified
ELPI has provided further insight into the droplet species that are likely generated, as well
as their deposition behavior. Taken together with the studies investigating the electrical
properties of HFA based solutions and suspensions, an improved understanding of charge
formation within these formulations in relation with the electrostatic properties of the
aerosols was provided.

VII. CALIBRATION OF THE MODIFIED ELECTRICAL LOW PRESSURE
IMPACTOR FOR USE WITH PRESSURIZED PHARMACEUTICAL
AEROSOLS

VII.A. Introduction

The modified Electrical Low Pressure Impactor (ELPI) has been employed to
characterize the electrostatic properties of pressurized metered dose inhalers (Glover
and Chan 2004a, Orban and Peart 2004, Kwok et al. 2005, Kwok et al. 2006), dry
powder inhalers (Glover and Chan 2004b, Mikkanen et al. 2004, Kwok and Chan 2008,
Telko et al. 2007, Young et al. 2007) and nebulizers (Kwok and Chan 2004) as a
function of particle size. In most of these studies, it is not clear whether using the ELPI
in this fashion yields an equivalent particle size distribution to other cascade impactor
data (Glover and Chan 2004a, Kwok et al. 2005, Kwok et al. 2006). Telko et al. found
that when aerosols produced by experimental DPIs containing micronized albuterol
sulfate alone and those containing 1% albuterol sulfate in lactose were simultaneously
sampled into a modified ELPI and an Andersen Cascade Impactor (ACI), the
aerodynamic particle size distributions (aPSDs) obtained were comparable; however
their study did not use the standard compendial experimental setup (Telko et al. 2007).
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Recent evidence suggests that the ELPI appears to underestimate the particle
size of aerosols produced by commercially available pMDIs (Orban and Peart 2004,
Keil et al. 2006). While other studies have not directly compared the ELPI with other
conventional cascade impactors, they have reported aPSDs determined using the
modified ELPI. For example, the mass median aerodynamic diameter (MMAD) for
Ventolin HFA pMDI (90 μg emitted dose of albuterol) was reported to be 1.82 ± 0.01
μm (Kwok et al. 2006) determined using the ELPI whereas the MMAD obtained with
the ACI was reported to be 2.40 μm (Cripps et al. 2000).
Because of the current interest in apportioning charge to various size fractions of
aerosols produced by pharmaceutical systems, the modified ELPI has been recalibrated
using four independent, polydisperse pharmaceutical aerosols with different median
diameters. After the recalibration procedure, the new ELPI cut-off diameters were
validated using a previously untested commercially available pMDI.

VII.B. Materials

QVAR®, Ventolin CFC®, Flovent HFA® and Vanceril® (Table VII.1) were
obtained commercially. These were tested before their expiry dates and used as
“calibration standards”. A fifth product, Ventolin HFA (Table VII.1) was tested after
the ELPI recalibration procedure was complete, to validate the new calibration and
compare the aPSDs obtained by performing side-by-side experiments in the ELPI and
the ACI.

Table VII.1. Commercially Available pMDIs Used in this Study.
Product

Active Drug
(Labeled Dose)a

Supplier

Propellant
System

Qvar

Beclomethasone Dipropionate Ivax Laboratories Inc., Miami, FL,
USA, Lot # ED037A
40 μg

Ventolin

Albuterol Base
90 μg

GlaxoSmithKline, Raleigh, NC,
USA, Lot # 1ZP0757

CFC 11/12 Bespak

Polymer

Polymer

Flovent HFA

Fluticasone Propionate
44 μg

GlaxoSmithKline, Raleigh, NC,
USA, Lot # 0173

HFA 134a

Polymer

Polymer

Vanceril

Beclomethasone Dipropionate
42 μg

Polymer

Polymer

Polymer

Polymer

Valois

Schering Corporation, Kenilworth, NJ, CFC 11/12 Bespak
USA Lot # 1-AMA-226

GlaxoSmithKline, Raleigh, NC,
Albuterol Sulfate 108 μg
USA, Lot # 4ZP3714
(Equivalent to 90 μg of
Albuterol Base)
a
Label claim doses represent the dose delivered from the mouthpiece actuator
Ventolin HFA

HFA 134a

Metering Valve Construction
Metering
Manufacturer Valve Stem
Chamber
3M
Stainless Steel Stainless Steel

HFA 134a

Valois
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VII.C. Methods

VII.C.1.

Determination of Aerodynamic Particle Size Distributions (aPSDs) of
Commercially Available pMDIs using the ACI and the Modified ELPI

An ACI was employed to generate the aPSD data for the four “calibration” pMDIs,
which were used to calibrate the modified ELPI. The ACI used in this study was
mensurated to ensure that the instrument was within its intended dimensional and
engineering specifications by MSP Corporation (St Paul, MN, USA). Calibration of the
ELPI used in the study was performed by Dekati Ltd., Tampere, Finland (ELPI); Appendix
A.I provides the ELPI cut-off diameters. All pMDIs were tested under standard conditions
at temperatures between 23-24 ºC and relative humidity ranging from 20-40%. Five
replicate experiments were performed for a single canister of each product using a single
ACI and modified ELPI.

VII.C.1.1. Andersen Cascade Impactor

Single actuation experiments were performed to assess the aPSDs of the emitted
dose from each of the commercially available pMDIs listed in Table VII.1 using the ACI
(8-stage Non-Viable Cascade Impactor Mark II; Thermo Electron Corporation, Franklin,
MA) at a volumetric flow rate of 28.3 L/min according to standard compendial (USP 29/
NF 24 First Supplement 2006) methods. At a flow rate of 28.3 L/min the aerodynamic cutoff diameters of the stages are: 9.0, 5.8, 4.7, 3.3, 2.1, 1.1, 0.7 and 0.4 μm. A glass fiber
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filter following the final impactor stage captures drug particles smaller than 0.4 μm. The
impaction plates were coated to minimize any particle re-entrainment or “bounce” using
316 Silicone Release Spray (Dow Corning, Midland, MI, USA).

VII.C.1.2. Modified Electrical Low Pressure Impactor

The pMDI products were also tested using the modified ELPI (Dekati Ltd.,
Tampere, Finland) as described in Chapter III.B. The ELPI was allowed to stabilize for an
hour prior to operation while set-up requirements such as air leakage testing were
performed in accord with the manufacturer’s instructions and specifications. The ELPI was
assembled as shown in Figure III.1 (the ELPI stages are numbered by the manufacturer
starting from the base of the instrument). The manufacturer-reported cut-off diameters are
shown in Table III.1. The modified ELPI was operated at a pressure of 100 mbar (below its
lowest stage) to produce a flow rate of approximately 29 L/min, verified with an external
flowmeter (Sierra Instruments Inc., Monterey, CA, USA). The aPSD of the drug clouds
produced by each pMDI was characterized using single actuations into a previously
cleaned ELPI with silicone-coated (DS-515 grease spray; Dekati Ltd., Tampere, Finland)
aluminum substrates on each of the impaction plates.
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VII.C.1.3. Procedure for Determination of Aerodynamic Particle Size Distributions
(aPSDs) of Commercially Available pMDIs using the ACI and the
Modified ELPI

Prior to each experimental run, the canister was primed according to the patient
information leaflet for each of the individual pMDIs. The primed canister, fitted with a
clean actuator, was weighed, shaken for 5 sec, and actuated into the cascade impactor. The
vacuum pump was turned off 10 or 20 sec after the actuation was completed for the ACI
and the ELPI, respectively. The inhaler was reweighed as a procedural check to ensure
accurate valve function, by checking to assess that the shot weight was within 5% of the
target weight for that product. The mass of drug collected on the actuator, USP induction
port, the ELPI inlet (in case of the ELPI) and the impactor stages for all the pMDIs was
determined using validated HPLC analytical methods (Chapter III.C.2.1 & III.C.2.2).
The total emitted dose was determined for each actuation by summation of the
masses collected in the induction port and the cascade impactor stages. The average
emitted dose from each pMDI was determined from 5 single shot cascade impactor
experiments in which drug recovery fell within the USP mass balance limits (label claim ±
25%; USP 29 / NF 24 First Supplement 2006). The amount of drug penetrating the
impactor below the upper impaction stage of either ACI or ELPI was determined for each
product and compared statistically using t-tests, to assure the comparability of the aerosol
clouds being used as the ELPI calibration standards. Statistical significance was assessed at
the p < 0.05 level throughout. The mass of drug penetrating both impactors and depositing
on the individual stages below the top stage (Stage 0 of the ACI, Stage 13 of the ELPI) was
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tabulated to produce cumulative percent drug undersize profiles of the output cloud from
each pMDI.

VII.C.2. Curve Fitting of the ACI aPSD Data for the Calibration Aerosols

Four sets of n = 5 cumulative percent drug undersize data obtained from the ACI
for the calibration pMDIs were fitted using least mean square nonlinear regression analysis
to determine best estimates for the MMAD and the GSD of each cloud by fitting the data
to the cumulative distribution function (CDF) (Dunbar and Hickey 2000) shown in
Equation VII.1.
y = [100*(0.5+0.5 ERF {[1/(20.5 * SIGMA)]*[loge(x) – MEAN]})]

Equation VII.1

ERF is the error function = 2/π0.5. ∫exp -{[1/(20.5 *SIGMA)]*[loge(x) – MEAN]}2. dx
where eMEAN and eSIGMA are the MMAD and GSD of the log-normally distributed data
(Tobias 1993).
The nonlinear regression software, SCIENTIST® for Windows (Micromath
Research, St. Louis, MO), was used to fit the lognormal cumulative distribution function to
the experimentally obtained ACI data. The program required three types of electronic files
for curve fitting: a Model File (*.EQN), a Parameter File (*.PAR) and a Data File
(*.MMD). The model file and parameter file are shown in Appendix A.VI.1. The model
file defined the 50% aerodynamic cut-off diameter (x) as the independent variable in μm,
cumulative % undersize (y) as a dependent variable and MEAN and SIGMA as the
parameters. The parameters, MEAN and SIGMA, were assigned initial values obtained
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from linear interpolation of the cumulative percent undersize vs. aerodynamic cut-off
diameter profiles. The model file was compiled and a non-weighted non-linear least
squares regression analysis was performed. This allowed for a more precise estimation of
the parameters, MEAN and SIGMA, for the particle size distribution of the calibration
pMDI aerosols. The analysis resulted in the SCIENTIST Plot for the cumulative %
undersize vs. aerodynamic diameter and the Statistical Output, as shown in Appendix
A.VI.2 and A.VI.3.
The parameters used to assess the goodness of fit of the lognormal distribution
model for curve-fitting the ACI cumulative % undersize data were the coefficient of
determination (COD) and the Model Selection Criteria (MSC).
Coefficient of Determination (COD) is calculated as follows by the SCIENTIST
software:
n

COD =

∑ (Y
i =1

exp,i

n

− Yexp ) 2 − ∑ (Yexp,i − Ycalc ,i ) 2
i =1

n

∑ (Y
i =1

exp,i

− Yexp )

Equation VII.2

2

where Yexp,i and Ycalc,i are the experimental and calculated (model predicted) values of
cumulative % undersize, respectively, n is the number of data points and Yexp is the mean
of the experimental data. COD is a measure of the fraction of the total variance accounted
for by the model. The closer the value of COD to 1, the better the model fits the data.
MSC is calculated by the SCIENTIST Software as follows:
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⎜ ∑ (Yexp,i − Yexp ) 2
MSC = ln⎜ in=1
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⎜ ∑ (Yexp,i − Ycalc )
⎝ i =1

⎞
⎟
⎟ − 2p/n
⎟
⎟
⎠

Equation VII.3

where p is the number of parameters required to fit the data and n is the number of data
points. The most appropriate model will have the highest MSC value. In this study, the
lognormal cumulative distribution function was the only model used; for all the calibration
pMDI aerosols, an MSC value greater than 5 was obtained which is considered to be an
indication of a good model.

VII.C.3.

Calculation of Aerodynamic Cut-off Diameters of the Modified ELPI
Using the ACI Curve Fitted Data

Individual values for the cumulative percentage of drug penetrating below a given
ELPI stage were tabulated. The curves of best fit from the ACI and thus the best estimates
for MMAD and GSD, were assumed also to describe the clouds entering the ELPI from
each product. Equation VII.1 cannot be solved analytically for the aerodynamic cut-off
diameter, hence MMAD and GSD were fixed at their product-specific best estimates and
solutions for the cut-off diameters were determined for each stage of the ELPI by
reiterating numerical solutions for Equation VII.1 using the LOGNORMDIST function in
Microsoft® Office Excel 2003 (Microsoft Corp. Seattle, WA, USA).
For the cumulative percentage of drug penetrating below a particular stage of the
ELPI (which represents the left hand side, LHS, of Equation VII.1), a series of assumed
values for the cut-off diameter were used to calculate the value of the right hand side, RHS,
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of Equation VII.1. The data was processed in an iterative manner until the quotient of LHS
/ RHS approached unity. Iteration ended when the following end point was obtained:
0.99999 < LHS / RHS < 1.00001; the cut-off diameter producing this condition was then
noted as the new cut-off diameter value for the ELPI stage in question. Mean (±SD) values
for the cut-off diameter, for each product and each stage, were determined from the 5
separate cascade impaction runs performed with each product. Confidence limits for these
product-specific mean new ELPI cut-off diameter values were also calculated for each of
the ELPI stages using the same procedure with estimates of the MMAD and GSD values
set equal to their 95% confidence limits after curve fitting the ACI data for each calibration
pMDI.

VII.C.4. Validation of the Recalibration of the Modified ELPI

In order to validate the recalibration of the modified ELPI and the cut-off diameters
calculated from the procedure, a single canister of a fifth product, Ventolin HFA, was
studied after the ELPI recalibration procedure had been completed. Ventolin HFA was
tested by collecting five single actuations in the ACI in accord with the USP and the
procedures repeated in the modified ELPI to determine the aPSDs as described earlier in
Section VII.C.1. Mass of drug penetrating both the impactors and depositing on the
individual stages of the ACI and the ELPI (without excluding the mass deposited on the
topmost stage of the impactor) was tabulated to produce cumulative percent drug undersize
profiles of the output cloud from each pMDI.
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VII.D. Results and Discussion
VII.D.1.

Determination of Aerodynamic Particle Size Distributions (aPSDs) of
Commercially Available pMDIs using the ACI and the Modified ELPI

In the present study, the corona charger as well as the charger frame of the ELPI
was removed to create the modified ELPI; this arrangement shortens the aerosol flow path
into the ELPI and makes the aerosol entry conditions comparable to those in the ACI. Most
pharmaceutical investigators use the ELPI without the corona charger while keeping the
hollow charger frame atop the impactor in place (Glover and Chan 2004a, Kwok et al.
2005, Kwok et al. 2006, Telko et al. 2007). As part of the ELPI validation studies, Keil
determined the aPSD of Ventolin CFC using the ELPI by chemical analysis and has shown
that the impactor dose recovered following pMDI actuation into the ELPI with the corona
charger in place (29.7 ± 5.5 μg) or into the ELPI in the absence of both the corona charger
and the frame (28.9 ± 3.0 μg) were statistically indistinguishable (p = 0.7636) (Keil 2005).
Table VII.2 shows that the mass of drug depositing in the actuator as well as the
USP induction port for all the calibration pMDIs were comparable between the ACI and
the ELPI experiments with the exception of Ventolin CFC for which the USP induction
port dose was statistically different. The emitted doses from the calibration pMDIs for the
ACI and the ELPI experiments were statistically comparable with the exception of the
surfactant-free formulation, Flovent HFA, which showed a small but statistically
significant difference (p = 0.0189) for the sprays used for calibration purposes in this
study, as shown in Table VII.2.

Table VII.2. Emitted Dose, Actuator Dose, USP Induction Port Dose and Impactor Dose (Dose Collected on All the Stages
of the Cascade Impactor) for Each of the Four pMDIs Used for Calibration Purposes.
Product
Label
Impactor
Mass collected (μg) ± SD
Claim
Impactor Doseb
Total Emitted
Actuator
USP Induction Porta
Dose
Qvar

Ventolin
CFC
Flovent
HFA
Vanceril

40 μg

90 μg

44 μg

42 μg

ACI

36.87 (1.17)

9.68 (1.29)

17.45 (3.44)

19.42 (4.53)

ELPI

37.92 (2.74)

12.76 (1.72)

17.54 (1.09)

20.71 (3.05)

ACI

88.54 (5.22)

14.14 (1.43)

47.77 (3.14)*

40.76 (4.35)*

ELPI

87.64 (9.68)

12.07 (1.11)

55.94 (5.00)*

31.70 (5.48)*

ACI

37.79 (1.92)*

8.44 (0.84)

16.92 (1.27)

20.87 (1.39)*

ELPI

34.43 (1.69)*

6.62 (0.37)

16.38 (0.91)

18.04 (1.11)*

ACI

37.34 (1.79)

8.58 (2.31)

20.98 (0.96)

16.36 (1.42)*

ELPI

34.45 (2.27)

7.06 (1.70)

22.65 (1.60)

11.80 (1.52)*

a

Mass of drug recovered from the mouthpiece adaptor included. For the ELPI experiments, mass of drug recovered from the
ELPI inlet also included.
b
Mass of drug collected on all stages of the cascade impactor.
*Difference in the drug deposition between the ACI and the ELPI experiments statistically significant.
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The mass of drug penetrating both impactors and depositing on all the individual
stages for the ACI and the ELPI was tabulated to produce cumulative percent drug
undersize profiles of the output cloud from each of the four calibration pMDIs as
illustrated in Figure VII.1. Comparison of the aPSDs of the four calibration pMDIs
determined in the present study using the ACI following standard compendial procedures
and the modified ELPI provided evidence that the modified ELPI undersized pMDI
aerosols (Figure VII.1). Table VII.3 summarizes the MMADs and GSDs for the four
pMDIs determined by linear interpolation for both the ACI and the ELPI experiments
along with the MMADs reported in the literature obtained using the ACI. For example, as
shown in Table VII.3, the MMADs for both QVAR and Ventolin CFC determined in the
present study using the modified ELPI with the manufacturer’s calibration (0.60 ± 0.05 and
1.71 ± 0.05 μm, respectively) were smaller than those determined using the ACI
(0.94±0.06 and 2.20±0.04 μm, respectively). In comparison, the literature reports MMADs
for QVAR and Ventolin CFC, in the ACI, of 1.1 μm (Leach et al. 1998) and 2.2 μm
(Mitchell et al. 1999), respectively. Kamiya et al. have reported that comparable aPSDs are
obtained for Vanceril using the ACI (MMAD: 3.86 ± 0.12 μm) and the Next Generation
Cascade Impactor (NGI) (MMAD: 3.69 ± 0.19 μm) (Kamiya et al. 2004); in contrast, it
was observed that the MMAD of Vanceril (3.13 ± 0.07 μm) obtained using the ELPI in
this study was smaller than those obtained using both the ACI and the NGI.

Figure VII.1. Comparison of Aerodynamic Particle Size Distributions of the Calibration pMDI Aerosols Determined from
Single Actuations into the ACI and the Modified ELPI (n = 5). Error Bars Represent Standard Deviation.
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Summary of MMADs and GSDs of the Calibration pMDI Aerosols Along
with the Literature Reported Values for the MMADs
Product
Impactor
GSD (Linear
MMAD (μm)
Inpterpolation)
Literature
Linear Interpolation
Qvar
ACI
1.1a
0.94±0.06
1.80
ELPI
0.60±0.05
2.21
b
2.20±0.04
1.65
Ventolin CFC
ACI
2.2
ELPI
1.71±0.05
1.84
Flovent HFA
ACI
2.51±0.10
1.65
ELPI
2.02±0.03
1.75
3.86±0.12
1.52
Vanceril
ACI
3.9c
ELPI
3.13±0.07
1.65
a
b
c
Leach et al. 1998, Mitchell et al. 1999, Kamiya et al. 2004.
Table VII.3.

The ELPI was originally designed for real time particle sizing of aerosols using
electrical detection (Keskinen et al. 1992). The performance of the ELPI as a particle size
analyzer when used with the corona charger in comparison to a Scanning Mobility Particle
Sizer (SMPS), for charged dioctyl sebacate (DOS) droplets in isopropyl alcohol, has been
investigated and good agreement between the two techniques was reported (Maricq et al.
2000, Marjamaki et al. 2000). Telko et al. have also employed the ELPI in its standard
mode of operation (with the corona charger switched on) to determine aPSDs of
pharmaceutical aerosols via electrical detection (Telko et al. 2007). The authors found that
the aPSDs of experimental DPIs containing albuterol sulfate-lactose blends determined
using the ELPI via electrical detection compared well with those obtained subsequently via
gravimetric analysis. There was a discrepancy in the particle size observed on the lower
stages where the use of the gravimetric sizing technique was reported to be limited by the
sensitivity of the analytical balance used (Telko et al. 2007). The aPSDs obtained by both
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these techniques, however, were not specific to drug mass and the results obtained
therefore may be of limited use for characterization of pharmaceutical aerosols.
In a separate experiment, Telko et al. also determined the aPSDs of these
experimental albuterol sulfate - lactose blend DPIs sampled simultaneously into a ELPI
and ACI and reported that the MMAD determined with the ELPI was 2.1 μm and with the
ACI, 2.2 μm (Telko et al. 2007). However, these data were obtained with a noncompendial set up and the authors did not validate the data against the compendial
apparatus. Furthermore, the flowrate used by the authors was slightly outside the
acceptable range for the ACI (26.8 - 29.7 L/min; USP 29 / NF 24 First Supplement 2006).
The cut-off diameters are not well established for the USP Apparatus III (ACI with a
preseparator) in the airflow range 30 - 100 L/min (USP 29 / NF 24 First Supplement 2006).
While it is not recommended that the cut-off diameters for the ACI at 30 L/min be
calculated using Equation VII.4 (USP 29 / NF 24 First Supplement 2006), it is interesting
to note that the calculated cut-off diameters (D50) at Q = 30 L/min are smaller than the
corresponding cut-off diameters at Qn = 28.3 L/min.
D50,Q = D50,Qn (Qn / Q) 0.5

Equation VII.4

For example, cut-off diameters for the ACI stages 1 and 6 at 28.3 L/min are 5.8 and
0.7 μm, respectively; in comparison, the calculated cut-off diameters at 30 L/min for stages
1 and 6 were 5.63 and 0.67 μm, respectively. Since, the aPSDs determined by Telko et al
using the modified ELPI were in good agreement with those determined using the ACI at
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30 L/min, it may also be speculated that the ELPI possibly undersized the experimental
DPIs tested.
A possible explanation for undersizing of aerosols produced by pMDIs by the
modified ELPI is likely found in the manner in which the ELPI was originally calibrated.
Aerosols (e.g., polystyrene latex, oleic acid, ammonium fluorescein, sodium chloride
particles) generated for calibration of instruments used for aerosol characterization can be
monodisperse or polydisperse, wet or dry, charged or uncharged, spherical or nonspherical
(Chen and John 2001). Since aerosol particles are usually charged by static electrification
after formation, these aerosols are passed through a neutralizer containing a bipolar ion
source (e.g.

63

Ni, 85Kr,

241

Am) in order to reduce the number of charges on particles to

charge equilibrium. In addition, a concentrator or a diluter may be required to adjust the
aerosol concentration (Chen and John 2001). Conventional cascade impactors are typically
calibrated using charge neutralized aerosol particles of known size and these particles are
collected in an electrically conductive impactor (Marple et al. 2003, Garmise and Hickey
2008).
For an instrument designed for real time particle size measurement, the calibration
process would determine a relationship between the response of the instrument (e.g.,
electronic signal) and the property (e.g., particle size, mass concentration, number
concentration) being measured (Chen and John 2001). The ELPI, which was originally
designed to measure real time particle size distributions by electrical detection, has been
calibrated using charged monodisperse aerosols of di-octyl sebacate (DOS) with the
exception of the topmost stage, stage 13, which has been calibrated using a fluorimetric
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method (Keskinen et al. 1999, Marjamaki et al. 2000). In order to produce aerosol droplets
in the wide size range of 0.03 - 10 μm corresponding to the ELPI cut-off diameters, two
different aerosol generation techniques were employed (Marjamaki et al. 2000). Droplets
in the size range of 0.015 - 0.9 μm were generated using an evaporation-condensation
generator that produced polydisperse aerosols, which were then size classified according to
their electrical mobility using a differential mobility analyzer before introducing them into
the ELPI. The vibrating orifice aerosol generator was used to produce monodisperse
aerosol droplets ranging in size from 0.9 - 11 μm; these aerosols were first neutralized to
charge equilibrium and then highly charged by passing through the corona discharge unit
before they entered the impactor (Marjamaki et al. 2000). Finally, the impactor was
calibrated using the electrical current, rather than mass data, since the current signal
produced by the charged monodisperse calibration aerosol droplets was related to the
number and mass concentration (Keskinen et al. 1999, Marjamaki et al. 2000).
Because the basis of the ELPI’s calibration assumes the sizing of highly charged
aerosol particles and droplets, the particle size data reported for pharmaceutical aerosols in
earlier studies in which the modified ELPI has been employed should be viewed with
caution. In those studies the calibration of the ELPI was assumed to remain unchanged
even though triboelectrification, as commonly seen in many pharmaceutical systems,
cannot impart charges of the same magnitude as the corona discharge employed by the
unmodified ELPI. Therefore, in order to use the modified ELPI as a sizing instrument
paired with chemical analysis of drug depositing on its stages, recalibration was required.
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As an alternative to a comprehensive and expensive recalibration of the ELPI with
monodisperse aerosols, the present study utilized four commercially available pMDIs,
representing small (Qvar), medium (Ventolin CFC and Flovent HFA) and large (Vanceril)
aerosols as polydisperse calibration standards. The ACI, USP Apparatus I, (USP 29 / NF
24 First Supplement 2006) was used as the reference cascade impactor for determination of
each calibration aPSD. The use of a polydisperse calibration method precludes the
determination of the cut-off properties of the topmost stage (Stage 13) of the ELPI. Hence,
it was necessary to recalculate the cascade impactor doses of the pMDIs used as
‘calibration’ aerosols for the ACI and the ELPI experiments in order to exclude the drug
collected on the top stages (Stage 0 of the ACI, Stage 13 of the ELPI).
Table VII.4 summarizes the emitted dose, actuator dose, USP induction port dose,
top stage dose, and impactor dose (dose collected below top stage of the impactor) for each
of the four pMDIs used for calibration purposes. It was observed that the mass of drug
depositing on the ELPI inlet port and the upper stage (stage 13) were consistently < 3% of
the total emitted dose for all tested pMDIs; the deposition on the upper stage (stage 0) of
the ACI for each inhaler was also found to be less than 3% of the impactor dose. The
ballistic portion of each pMDI’s output was collected primarily within the USP induction
port (Table VII.4) and it was therefore considered reasonable that selective sampling into
the different aerosol inlets directly atop the ACI and the ELPI would not pose a problem
when using the ACI data for each pMDI product to recalibrate the modified ELPI.

Table VII.4.
Product

Qvar

Ventolin
CFC
Flovent
HFA
Vanceril

Emitted dose, Actuator Dose, USP Induction Port Dose, Top Stage Dose, and Impactor Dose (Dose Collected
Below Top Stage of the Impactor) for Each of the Four pMDIs Used for Calibration Purposes
Label
Impactor
Mass collected (SD) in μg
Claim
Inlet port
Impactor Dosec
Total Emitted
Actuator
dose
Top Stageb
USP Induction Porta
40 μg

90 μg

44 μg

42 μg

ACI

36.87 (1.17)

9.68 (1.29)

17.45 (3.44)

0.21 (0.07)

19.22 (4.59)

ELPI

37.92 (2.74)

12.76 (1.72)

16.69 (1.10)

0.73 (0.10)

20.51 (3.06)

ACI

88.54 (5.22)

14.14 (1.43)

47.77 (3.14)*

0.84 (0.51)

39.93 (4.12)*

ELPI

87.64 (9.68)

12.07 (1.11)

55.94 (5.00)*

0.33 (0.21)

31.37 (5.31)*

ACI

37.79 (1.92)*

8.44 (0.84)

16.92 (1.27)

0.46 (0.14)

20.41 (1.38)*

ELPI

34.43 (1.69)*

6.62 (0.37)

16.38 (0.91)

0.15 (0.24)

17.90 (1.17)*

ACI

37.34 (1.79)

8.58 (2.31)

20.98 (0.96)

0.96 (1.08)

15.40 (0.70)*

ELPI

34.45 (2.27)

7.06 (1.70)

22.65 (1.60)

0.16 (0.06)

11.64 (1.49)*

a

Includes mass of drug recovered from the mouthpiece adaptor for both the ACI and the ELPI experiments.
Includes mass of drug recovered from the ELPI inlet (Figure III.3) for the ELPI experiments which was consistently < 3% of
the emitted dose for all the pMDIs tested.
c
Mass of drug collected below the topmost stage (Stage 0 of the ACI, Stage 13 of the ELPI) of each impactor.
*Difference in the drug deposition between the ACI and the ELPI experiments statistically significant.
b
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The total dose collecting on all the stages below the top stage (Stage 0 of the ACI,
stage 13 of the ELPI), i.e., the recalculated impactor dose was statistically comparable (p >
0.05) between the ACI and ELPI experiments for QVAR whereas there was a small but
statistically significant difference (p < 0.05) in the recalculated impactor doses between the
ACI and the ELPI for its higher variance suspension counterparts as shown in Table VII.4.
Because these apparent statistical differences in impactor dose could not be attributed to
differences in the masses of drug collected in the experimentally variable portion of each
inlet configuration, i.e., the ELPI inlet and top stage deposition (Table VII.4), it was
reasonable to assume that the aerosols depositing from each pMDI in the ACI and the
modified ELPI had comparable aPSDs. This assumption would be reasonable provided the
droplet evaporation for the pMDI aerosols sampled inside the two cascade impactors was
comparable.
The ELPI is a low-pressure impactor and in comparison to the ACI (which operates
at atmospheric pressure), the downstream pressure measured at the ELPI stage 5 is
equivalent to the pressure at the base of the ACI (90 - 100 kPa); stages 1 - 4 of the ELPI
are at pressures lower than 90 kPa (Appendix A.I, Greenspan 2008). Since the downstream
pressures for stages 5 - 13 of the ELPI and all the ACI stages are equivalent, droplet
evaporation of the pMDI aerosols may be considered to be comparable for those stages as
well. From the mass distribution data obtained for the ELPI experiments, it was observed
that drug deposited predominantly on stages 6 and above, with the exception of QVAR,
suggesting therefore that the aerosol clouds being sampled into the ACI and the EPI would
be comparable.
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VII.D.2. Curve Fitting of the ACI aPSD Data for the Calibration Aerosols

The mass distribution data from stages 1 - 7 plus filter of the ACI in each single
actuation experiment was expressed as a percentage of the total impactor dose, which is the
total drug mass collected on the filter and stages 1 - 7, for each product (n = 5). Drug
deposition on stage 0, the topmost stage of the ACI, was not included in the determination
of total impactor dose since the upper limit of the size range of drug particles depositing on
that stage is unknown. The aPSDs of each of these pMDI aerosols followed a lognormal
distribution. The lognormal distribution of the aPSDs of pMDIs can be described in terms
of two variables, a single MMAD (μm) and a dimensionless geometric standard deviation
(GSD) (Thiel 2002). The cumulative percent drug undersize data determined using the ACI
was therefore fitted to a lognormal distribution function using non-linear regression
analysis.
Figure VII.2 shows the mean results for cumulative percent drug undersize versus
the aerodynamic cut-off diameter for each stage of this ACI after mensuration in accord
with the USP (USP 29 / NF 24 First Supplement 2006). Also shown, as continuous curves,
are the results of curve fitting for each product. The numerical results of curve fitting the
ACI data and its 95% confidence limits are shown in Table VII.5. Also shown in the table
are the MMADs for the calibration pMDIs reported in the literature obtained using the
ACI. The MMADs obtained from curve fitting were not statistically different from those
obtained for all the calibration pMDIs when calculated by linear interpolation of data,
which included drug deposition on stage 0 of the ACI.
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Figure VII.2. Mean Cumulative Percent of Drug Mass Undersize versus Aerodynamic
Diameter (n = 5), Following Collection of Single Actuations of Qvar,
Ventolin CFC, Flovent HFA, and Vanceril in the ACI at 28.3 L/min. The
Solid Profiles are the Result of Curve Fitting to Equation VII.1. Model
Selection Criteria Results Exceeded 5 in all Cases and Values for all
Coefficients of Determination (COD) > 0.99. Error Bars are Sample
Standard Deviations.
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Table VII.5.

Product

Qvar

Numerical Results of Curve-Fitting the Cumulative Percent Undersize Data from the ACI for Each Aerosol
Product to Equation VII.1. The Best Estimates for MMAD and GSD are Shown with their 95% Confidence
Intervals along with the MMADs Reported in Literature
MMAD (μm)a
Curve Fit

Literature

0.93

1.1b

Confidence
Interval (μm)

GSD

Confidence
Interval

Model Selection
Criteria (MSC)

Coefficient of
Determination
(COD)

0.91 – 0.95

1.64

1.58 – 1.70

5.3828

0.9957

c

Ventolin
2.18
2.2
2.16 – 2.20
1.54
1.52 – 1.55
7.7427
0.9996
CFC
Flovent
2.46
2.44 – 2.50
1.55
1.51 – 1.56
6.6740
0.9962
HFA
Vanceril
3.67
3.9d
3.62 – 3.73
1.4
1.36 – 1.42
5.4910
0.9985
a
For numerical fitting of the ACI data in this study, drug deposition on stage 0 was not included in the determination of total
impactor dose since the upper limit of the size range of drug particles depositing on stage 0 is not known.
b
Leach et al. 1998, cMitchell et al. 1999, dKamiya et al. 2004.
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The MMADs obtained from curve fitting were comparable with those reported in
the literature even though the USP technique used in the literature for determination of
MMADs includes drug deposition data on stage 0 of the ACI. The curve fitting procedure
produced excellent fits of the ACI cumulative data which were well modeled as monomodal and log-normally distributed as indicated by the goodness-of-fit parameters; MSC >
5 and COD > 0.99 for all the pMDIs. Although the fit for cumulative deposition of drug
below stage 4 deviated slightly from the experimental results for Vanceril (Figure VII.2),
the COD value suggested that 99.6% of the total variance was accounted for by the model
used to fit the cumulative percent BDP undersize data for Vanceril. In addition, a MSC
value of 5.4910 also gave an indication of the goodness-of-fit of the lognormal function
used in curve fitting the Vanceril ACI data.

VII.D.3. Calculation of the Aerodynamic Cut-off Diameters of the Modified ELPI
Using the ACI Curve Fitted Data

The curves of best fit from the ACI (Figure VII.2), and thus the best estimates for
MMAD and GSD (Table VII.5), were also assumed to describe the clouds penetrating
beneath the topmost stage (stage 13) of the ELPI. Because Equation VII.1 cannot be solved
analytically for aerodynamic diameter (and the cut-off diameter of the ELPI stages) (Thiel
2002), MMAD and GSD were fixed at their product-specific best estimates and solutions
for the cut-off diameter were determined for each stage of the ELPI by the iterative
technique described in Section VII.C.3. This procedure resulted in a series of product-
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specific numerical solutions or “estimates” for the cut-off diameters for the major stages of
the ELPI. For example, if 79% of the cloud from a single shot of Qvar was shown to have
aerodynamic diameters that enabled penetration of the drug beneath stage 8 of the ELPI,
this would enable the substitution of a value of 79 (%) for y (LHS of Equation VII.1) while
MMAD and GSD are assigned their best estimates from Table VII.5 (0.93 μm and 1.64,
respectively). Numerical solution of Equation VII.1 for aerodynamic diameter (x) would
then produce a solution = 1.37 (μm). This value (1.37) was then assigned to the cut-off
diameter of stage 8 for that individual experiment. Because each experiment was
replicated, this resulted in 5 individual estimates along with a mean and sample standard
deviation for the cut-off diameter of stage 8 from the Qvar experiments.
Table VII.6 shows the means and standard deviations of the cut-off diameters for
the individual stages of the ELPI for each of the calibration products. The mean cut-off
diameters calculated using each of the four calibration pMDIs have been tabulated in
Appendix A.VI.4. The calibration aerosols used in this study were polydisperse in nature,
hence on certain stages of the ELPI, no drug was detected and consequently cut-off
diameters could not be calculated for those stages from some of the calibration pMDI
aerosols. Cut-off diameter for stage 1 could not be obtained from any of the calibration
pMDIs since no drug was detected on that stage. Cut-off diameters for stages 2 - 5 could
be calculated using cumulative percent undersize data from QVAR pMDI aerosols alone
since the drug clouds failed to penetrate beyond stage 6 for Ventolin CFC and beyond
stage 7 for Flovent HFA and Vanceril.
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Table VII.6.

Calculated Aerodynamic Cut-off Diameters (μm) of the Different ELPI
Stages Based on the Replicate Results (n = 5) for Each of the 4 pMDIs
Studied as Calibration Standards. Results Expressed as Mean (SD).
Qvar
Ventolin CFC
Flovent HFA
Vanceril

Stage #
a
a
a
a
1
a
a
a
2
0.28 (0.01)
a
a
a
3
0.35 (0.01)
a
a
a
4
0.44 (0.02)
a
a
a
5
0.56 (0.01)
a
a
6
0.70 (0.02)
0.77 (0.03)
7
0.98 (0.06)
1.03 (0.02)
0.98 (0.01)
1.79 (0.35)
8
1.37 (0.14)
1.42 (0.01)
1.39 (0.02)
1.65 (0.18)
9
2.10 (0.12)
2.08 (0.04)
2.01 (0.04)
2.31 (0.08)
10
2.64 (0.24)
3.15 (0.15)
2.93 (0.06)
3.01 (0.08)
11
3.39 (0.22)
5.08 (0.31)
4.62 (0.08)
4.54 (0.07)
b
b
a
12
6.37 (0.21)
c
c
c
c
13
a
Drug mass < LOQ
b
Stages 12 and 13 were combined since drug detected on individual stages in preliminary
experiments was often < LOQ
c
Polydisperse calibration provides no information on the cut-off of the uppermost stage
For stage 6, cut-off diameters could be calculated from two aerosols, QVAR and
Ventolin CFC. Drug deposition data from all the calibration pMDI aerosols could be used
to calculate cut-off diameters for stages 7 - 11; higher degree of confidence can be placed
on the calculated cut-off diameters for stages 7 - 11 since most of the drug deposited

predominantly within this size range for all the four calibration pMDIs. The cut-off
diameter for stage 12 could be calculated from Vanceril data alone since no drug was
detected on stage 12 for any of the other calibration pMDIs. The cut-off diameter for the
topmost stage, stage 13, could not be calculated using this technique from any of the
calibration aerosols since the upper cut-off diameter of the polydisperse calibration
aerosols depositing on the topmost stage was not known.
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An inclusion criterion was set for determining the final recalibrated cut-off
diameters from the values obtained in Table VII.6. Those calculated cut-off diameters for
which the mean cumulative percent of the impactor dose depositing below a given stage
fell within the range of 3 - 97 % (Table VII.7) were chosen.

Table VII.7. Mean Cumulative Percent of the Impactor Doses of the Four Calibration
pMDIs Used in the Study (n = 5).
Stage No.
Qvar
Ventolin CFC
Flovent HFA
Vanceril
Stage 1
0
0
0
0
Stage 2
0.75
0
0
0
Stage 3
2.63
0
0
0
0
0
0
Stage 4
6.41
0
0
0.73
Stage 5
15.74
0.77
0
0.73
Stage 6
28.48
1.55
0.81
Stage 7
53.92
4.12
2.01
Stage 8
77.91
16.07
8.98
Stage 9
94.84
45.73
31.69
7.9
Stage 10
98.09
80.22
65.59
27.18
Stage 11
99.52
97.43
92.81
74.08
Stage 12
99.52
97.43
98.38
95.27
Stage 13
100
100
100
100
This inclusion criteria was chosen so that the data fell in the linear portion of the
lognormal distribution for each of the products since the reliability of cut-off diameters
obtained would decrease for stages when drug deposition is low, i.e., the tail ends of the
lognormal curve. The values of cumulative percent undersize data for the pMDIs marked
in bold in Table VII.7 fell within the linear portion of the cumulative percent undersize vs.
aerodynamic size curve; the cut-off diameters calculated using those values were averaged.
Table VII.8 summarizes the final cut-off diameters for the ELPI stages 4 - 12 calculated
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using this technique. For comparative purposes, the manufacturer’s claims of the cut-off
diameter for each stage of the ELPI have also been tabulated (Table VII.8).

Table VII.8.

Mean Recalibration Values for the Aerodynamic Cut-off Diameter of the
ELPI Stages Compared to the Values Provided by Dekati.
ELPI Stage #
Dekati Cut-off
Mean Calculated CutDekati d50a/ Mean
Calculated d50
Diameter (μm)
off Diameter (μm)
b
b
1
0.03
b
b
2
0.06
b
b
3
0.10
4
0.16
0.44
0.37
5
0.27
0.56
0.48
6
0.39
0.70
0.56
7
0.62
1.01
0.62
8
0.96
1.40
0.69
9
1.62
2.12
0.76
10
2.42
3.03
0.80
11
4.05
4.75
0.85
12
6.67
6.37
1.05
c
c
13
10.08
a
d50: Aerodynamic Cut-off Diameter
b
Cumulative percent undersize data fell out of the inclusion criteria
c
Polydisperse calibration does not provide information on the cut-off diameter of the
topmost stage

Table VII.9 shows the cut-off diameters of the ELPI stages calculated using the
95% confidence intervals of the best estimates of the MMAD and GSD for all the four
calibration pMDIs.

Table VII.9. Mean Values of 50% Cut-off Diameters for ELPI Stages 4 - 12 Calculated Using 95% Confidence Intervals of
the Best Estimates of MMADs and GSDs Obtained from Curve-Fitting the ACI Cumulative Data for the Four
Calibration pMDIs
Mean Calculated Cut-Off Diameters (μm) of ELPI Stages 4 - 12
Using Upper CIsa of
Using Lower CIa of
Using Upper CIa of
Using
Mean
Estimates
Using
Lower CIsa of
Stage No.
a
of MMAD & GSD from MMAD & GSD from ACI MMAD & GSD from ACI MMAD & Upper CI of MMAD & Lower CIa of
Curve Fit
Curve Fit
GSD from ACI Curve Fit GSD from ACI Curve Fit
ACI Curve Fit
Stage 4
0.44
0.45
0.42
0.40
0.47
Stage 5
0.56
0.57
0.56
0.53
0.60
Stage 6
0.70
0.70
0.70
0.67
0.73
Stage 7
1.00
1.00
1.01
0.98
1.03
Stage 8
1.40
1.38
1.41
1.37
1.42
Stage 9
2.12
2.09
2.17
2.11
2.15
Stage 10
3.03
2.99
3.07
3.00
3.06
Stage 11
4.75
4.60
4.89
4.79
4.71
Stage 12
6.37
6.06
6.70
6.50
6.25
a

CIs: 95% Confidence Intervals on estimates of MMAD and GSD obtained from curve fitting the ACI cumulative data of the
four calibration pMDIs (Qvar, Ventolin CFC, Flovent HFA and Vanceril) to a lognormal cumulative distribution function.
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The cut-off diameters summarized in Table VII.9 were not statistically different (p>0.05)
from those calculated using the best estimates of MMAD and GSD for the ELPI stages 4 11. However, the difference became statistically significant (p < 0.05) for stage 12 due to a
larger variance in stage 12 deposition associated with testing Vanceril.
The manufacturer’s reported cut-off diameters and the mean cut-off diameters
calculated from the mean estimates of the MMAD and GSD have been compared in Table
VII.8. Of greatest note is the increasing margin of error in the calculated cut-off diameters
of the lower stages of the ELPI, i.e., the impactor stages with smaller cut-off diameters
deviated more markedly than the upper stages from values claimed for corona-charged
aerosols. For example, the calculated stage cut-off diameter for the ELPI Stages 4 and 12
were determined to be 0.44 and 6.37 μm, respectively as compared to the manufacturer’s
reported cut-off diameters (0.16 and 6.67 μm for Stages 4 and 12, respectively).
While particle charging theory is a complex function of size (Hinds 1999), the trend
of increasing errors as aerosol size became smaller (Table VII.8) suggests that the ELPI
may behave differently when separating corona-charged aerosol particles. Briefly, it is
possible that deposition of charged particles in this impactor may be influenced by
mechanisms in addition to impaction. Electrophoretic mobility of charged particles, for
example, increases substantially as size decreases. Further investigation into the influence
of electrostatics on in vitro aerosol separation during testing therefore appears warranted
but is not included in the scope of this study.
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VII.D.4. Validation of the Recalibration of the Modified ELPI

To validate the recalibration of the modified ELPI and the cut-off diameters
calculated for the modified ELPI, a single canister of a fifth product, Ventolin HFA, was
studied after the ELPI recalibration procedure had been completed. Ventolin HFA was
tested by collecting five single actuations in the ACI in accord with the USP and the
procedures repeated in the modified ELPI. Table VII.10 shows that both the actuator
deposition as well as drug deposited in the USP induction port for Ventolin HFA aerosols
were statistically comparable (p > 0.05) between the ACI and the ELPI experiments.

Table VII.10. Summary of Mass Recovery from Ventolin HFA using ACI and modified
ELPI (n = 5, 5 shots / can, 1 can)
Impactor
Mass Recovered (μg)
Emitted dose

Actuator

USP Induction
Porta

Impactor Doseb

ACI

97.46 (10.35)*

13.57 (1.82)

44.47 (4.66)

52.99 (6.74)*

ELPI

78.26 (6.03)*

13.52 (1.59)

41.70 (4.61)

36.55 (2.79)*

a

Includes mass of drug recovered from the mouthpiece adaptor and the ELPI Inlet.
Mass of drug collected on all stages of each impactor (Stages 0 - 7 & filter of the ACI,
Stages 1-13 of the ELPI).
*Difference in the drug deposition between the ACI and ELPI experiments statistically
significant.

b

The mean emitted dose of Ventolin HFA was statistically higher (p < 0.05) for the
ACI when compared to that obtained from the ELPI experiments (Table VII.10). While the
total mass recovery for these single shot experiments was more variable for Ventolin HFA
(a surfactant-free formulation of albuterol sulfate in HFA 134a) than for any of the other
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products, the mass depositing on the ELPI inlet was less than 0.5% of the emitted dose in
all cases. Not surprisingly, the mean impactor dose of Ventolin HFA obtained in the ACI
was significantly higher (p < 0.05) than that obtained from the ELPI.
Cumulative percent mass undersize for Ventolin HFA was calculated for each experiment
and plotted using the ACI cut points taken from (USP 29 / NF 24 First Supplement 2006)
while the single actuation data from the modified ELPI was treated in two ways; cut-off
diameter values were taken either from Dekati (Table III.1) or from the results of the
recalibration shown in Table VII.8. Figure VII.3 shows the results of this procedure.
Figure VII.3. Mean Cumulative Percent Undersize Versus Aerodynamic Diameter (n =
5), Following Collection of Single Actuations of Ventolin HFA in ACI
(Circle), Ventolin HFA in the Modified ELPI with Cut-Off Diameters taken
from Dekati (Triangle) or Calculated in this Study (Inverted Triangle). The
Profiles are Simple Linear Interpolations Between Data Points. Error Bars
are Sample Standard Deviations.
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The MMAD for Ventolin HFA pMDI aerosols using the modified ELPI with the
manufacturer-supplied cut-off diameters was 2.06 ± 0.08 μm. The MMAD of Ventolin
HFA obtained using the calculated cut-points for the ELPI (Table VII.8) was 2.63 ± 0.09
μm, which was statistically comparable (p = 0.0852) to that determined using the ACI
(2.73 ± 0.09 μm). This study showed that the aPSDs for Ventolin HFA were
indistinguishable when determined in the modified ELPI or the ACI, provided the new cut
points described in Table VII.8 were used for the aerodynamic particle size analysis.
The use of an instrument at operating conditions and parameters different from
those utilized when the instrument was originally calibrated may render that calibration
inappropriate and hence recalibrating the instrument under the modified conditions is
essential to operate the instrument with confidence (Chen and John 2001). It is reasonable
to assume that the modified ELPI subdivides particles primarily by impaction, in a similar
fashion to the ACI and other cascade impactors, which was the basis of this recalibration
exercise in which the stage cut points for known aerosols in the ELPI were determined by
direct comparison to a mensurated ACI, used as a calibration instrument. Previous studies
have shown that aPSDs of pharmaceutical aerosols determined using different ACIs can be
variable due to inter-impactor stage cut-points variability (Stein and Olson 1997).
However, the present study was an attempt to calibrate a single ELPI in comparison with
an ACI, both of which have been utilized in the same research laboratory and was not
intended to investigate inter-impactor variability of PSD data from multiple ELPI and ACI
cascade impactors. To this end, it was ensured that both the ACI and the ELPI used for
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these experiments were duly mensurated by MSP Corporation of St. Paul, MN, USA and
Dekati, Inc. of Tampere, Finland, respectively.
In summary, the study showed that in the absence of a comprehensive recalibration
of the ELPI using monodisperse aerosols, commercially available, polydisperse aerosols
may be used as calibration standards in a reference cascade impactor and that this
constitutes a practical way of calibrating alternative particle sizing instruments.

VIII. OVERALL DISCUSSION AND SUMMARY

Aerosol electrostatics is considered to be an important property of
pharmaceutical aerosols. Previous studies have shown that the electrostatic properties of
pMDI aerosols characterized using the aerosol electrometer and the modified electrical low
pressure impactor (ELPI) are a function of both formulation and packaging components
(Peart et al. 1998, Glover and Chan 2004a, Kwok et al. 2005). The modified Electrical
Low Pressure Impactor (ELPI) enables measurement of the charge distribution of aerosol
clouds as a function of particle size, and the simultaneous determination of the mass
distribution using chemical analysis. However, in order to fully assess the cause and effects
of pMDI aerosol electrostatics in terms of its biological and regulatory implications, it is
necessary to understand the basic charging mechanisms inside the pMDI formulation as
well as the electrostatic properties of aerosols produced by these HFA based pMDI
formulations.
Electrical properties of the formulation within the pMDI canister are not well
characterized, primarily due to a lack of consensus on charge generation mechanisms and
the experimental difficulties associated with the measurement of electrical properties in
non-aqueous liquefied propellants (Sidhu et al. 1993, Sandstrom et al. 1994, Rogueda
2002, Traini et al. 2005). Electrical resistivity of experimental HFA 134a based
beclomethasone dipropionate (BDP) solutions and albuterol sulfate suspensions were
188
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determined in order to establish the presence of ionic species in these systems. Although
HFA 134a has high resistivity, which could not be measured reliably, the presence of
ethanol in the control HFA solutions tested increased the conductivity of the formulation,
which resulted in a decrease in the resistivity. The mean electrical resistivity of a 7%
ethanol / 93% HFA 134a blend (0.83 ± 0.02 MΩ.cm) was significantly lower in magnitude
than that reported for HFA 134a in the literature (180 MΩ.cm; Solvay Fluor Product
Bulletin 2001). The presence of water in ethanol may confound the results obtained for
resistivity measurements of the ethanol - HFA based formulations. For albuterol sulfate
suspensions in HFA 134a containing ethanol and oleic acid, the resistivity measurements
decreased with increased ethanol concentrations. The mean resistivity of an albuterol
sulfate suspension containing 0.02% oleic acid in 5% ethanol / 95% HFA 134a was 1.74 ±
0.02 MΩ.cm, which was higher than that obtained for a suspension in 10% ethanol / 90%
HFA 134a (0.37 ± 0.01 MΩ.cm). The resistivity measurements suggested that ethanolcontaining HFA formulations are relatively polar and may likely produce charged species
in these systems.
Electrophoretic mobility studies were performed to investigate the surface charge
of albuterol sulfate suspensions in HFA 134a. Albuterol sulfate demonstrated a positive
zeta potential (75.9 ± 26.2 mV) in a simple suspension in 100% HFA 134a, although, there
was variability in the measurements. It may be hypothesized that surface charge formation
in such formulations may be due to the presence of trace water (59 ± 7 ppm) or impurities.
In addition to these simple albuterol sulfate suspensions, albuterol sulfate suspensions in
HFA 134a containing oleic acid and ethanol were also investigated. The electrophoretic
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mobility and the corresponding zeta potential of albuterol sulfate decreased in the presence
of oleic acid and ethanol. The zeta potential value decreased from 39.5 ± 7.8 mV for an
albuterol sulfate suspension containing 0.02% oleic acid in a 5% ethanol / 95% HFA 134a
blend to 15.4 ± 9.7 mV for a suspension in a 15% ethanol / 85% HFA 134a blend.
However, the limitation of this technique is that dilute particle concentrations are required.
Unfortunately, these dilute concentrations do not reflect the concentration of drug present
in commercially available suspension pMDIs and hence the results obtained are difficult to
extrapolate to commercial products.
In order to gain an improved understanding of the possible interactions within
pMDI suspensions on the molecular level, a pilot study was performed, wherein molecular
models of a simple pMDI formulation containing an albuterol sulfate crystal unit cell in
HFA 134a were constructed and optimized using molecular modeling software, Sybyl. The
interactions between the drug and propellant molecules were investigated using the
Hydropathic INTeractions (HINT) program. The total HINT score was predominantly
negative (-7597 ± 2063) signifying unfavorable interactions between the albuterol sulfate
unit cell and the surrounding HFA 134a molecules. In practice, this observation is not
unexpected. It is well recognized that HFA based suspension pMDIs have an increased
propensity for drug adhesion to the canister inner surface and the use of fluorocarbon
polymer coating, e.g., PTFE (polytetrafluoroethylene), on the canister inner surfaces to
minimize drug adhesion has been documented in the patent literature (Ashurst et al.
2000a).
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Although the majority of the interactions between the albuterol sulfate unit cell and
individual HFA 134a molecules were unfavorable, approximately 23% of the total number
of HFA 134a molecules surrounding the albuterol sulfate unit cell showed net favorable
interactions with the unit cell. Unfavorable hydrophobic-polar interactions were likely
between carbon atoms of HFA 134a and polar groups of albuterol sulfate, while base-base
interactions may be accounted for by the unfavorable interactions between the fluorine
atoms of HFA 134a and sulfate group of albuterol sulfate. Hydrophobic interactions
between carbon atoms of HFA 134a and those present on the side chain of albuterol sulfate
and polar acid-base interactions between the hydroxyl or amine group of albuterol sulfate
with the fluorine atoms of HFA 134a contributed to the favorable or positive interaction
scores.
Molecular modeling studies of interactions within a complex formulation, e.g.,
interactions within a molecular model containing albuterol sulfate unit cell, oleic acid and
ethanol molecules solvated in a HFA 134a solvent box, were significantly more
challenging compared to the two-component system. Since, the oleic acid and ethanol
molecules were arbitrarily placed around the albuterol sulfate unit cell in the molecular
model, it was not possible to take into consideration the interactions between the solvated
components within the model for every likely conformation with respect to the interacting
molecules. However, an indication of the likely types of interactions could be obtained
from the analysis of these models. In order to gain confidence in the HINT score analysis
of the likely types of interactions within these pMDIs, an increased number of replicates
would be required. Molecular modeling in conjunction with the analysis of interactions
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using the HINT program may serve as a useful tool to provide a better understanding of
interactions between pMDI formulation components on a molecular level in a propellant
medium. Studies could also usefully be extended to the investigation of canister coating
materials used in pMDI canisters.
Electrostatic charge characterization of commercial HFA based solution and
suspension pMDIs using a modified ELPI has previously been reported (Kwok et al.
2005), however, a systematic study investigating the differences in the electrostatic
charging characteristics of solution and suspension HFA pMDIs is deficient. HFA
propelled beclomethasone dipropionate (BDP) solution pMDIs and albuterol sulfate
suspension pMDIs were chosen as the model pMDIs to investigate the influence of
formulation components on the aerosol charge determined using the modified ELPI. It was
hypothesized that since BDP solution pMDIs are a homogeneous system each aerosol
droplet would have a uniform distribution of drug and excipients, and may exhibit similar
charging characteristics resulting in a unipolar charge distribution. Not surprisingly,
QVAR 40, a commercially available BDP HFA solution pMDI, produced predominantly
unipolar electropositive aerosol clouds with a mean total net electrostatic charge of +449 ±
254 pC.
The experimental 100% HFA 134a pMDIs produced primarily net electropositively
charged aerosol clouds (mean net inherent charge: 68 ± 100 pC). The mean net inherent
charge for ethanol / propellant blend aerosol clouds was also predominantly net
electropositive (108 ± 11 pC). The experimental BDP solution pMDIs produced
predominantly electropositive clouds with a mean net electrostatic charge of 160 ± 30 pC,
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which was significantly higher (p = 0.0069) than that obtained for the ethanol / propellant
blend pMDIs. The addition of BDP to an ethanol / propellant HFA 134a blend did not
affect the unipolar charge distribution profile observed for the ethanol - propellant blend.
The predominant effect of ethanol as a polar cosolvent on the electrical properties of the
control HFA based solutions was confirmed from the electrical resistivity measurements.
The addition of ethanol decreased the resistivity of pure propellant HFA 134a suggesting
that addition of ethanol increased the polar nature of the propellant as well as the
conductivity of the solution.
Ventolin HFA, an albuterol sulfate HFA suspension pMDI, produced bipolar
aerosol clouds with a mean net FPD charge (particles smaller than 4.05 μm, manufacturer
reported cut-off diameter for ELPI stage 11) of –232 ± 37 pC, which was comparable to
the FPD charge (particles smaller than 5 μm) reported in the literature for Ventolin HFA (231 ± 3 pC), measured using an aerosol electrometer (Kulphaisal 2003). Propellant HFA
134a pMDIs produced primarily net electropositively charged clouds (mean net inherent
charge: 59 ± 45 pC). The mean net charge of the propellant droplets on the individual
stages, stages 1 - 12 of the ELPI, was found to be negligible in comparison to that of the
experimental albuterol sulfate pMDI aerosols, which produced bipolar charged aerosol
clouds. Particles depositing on stages 1 - 6 were net electronegatively charged.
Interestingly, negligible albuterol sulfate was detected on stage 5, while 0.05 ± 0.01 μg
(less than 0.1% of the emitted dose) penetrated beyond stage 5. Particles depositing on
stages 7 - 12 were net electropositively charged; chemical analysis showed that albuterol
deposited predominantly on stages 7 - 12. This observation compares favorably with the
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zeta potential measurements for albuterol sulfate suspensions in HFA 134a since albuterol
sulfate particles were observed to acquire a positive zeta potential (75.9 ± 26.2 mV) in
HFA 134a. The electronegative charge on the ELPI stages 1 - 5 has previously been
attributed to non-drug (propellant) containing droplets (Kwok et al. 2005). However, the
systematic investigation of the electrostatic charging properties of propellant HFA 134a
pMDIs and albuterol sulfate suspension pMDIs adopted in the study demonstrated that the
electronegative charge on the lower stages of the ELPI was not due to propellant droplets.
The influence of soluble impurities in the experimental albuterol sulfate suspension
pMDIs on the electrostatic charge was investigated by filtering the suspensions and
analyzing the electrostatic properties of the filtrates. In the absence of suspended albuterol
sulfate particles in the formulation, the electrostatic charging characteristics of aerosols
produced by the filtrates of the experimental albuterol sulfate pMDIs were similar to those
produced by the filtrates of control 100% HFA 134a pMDIs. The absence of highly
charged particles on the Stages 1-4 of the ELPI suggests that soluble albuterol impurities
or the propellant HFA 134a itself may not be responsible for the highly electronegative
charge on the lower stages of the ELPI for the albuterol sulfate pMDIs.
Interestingly, the number concentration of albuterol particles deposited on stages 14 of the ELPI calculated on the basis of the mass of albuterol (0.05 ± 0.01 μg) deposited on
those stages for the experimental albuterol sulfate pMDIs was approximately 75% of the
total particle number concentration on stages 1-13 of the ELPI. It may be possible that this
large number of submicron particles of albuterol detected on stages 1 - 4 could be
responsible for the electronegative charge. Although sub-micron particles do not have
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appreciable mass, it might be more relevant to measure the particle number or surface area
to understand their impact. Furthermore, the addition of albuterol sulfate to propellant
HFA 134a appeared to modify the triboelectric properties of the non-drug droplets. It was
hypothesized that the interactions between HFA 134a droplets and the valve stem on
actuation of the pMDI would be influenced by albuterol sulfate particles such that the
droplets emitted from the actuator orifice contained both positively and negatively charged
species.
Recent evidence suggests that the modified ELPI appears to underestimate the
particle size of aerosols produced by commercially available pMDIs in comparison to that
obtained using the ACI (Orban and Peart 2004, Keil et al. 2006). The ELPI, which was
originally designed to measure real time particle size distributions by electrical detection,
has been calibrated using charged monodisperse aerosols of di-octyl sebacate (DOS) with
the exception of the topmost stage, stage 13, which has been calibrated using a fluorimetric
method (Keskinen et al. 1999, Marjamaki et al. 2000). The modified ELPI (charger-free),
however, has been used for sizing pharmaceutical aerosols by chemical analysis of drug
deposited on each stage of the ELPI. Triboelectrification, as commonly seen in many
pharmaceutical systems, cannot impart charges of the same magnitude as the corona
discharge employed by the unmodified ELPI, hence the electrical calibration of the ELPI
cannot be assumed to remain unchanged in the modified ELPI.
The present study utilized four commercially available pMDIs, representing small
(Qvar), medium (Ventolin CFC and Flovent HFA) and large (Vanceril) aerosols as
polydisperse calibration standards. The ACI was used as the reference cascade impactor
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for determination of each calibration aPSD. The use of a polydisperse calibration method
precluded the determination of the cut-off properties of the topmost stage (Stage 13) of the
ELPI. The mean cut-off diameters for stages 4 - 12 obtained following recalibration of the
modified ELPI were 0.44, 0.56, 0.70, 1.01, 1.40, 2.12, 3.03, 4.75, 6.37 μm, respectively,
which were found to deviate increasingly from the manufacturer-supplied values (0.16,
0.26, 0.39, 0.62, 0.96, 1.62, 2.42, 4.05, 6.67 μm, respectively) as aerodynamic diameter
decreased suggesting that the ELPI may behave differently when separating coronacharged aerosol particles. It is possible that deposition of charged particles in this impactor
may be influenced by mechanisms in addition to impaction. Further investigation into the
influence of electrostatic charge on in vitro aerosol separation during in vitro testing
appears warranted but is not included in the scope of this study. Validation of the ELPI
recalibration was performed by determining the aPSD of Ventolin HFA using the modified
ELPI and the ACI. Ventolin HFA’s MMAD determined using the modified ELPI with the
manufacturer-supplied d50s was 2.06 ± 0.08 μm. The MMAD calculated using the
recalibrated d50s was 2.63 ± 0.09 μm, which was statistically indistinguishable (p =
0.0852) from that determined for Ventolin HFA using the ACI (2.73 ± 0.09 μm). The
aPSDs for Ventolin HFA were indistinguishable when determined in the modified ELPI or
the ACI, provided the calculated cut-off diameters were used for the aerodynamic particle
size analysis.
In summary, the electrical resistivity and electrophoretic mobility
measurements confirmed the presence of charged species within HFA based solutions and
suspensions although the nature of these species remains unknown. These measurements
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were influenced by the concentration of cosolvent (ethanol) and to a lesser extent by the
presence of soluble drug (BDP) and surfactant (oleic acid). The presence of moisture in the
formulations was also considered to influence the formation of charged species. Pilot
molecular modeling studies, in conjunction with the analysis of interactions using HINT,
provided an improved understanding of the possible interactions within albuterol sulfate
HFA suspension pMDIs. A systematic investigation of the electrical properties of droplets
generated by HFA solution and suspension pMDIs demonstrated that the electrical
properties were a function of the formulation type (solution or suspension) and the
formulation components, as well as the particle size. Taken together with the studies
investigating the electrical properties of HFA based solutions and suspensions, an
improved understanding of charge formation within these formulations in relation with the
electrostatic properties of the aerosols was provided. Finally, the present study also showed
that in the absence of a comprehensive recalibration of the ELPI using monodisperse
aerosols, commercially available, polydisperse aerosols may be used as calibration
standards in a reference cascade impactor and that this constitutes a practical way of
calibrating alternative particle sizing instruments.
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A.I

Dekati Ltd. Charger Efficiency Curve and Impactor Data Sheet for the ELPI
used for Electrostatic Charge and Mass Distribution of pMDIs
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A.II. Dielectric Constant of Ethanol / HFA 134a Blend

The dielectric constant of a binary mixture can be approximately calculated based
on the simple equation (Jouyban et al. 2004)*:
εm = ε1φ1 + ε2φ2
where εm, ε1 and ε2 are the dielectric constants of the ethanol/HFA134a blend, HFA 134a
and ethanol, respectively, φ1 and φ2 are the weight fractions of HFA 134a and ethanol in
the mixture. For example, the dielectric constant for a 5% ethanol/95% HFA 134a blend
would be given by:
εm=9.5*0.95+ 25.3*0.05 = 10.29
Similarly, the dielectric constant for other compositions of the ethanol/HFA 134a
blends was calculated using the above equation as shown below:

Composition of Binary
Mixture
7% ethanol / 93%
HFA 134a blend
10% ethanol / 90%
HFA 134a blend
15% ethanol / 85%
HFA 134a blend

Weight Fraction
of HFA 134a
0.93

Weight Fraction
of Ethanol
0.07

Dielectric Constant
of the Mixture
10.61

0.90

0.10

11.08

0.85

0.15

11.87

*Jouyban, A., Soltanpur, S. and Chan, H-K. (2004). A Simple Relationship between
Dielectric Constant of Mixed Solvents with Solvent Composition and Temperature.
International Journal of Pharmaceutics, 269, 353-360.

A.III Summary of Net Positive and Negative HINT scores for interactions in albuterol sulfate HFA suspension pMDI
molecular models

A.III.1 Summary of Net Positive HINT scores for interactions between albuterol sulfate unit cell and HFA 134a molecules in
a model containing albuterol sulfate unit cell solvated in HFA 134a alone
Albuterol sulfate
unit cell in HFA
134a

No. of HFA
134a
molecules Hydrophobic H-bond Acid/Base Hydrophobic/ Polar

Base/Base

Total

Total Score/
HFA 134a
molecule

Range of Total Score/
HFA 134a molecule

1

21

1173

181

426

-610

-377

793

38

1.3 to 152

2

20

1359

373

542

-754

-480

1040

52

0.8 to 239

3

26

789

321

432

-632

-499

411

16

0.4 to 82

Mean

22

1107

292

467

-666

-452

748

35

-

SD

3

291

99

66

78

66

317

18

-

A.III.2 Summary of Net Negative HINT scores for interactions between albuterol sulfate unit cell and HFA 134a molecules
in a model containing albuterol sulfate unit cell solvated in HFA 134a alone
Albuterol sulfate
unit cell in HFA
134a

No. of HFA
Hydrophobic/
134a
molecules Hydrophobic H-bond Acid/Base
Polar
Base/Base

Total

Total Score/ HFA
134a molecule

Range of Total Score/
HFA 134a molecule

1

74

2985

1230

1493

-9497

-6127

-9915

-134

-1to -1080

2

56

2925

2210

1525

-9204

-6915

-9460

-169

-1 to -897

3

54

2584

1210

1274

-6288

-4441

-5660

-105

-1 to -962

Mean

61

2832

1550

1431

-8330

-5828

-8345

-136

-

SD

11

216

571

136

1774

1264

2336

32

-
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A.III.3 Summary of Net Positive HINT scores for interactions between albuterol sulfate unit cell and HFA 134a molecules in
a model containing albuterol sulfate unit cell solvated in HFA 134a in the presence of oleic acid and ethanol
Albuterol sulfate
unit cell in HFA
134a

No. of HFA
134a
Hydrophobic/
molecules Hydrophobic H-bond Acid/Base
Polar
Base/Base

Total

Total Score/ HFA
134a molecule

Range of Total Score/
HFA 134a molecule

1

41

1447

658

635

-1007

-648

1085

26

0 to 249

2

31

357

156

200

-207

-220

286

9

0 to 62

3

30

350

87

195

-239

-169

225

7

0 to 52

Mean

34

718

301

343

-484

-346

532

14

-

SD

6

631

312

253

453

263

480

11

-

A.III.4 Summary of Net Negative HINT scores for interactions between albuterol sulfate unit cell and HFA 134a molecules
in a model containing albuterol sulfate unit cell solvated in HFA 134a in the presence of oleic acid and ethanol
Albuterol sulfate
unit cell in HFA
134a

No. of HFA
134a
Hydrophobic/
molecules Hydrophobic H-bond Acid/Base
Polar
Base/Base

Total

Total Score/ HFA
134a molecule

Range of Total Score/
HFA 134a molecule

1

63

1752

728

986

-5629

-3881

-6043

-829

0 to -829

2

76

2091

1379

1218

-6844

-5337

-7492

-1026

0 to -1026

3

79

1926

1296

1097

-6626

-5345

-7653

-1119

0 to -1119

Mean

73

1923

1135

1100

-6366

-4854

-7063

-97

-

SD

9

170

354

116

648

843

887

1

-
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A.III.5 Summary of Net Positive HINT scores for interactions between oleic acid and HFA 134a molecules in a model
containing albuterol sulfate unit cell solvated in HFA 134a in the presence of oleic acid and ethanol
Oleic Acid in
HFA 134a

No. of HFA
134a
Hydrophobic/
molecules Hydrophobic H-bond Acid/Base
Polar
Base/Base

Total

Total Score/ HFA
134a molecule

Range of Total Score/
HFA 134a molecule

1

27

1446

0

25

-318

-30

1123

42

0 to 170

2

35

1250

0

51

-265

-72

965

28

0 to 105

3

59

3415

0

97

-532

-131

2845

48

0 to 156

Mean

40

2037

0

58

-372

-78

1314

39

-

SD

17

1197

0

37

142

51

475

11

-

A.III.6 Summary of Net Negative HINT scores for interactions between oleic acid and HFA 134a molecules in a model
containing albuterol sulfate unit cell solvated in HFA 134a in the presence of oleic acid and ethanol
Oleic Acid in
HFA 134a

No. of HFA
134a
Hydrophobic/
molecules Hydrophobic H-bond Acid/Base
Polar
Base/Base

Total

Total Score/ HFA
134a molecule

Range of Total Score/
HFA 134a molecule

1

26

726

444

618

-2130

-1413

-1755

-68

0 to -249

2

15

390

240

303

-1079

-619

-765

-51

0 to -215

3

14

630

348

516

-1310

-1178

-994

-71

0 to -296

Mean

18

582

344

479

-1506

-1070

-1171

-63

-

SD

7

173

102

161

552

408

518

11

-
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A.III.7 Summary of Net Positive HINT scores for interactions between ethanol and HFA 134a molecules in a model
containing albuterol sulfate unit cell solvated in HFA 134a in the presence of oleic acid and ethanol
Ethanol in HFA
134a

No. of HFA
134a
Hydrophobic/
molecules Hydrophobic H-bond Acid/Base
Polar
Base/Base

Total

Total Score/ HFA
134a molecule

Range of Total Score/
HFA 134a molecule

1

68

3087

301

315

-1442

-856

1405

21

0 to 94

2

73

4163

538

456

-1680

-1354

2123

29

0 to 128

3

81

4395

605

507

-1797

-1441

2269

28

0 to 109

Mean

74

3882

481

426

-1640

-1217

1932

26

-

SD

7

698

160

100

181

316

462

5

-

A.III.8 Summary of Net Negative HINT scores for interactions between ethanol and HFA 134a molecules in a model
containing albuterol sulfate unit cell solvated in HFA 134a in the presence of oleic acid and ethanol
Ethanol in HFA
134a

No. of HFA
134a
Hydrophobic/
Polar
molecules Hydrophobic H-bond Acid/Base
Base/Base

Total

Total Score/ HFA
134a molecule

Range of Total Score/
HFA 134a molecule

1

81

3036

2409

1081

-6802

-3529

-3804

-47

0 to -213

2

63

2949

2147

1017

-7014

-3456

-4357

-69

0 to -326

3

62

2692

2057

901

-6228

-3179

-3757

-61

0 to -292

Mean

69

2892

2204

1000

-6681

-3388

-3973

-59

-

SD

11

179

183

91

407

185

334

11

-
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A.IV. Summary of Background Measurements and Electrical Properties of
Commercial and Control HFA Solution and Suspension pMDIs
A.IV.1. Commercial and Control HFA Solution pMDIs

A.IV.1.1. Background Measurements for QVAR 40 pMDIs – Total Net Inherent Charge
Measurement #
Total Net Charge (pC)
Before pMDI Actuation
After pMDI Actuation
1
0.04
0.29
2
0.06
0.29
3
-0.08
0.44
4
0.01
0.04
5
-0.03
0.25
Mean
0.00
0.26
SD
0.06
0.14
% CV
4.04E+18
54.87

A.IV.1.2.Background Measurements for QVAR 80 pMDIs – Total Net Inherent Charge
Measurement #
Total Net Charge (pC)
Before pMDI Actuation
After pMDI Actuation
1
0.13
-0.40
2
0.00
0.20
3
-0.06
-0.10
4
-0.04
-0.14
5
-0.10
-0.03
Mean
-0.01
-0.09
SD
0.09
0.22
% CV
-630.03
-229.60

A.IV.1.3.

Shot
No.

Stage 1 Stage 2
1
-0.44 3.96
2
5.73 12.62
3
1.28
0.65
4
1.67
7.25
5
5.04
7.81
Mean 2.66
6.46
SD
2.63
4.48
% CV 98.90 69.40

Shot
No.

Stage 1
1
15.78
2
14.88
3
12.49
4
13.99
5
5.66
Mean 12.56
SD
4.04
% CV 32.20

Stage 3
2.85
14.35
-9.11
4.86
1.50
2.89
8.38
290.05

Stage 4 Stage 5
15.36 28.34
47.25 74.99
15.16 36.43
27.30 39.56
30.43 43.10
27.10 44.48
13.20 17.90
48.73 40.25

A.IV.1.4.
Stage 2
20.45
37.62
21.53
7.63
16.28
20.70
10.92
52.78

Stage 3
9.46
78.92
11.92
36.34
56.76
38.68
29.67
76.71

Total net
charge
Stage 10 Stage 11 Stage 12
(pC)
12.54
8.36
24.93
264.93
33.84
33.85
53.34
738.32
18.49
33.03
49.36
342.55
20.38
20.21
30.28
390.73
32.76
36.46
58.66
500.70
23.60
26.38
43.31
447.44
9.32
11.88
14.84
183.70
41.06
39.51
45.04
34.25

FPD
charge
(pC)
231.64
651.13
260.15
340.24
405.57
377.75
167.40
44.32

Total net
charge
Stage 10 Stage 11 Stage 12
(pC)
78.53
59.38
79.16 1133.14
93.25
85.38
98.21 1711.84
38.48
35.75
69.01
799.05
105.76 117.26 142.60 1582.66
89.15
86.99
108.83 1340.87
81.03
76.95
99.56 1313.51
25.71
30.84
28.68
363.68
31.73
40.07
28.80
27.69

FPD
charge
(pC)
994.60
1528.25
694.30
1322.81
1145.05
1137.00
317.78
27.95

QVAR 40 - Net Inherent Charge (pC) 5 shots/ can, 1 can
Stage 6
47.77
135.11
61.12
76.02
80.97
80.20
33.35
41.58

Stage 7
51.38
144.48
59.60
70.60
85.29
82.27
37.03
45.01

Stage 8
47.51
117.32
45.30
62.84
74.89
69.57
29.28
42.09

Stage 9
22.37
65.44
31.23
29.76
43.78
38.52
16.90
43.89

QVAR 80 - Net Inherent Charge (pC) 5 shots/ can, 1 can

Stage 4 Stage 5
68.43 107.34
174.34 228.44
43.30 78.27
155.25 201.93
136.40 154.48
115.54 154.09
56.81 62.75
49.16 40.72

Stage 6
182.96
275.56
146.03
246.48
190.24
208.25
52.03
24.98

Stage 7
196.88
253.46
148.08
225.54
199.86
204.76
39.06
19.08

Stage 8
188.91
225.41
125.49
198.94
176.95
183.14
36.85
20.12

Stage 9
125.86
146.37
68.71
130.95
119.27
118.23
29.43
24.89
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A.IV.1.5. QVAR 40 - Charge to mass ratio (pC/μg), 5 shots/can, 1 can
Shot No. Stage 4 Stage 5
Stage 6
Stage 7 Stage 8 Stage 9 Stage 10
1
10.62
10.91
9.91
9.48
9.56
10.33
29.36
2
38.63
30.10
28.34
24.96
23.83
30.02
88.50
3
9.24
11.69
10.60
9.49
8.70
15.00
55.33
4
19.18
18.31
14.49
12.02
11.81
11.42
21.62
5
21.58
19.13
15.73
14.07
13.83
19.60
61.82
Mean
19.85
18.03
15.81
14.00
13.55
17.27
51.32
SD
11.77
7.71
7.43
6.42
6.09
7.99
26.80
% CV
59.28
42.77
46.96
45.82
44.95
46.28
52.22

A.IV.1.6.
Shot No. Stage 4
1
25.67
2
74.00
3
15.71
4
72.59
5
51.18
Mean
47.83
SD
26.61
% CV
55.63

QVAR 80 - Charge to mass ratio (pC/μg), 5 shots/can, 1 can
Stage 5
Stage 6
Stage 7 Stage 8 Stage 9 Stage 10
23.29
21.17
17.89
19.75
25.45
63.68
53.84
32.18
29.78
35.43
63.09
366.34
15.23
14.89
12.80
11.95
12.38
25.38
51.81
30.00
27.14
29.78
55.73
313.79
35.93
23.31
22.48
26.77
54.47
36.02
24.31
22.02
24.74
42.22
192.30
17.04
6.96
6.87
9.11
22.02
172.68
47.30
28.64
31.19
36.84
52.16
89.80
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A.IV.1.7

Background Measurements for repackaged QVAR 40 pMDIs – Total Net
Inherent Charge
Can #
Shot #
Total Net Charge (pC)
Before pMDI Actuation
After pMDI Actuation
1
1
0.47
0.30
2
0.01
0.32
3
-0.17
0.26
2
1
0.08
0.28
2
0.05
0.12
3
0.26
0.66
3
1
-0.03
-0.60
2
-0.02
0.09
3
0.02
0.06
Mean
0.07
0.17
SD
0.19
0.34
% CV
250.51
204.10

A.IV.1.8. Repackaged QVAR 40 (Transferred to Al canister fitted with Valois DF10/50 metered valve) Shot
Can #
Net Inherent Charge (pC) 3 shots/ can, 3 cans
# Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Stage 7 Stage 8 Stage 9 Stage 10 Stage 11 Stage 12
1
1
-0.53 0.09
2.47
9.15 20.63 26.73 26.77 21.41 11.72
6.39
3.08
16.63
2
-3.24 -4.79 -1.26 8.44 19.08 22.92 21.09 16.72 12.42
4.38
8.17
12.58
3
-5.66 -5.50 -0.64 9.61 23.66 31.09 29.38 23.30 17.87
9.27
17.85
29.68
2
1
-3.04 -3.12 -1.44 13.29 29.04 40.06 36.38 29.14 17.26
7.47
12.91
22.79
2
-2.12 -2.64 -2.95 8.48 18.92 31.02 36.09 28.35 22.19
9.81
12.05
23.26
3
-4.34 -3.34 1.65 16.41 30.19 42.31 38.20 28.83 26.09 13.25
18.52
28.11
3
1
-3.21 -4.73 -17.36 2.80 10.86 14.67 17.92 11.72 15.09
3.22
10.25
6.83
2
1.44
4.88
9.18 20.84 23.78 34.59 28.14 20.51 20.03 14.03
14.70
18.81
3
-3.22 -2.53 1.82 17.19 32.21 43.69 37.14 28.50 24.15 13.77
15.49
28.00
Mean
-2.66 -2.41 -0.95 11.80 23.15 31.90 30.12 23.17 18.54
9.07
12.56
20.74
SD
2.08
3.19
7.09
5.58
6.70
9.53
7.38
6.18
5.03
4.04
4.89
7.73
% CV
-78.19 -132.29 -747.61 47.31 28.93 29.88 24.49 26.69 27.12 44.58
38.96
37.27

Total net FPD
charge charge
(pC)
(pC)
144.54
116.51
179.92
200.73
182.47
235.88
68.06
210.92
236.22
175.03
56.20
32.11

124.83
95.76
132.38
165.04
147.15
189.25
50.98
177.42
192.72
141.73
46.67
32.93
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Can #

Shot #

1

1
2
3
1
2
3
1
2
3

2

3

Mean
SD
% CV

A.IV.1.10
Can #
1
2
3

A.IV.1.9. Repackaged QVAR (Transferred to Al canister fitted with Valois
DF10/50 metered valve) - Charge to mass ratio (pC/μg), 3 shots/can, 3 cans
Stage 4
Stage 5 Stage 6 Stage 7 Stage 8 Stage 9 Stage 10
9.15
20.62
17.77
12.76
9.91
8.31
13.55
15.47
17.88
13.69
10.20
8.34
10.93
11.36
16.44
23.99
18.91
14.84
11.34
15.73
21.70
26.96
32.95
26.66
18.68
14.81
14.86
18.83
16.84
18.74
20.23
18.87
13.47
16.89
21.75
21.89
23.41
23.13
18.93
16.64
27.73
36.36
2.92
7.80
5.32
4.91
3.24
5.89
2.89
38.05
25.83
20.36
14.49
9.77
11.80
16.52
28.94
25.93
19.47
14.81
19.25
25.46
18.47
22.24
19.11
14.79
11.37
14.60
18.71
10.77
7.24
6.56
4.92
4.12
6.49
9.43
58.32
32.56
34.31
33.26
36.25
44.47
50.37

Background measurements for HFA 134a Solution pMDIs – Total net
inherent charge
Total Net Charge (pC)
Shot #
Before pMDI Actuation After pMDI Actuation
1
0.30
0.82
2
0.02
-0.06
3
-0.03
0.01
1
0.66
0.68
2
0.43
0.39
3
-0.53
-0.10
1
0.23
0.64
2
-0.36
-0.81
3
0.09
0.39
Mean
0.06
0.21
SD
0.36
0.49
% CV
594.02
237.89

Can Shot A.IV.1.11. 100% HFA 134a with Valois DF 10/50 EPDM valves - Net Inherent Charge (pC) 3 shots/ can, Total net FPD
3 cans
charge charge
#
#
(pC)
(pC)
1

1
2
3
2
1
2
3
3
1
2
3
Mean
SD
% CV

Stage 1
14.25
12.32
15.38
2.73
6.55
7.17
9.89
13.48
14.64
10.71
4.39
40.98

Stage 2
18.10
16.60
20.17
1.63
3.43
7.56
9.63
18.08
20.31
12.83
7.34
57.19

Stage 3
23.15
20.20
25.15
2.40
-0.13
6.77
7.64
23.27
28.52
15.22
10.94
71.86

Stage 4
22.26
14.06
20.46
0.32
-9.98
1.31
-1.93
20.93
28.60
10.67
13.45
126.09

Stage 5
22.85
11.66
17.06
0.71
-11.60
0.82
-5.79
18.68
26.16
8.95
13.37
149.41

Stage 6 Stage 7 Stage 8
20.77 10.92
7.03
2.36
-5.63 -5.68
10.48
3.88
4.23
-0.13 -1.77 -0.86
-20.83 -15.64 -9.08
-5.13 -6.15 -3.88
-12.14 -4.64 -1.27
12.77
5.33
5.85
20.56
9.97
10.27
3.19
-0.41
0.73
14.36
8.66
6.46
449.72 -2086.68 880.72

Stage 9
8.46
-0.69
7.02
-0.60
-6.57
-0.47
4.77
8.59
14.10
3.85
6.40
166.32

Stage 10 Stage 11 Stage 12
3.24
10.49
7.61
-10.93
-0.72
-13.24
-0.50
7.58
0.70
-1.61
-0.15
-2.58
-11.21
-7.12
-15.30
-4.38
0.07
-4.67
0.94
3.89
6.57
2.06
9.00
1.94
9.20
16.02
14.93
-1.46
4.34
-0.45
6.59
7.09
9.78
-450.24 163.28 -2181.93

169.12
40.31
131.61
0.09
-97.47
-0.96
17.56
139.98
213.27
68.17
100.38
147.26

151.03
54.27
123.33
2.82
-75.06
3.62
7.10
129.04
182.33
64.28
86.16
134.04
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Can Shot A.IV.1.12. 7% Ethanol/93% HFA 134a pMDIs with Valois DF 10/50 EPDM valves - Net Inherent Charge Total net FPD
(pC) 3 shots/ can, 3 cans
charge charge
#
#
(pC)
(pC)
1

1
2
3
2
1
2
3
3
1
2
3
Mean
SD
% CV

Stage 1
-7.11
-5.62
-5.96
-6.63
-8.15
-6.67
-5.56
-6.20
-6.35
-6.47
0.81
-12.46

Stage 2 Stage 3
-2.91 7.51
-0.51 9.25
-2.02 5.81
-1.37 8.86
-3.17 10.62
-1.07 9.97
-1.34 7.06
-1.33 9.51
-2.58 6.34
-1.81 8.33
0.91 1.70
-50.18 20.38

Stage 4
15.19
16.35
12.10
16.25
17.30
17.70
15.76
16.19
11.55
15.38
2.15
14.00

Stage 5
16.79
15.23
13.84
16.90
17.11
15.93
15.91
16.92
13.05
15.74
1.45
9.22

Stage 6
18.52
18.12
15.44
17.14
19.91
18.26
17.37
17.45
14.21
17.38
1.69
9.72

Stage 7
15.97
14.34
14.06
13.64
15.91
13.95
14.20
13.01
11.07
14.02
1.48
10.53

Stage 8
11.54
9.89
9.60
10.18
11.21
9.49
10.75
8.32
7.55
9.84
1.30
13.17

Stage 9 Stage 10 Stage 11 Stage 12
14.31
5.95
10.01
17.36
8.54
4.25
5.78
13.60
9.43
3.51
6.90
8.61
10.43
5.63
10.74
11.95
14.59
4.02
8.53
8.61
8.83
4.20
4.35
9.72
9.26
5.16
9.71
12.11
8.48
4.35
7.90
16.85
9.24
4.14
6.42
13.70
10.35
4.58
7.82
12.50
2.40
0.81
2.13
3.24
23.19
17.75
27.29
25.89

123.15
109.22
91.32
113.70
116.48
104.66
110.41
111.46
88.35
107.64
11.33
10.53

95.76
89.84
75.81
91.03
99.35
90.59
88.57
86.70
68.22
87.32
9.66
11.06
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Can Shot
#
#
1

1
2
3
2
1
2
3
3
1
2
3
Mean
SD
% CV

A.IV.1.13. 0.08% BDP/7% Ethanol/93% HFA 134a pMDIs with Valois DF 10/50 EPDM valves - Net Total net
Inherent Charge (pC) 3 shots/ can, 3 cans
charge
(pC)
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Stage 7 Stage 8 Stage 9 Stage 10 Stage 11 Stage 12
1.41
7.38 -6.25 11.30 23.42 31.73
28.45
24.97 19.27
9.85
10.90
22.70
185.14
0.16
3.30 -7.33 4.77 15.39 23.84
20.88
17.70 14.69
6.95
8.62
18.55
127.53
150.99
2.03
3.20 -7.62 9.15 15.61 26.58
24.89
22.66 16.37
8.61
9.45
20.07
-2.67 -2.41 -0.84 12.53 25.16 32.98
30.36
24.94 17.12
8.72
11.79
20.56
178.24
-0.28 6.39 -2.58 8.74 19.88 24.97 24.23
21.27 17.74
10.78
16.28
20.84
168.27
123.02
4.35 -5.43 -15.61 3.59 14.90 25.79
26.08
22.27 17.78
8.02
8.90
12.39
8.70
4.40 -19.24 5.33 18.00 27.53
26.09
24.08 22.74
12.09
14.10
20.20
164.02
2.17
3.52 -8.28 11.00 24.23 38.46
38.76
32.04 29.85
13.23
12.37
14.60
211.95
0.39 -0.24 -11.16 7.53 16.78 24.64
20.34
14.58 16.42
7.87
13.80
14.90
125.85
1.81
2.23 -8.77 8.22 19.26 28.50 26.68
22.72 19.11
9.57
11.80
18.31
159.45
3.23
4.16
5.84
3.14
4.07
4.88
5.55
4.91
4.62
2.09
2.61
3.50
30.44
178.72 186.51 -66.65 38.28 21.10 17.13 20.81
21.58 24.15
21.88
22.12
19.10
19.09

FPD
charge
(pC)
151.53
100.35
121.48
145.89
131.14
101.74
129.72
184.98
97.15
129.33
28.65
22.15
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A.IV.2

Commercial and Control HFA Suspension pMDIs

A.V.2.1
Background Measurements for Ventolin HFA – Total Net Inherent Charge
Total Net Charge (pC)
Measurement #
Before pMDI Actuation
After pMDI Actuation
1
0.17
-0.25
2
-0.07
-0.05
3
0.00
-0.30
4
0.09
-0.12
5
-0.03
-0.88
Mean
0.03
-0.32
SD
0.10
0.33
% CV
303.30
-102.67

Shot
No. Stage 1
1 -25.29
2 -26.02
3 -31.23
4 -34.68
5 -28.58
Mean -29.16
SD
3.87
% CV -13.28

A.IV.2.2.
Stage 2
-62.29
-65.54
-70.95
-75.61
-66.83
-68.24
5.16
-7.56

Stage 3
-90.05
-96.02
-108.87
-117.75
-108.14
-104.17
11.04
-10.60

Total net
charge
Stage 10 Stage 11 Stage 12
(pC)
117.23
39.02
106.55 -137.66
126.45
47.90
94.09
-89.33
146.13
53.29
92.66
-104.36
165.24
55.65
97.80
-37.24
157.95
58.52
117.97
-29.00
142.60
50.88
101.81
-79.52
20.40
7.69
10.52
45.92
14.31
15.12
10.34
-57.74

Ventolin HFA - Net Inherent Charge (pC) 5 shots/ can, 1 can

Stage 4
-167.02
-180.13
-200.63
-194.95
-189.98
-186.54
13.26
-7.11

Stage 5 Stage 6
-140.42 -96.29
-154.15 -99.99
-168.01 -97.10
-160.58 -85.67
-176.03 -104.17
-159.84 -96.64
13.59 6.87
-8.50 -7.10

Stage 7
0.24
20.51
21.14
31.91
22.08
19.18
11.56
60.30

Stage 8
82.19
99.71
95.12
127.74
113.83
103.72
17.55
16.93

Stage 9
98.47
143.87
164.08
153.67
174.36
146.89
29.37
19.99

FPD
charge
(pC)
-283.23
-231.31
-250.32
-190.68
-205.51
-232.21
36.64
-15.78
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A.IV.2.3

Can #
1
2
3

Background measurements for Control Suspension pMDIs (Prefiltration) –
Total net inherent charge
Total Net Charge (pC)
Shot #
Before pMDI Actuation After pMDI Actuation
1
0.16
0.20
2
-0.43
0.03
3
0.15
0.14
1
0.26
0.08
2
0.48
0.24
3
0.68
0.47
1
0.50
0.32
2
0.15
0.27
3
0.12
-0.09
Mean
0.23
0.18
SD
0.32
0.17
% CV
137.85
90.44

Can Shot A.IV.2.4. 100% HFA 134a (Prefiltration) net inherent charge (pC) on each stage of the ELPI (3 shots/ can, Total net FPD
3 cans)
charge charge
#
#
(pC)
(pC)
1

1
2
3
2
1
2
3
3
1
2
3
Mean
SD
% CV

Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
1.30
2.42
4.78
8.39
9.23
1.07
1.66
3.34
5.83
5.74
1.06
1.47
3.61
6.95
7.09
3.72
6.69
8.62 14.03 13.57
-0.53
-2.79 -4.11 -6.62 -4.54
-2.08
-7.09 -10.39 -18.31 -15.74
1.00
0.53
0.22
-0.46 -0.39
0.51
-0.57 -1.47 -2.58 -1.89
-0.22
-1.90 -3.15 -5.01 -4.23
0.65
0.05
0.16
0.25
0.98
1.58
3.84
5.68
9.75
8.90
244.01 8408.43 3531.04 3961.07 905.25

Stage 6
15.84
8.71
10.49
22.40
-2.16
-14.94
0.05
-1.70
-3.20
3.94
11.40
289.23

Stage 7
12.35
6.47
8.13
16.81
3.26
-1.29
4.99
3.58
4.42
6.53
5.35
82.03

Stage 8
11.16
8.04
9.05
10.07
5.61
6.99
6.85
5.53
6.48
7.75
1.98
25.50

Stage 9 Stage 10 Stage 11 Stage 12
8.33
7.46
9.18
13.59
6.51
4.92
7.40
10.43
7.13
5.94
8.23
11.77
6.64
7.71
7.83
19.20
5.49
7.78
9.11
18.73
7.75
10.73
10.84
21.77
9.53
8.70
9.61
15.73
7.26
6.84
8.73
16.19
8.50
6.64
7.00
11.89
7.46
7.41
8.66
15.48
1.21
1.67
1.19
3.88
16.27
22.46
13.77
25.06

104.04 81.26
70.10 52.29
80.93 60.92
137.29 110.26
29.23
1.39
-11.76 -44.37
56.35 31.02
40.43 15.51
27.22
8.33
59.31 35.18
44.74 46.52
75.44 132.23
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Can Shot
#
#
1

1
2
3
2
1
2
3
3
1
2
3
Mean
SD
% CV

A.IV.2.5. 0.2% Albuterol sulfate/100% HFA 134a (Prefiltration) - Net inherent charge (pC) (3 shots/
Total net
can, 3 cans)
Stage charge
(pC)
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Stage 7 Stage 8 Stage 9 Stage 10 Stage 11 12
-85.39 -182.68 -188.85 -177.42 -87.88 -43.33 16.12 85.87 112.15 125.25
30.44 26.18 -369.56
-67.98 -160.06 -184.20 -205.63 -132.12 -86.90 -31.25 48.59 84.31 121.99
26.30 41.52 -545.45
-70.16 -154.26 -169.30 -175.65 -84.82 -36.35 -9.84 58.41 68.75 71.25
12.11 19.36 -470.51
-22.70 -56.72 -69.00 -68.87 -27.46 11.88 31.36 82.28 89.86 103.11
45.81 56.32 175.82
-45.03 -104.95 -128.80 -154.24 -78.88 -46.30 -16.48 42.77 59.29 73.39
20.45 25.33 -353.42
-16.23 -39.36 -45.80 -48.63 -15.00 18.79 36.54 79.36 76.02 72.42
29.19 39.04 186.33
-23.25 -54.95 -70.10 -87.20 -45.40 -6.80 32.60 76.20 69.20 65.20
26.10 28.90 10.41
-37.77 -86.42 -98.50 -107.00 -47.30 -9.20 33.90 62.50 71.00 85.00
31.40 42.10 -60.35
-37.31 -83.18 -92.10 -98.30 -44.80 -11.00 28.20 57.10 73.00 90.60
38.10 47.70 -32.11
-45.09 -102.51 -116.30 -124.77 -62.64 -23.25 13.45 65.90 78.17 89.81
28.87 36.28 -162.09
24.24 51.72 53.71 54.90 36.36 33.12 25.73 15.55 15.56 22.40
9.66
12.06 277.11
-53.77 -50.46 -46.18 -44.00 -58.04 -142.44 191.32 23.60 19.91 24.94
33.45 33.24 -171.00

FPD
charge
(pC)
-426.16
-613.25
-501.97
73.74
-399.23
118.11
-44.50
-133.79
-117.79
-227.20
264.01
-116.20
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A.IV.2.6
Can #
1
2
3

Background measurements for Control Suspension pMDIs (Postfiltration) –
Total net inherent charge
Shot #
Total Net Charge (pC)
Before pMDI Actuation After pMDI Actuation
1
0.13
0.07
2
0.39
-0.04
3
0.2
0.09
1
0.31
0.01
2
0
-0.11
3
0.15
-0.18
1
0.03
0.08
2
0.55
0.09
3
0.21
0.06
Mean
0.22
0.01
SD
0.17
0.10
% CV
79.77
1259.37

Can Shot A.IV.2.7. 100% HFA 134a (Postfiltration) net inherent charge (pC) on each stage of the ELPI (3 shots/ can, Total net FPD
3 cans)
charge charge
#
#
(pC)
(pC)
1

1
2
3
2
1
2
3
3
1
2
3
Mean
SD
% CV

Stage 1 Stage 2 Stage 3 Stage 4
14.95 21.02 18.79 25.37
9.92
13.03 12.39 19.64
8.78
11.41 10.84 17.17
-1.01
-6.10
-7.52 -10.94
0.82
-1.70
-1.74
-2.73
4.29
4.42
6.15
11.35
9.90
16.81 23.73 34.89
6.31
9.46
12.03 16.55
14.65 20.96 22.63 26.99
7.63
9.93
10.81 15.37
14.95 21.02 18.79 25.37
9.92
13.03 12.39 19.64

Stage 5 Stage 6
22.38 37.45
19.70 30.75
16.73 27.22
-9.18 -15.68
-2.54 -5.14
10.66 14.59
31.53 40.61
13.57 15.04
22.09 22.60
13.88 18.61
22.38 37.45
19.70 30.75

Stage 7
35.37
23.31
21.77
-10.26
-2.93
10.66
24.55
13.16
12.59
14.25
35.37
23.31

Stage 8
28.49
13.80
14.46
-2.25
2.49
10.11
15.23
8.87
9.44
11.18
28.49
13.80

Stage 9 Stage 10 Stage 11 Stage 12
18.40 17.24
16.48
25.20
8.21
8.65
8.04
12.76
9.04
9.65
8.92
14.99
-1.02
-0.53
1.88
8.57
2.56
2.19
3.50
7.42
8.06
8.33
9.46
15.69
15.61 15.48
16.19
18.26
4.97
3.53
3.99
5.77
7.20
6.33
6.78
10.28
8.11
7.88
8.36
13.21
18.40 17.24
16.48
25.20
8.21
8.65
8.04
12.76

281.14
180.21
170.98
-54.05
2.21
113.77
262.79
113.26
182.56
139.21
281.14
180.21

239.46
159.4
147.07
-64.49
-8.72
88.62
228.34
103.49
165.48
117.63
101.35
86.16
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Can Shot A.IV.2.8. 0.2% Albuterol sulfate/ 100% HFA 134a (Postfiltration) Net inherent charge (pC) (3 shots/ can, Total net FPD
3 cans)
charge charge
#
#
(pC)
(pC)
1

1
2
3
2
1
2
3
3
1
2
3
Mean
SD
% CV

Stage 1
8.66
9.75
8.71
5.84
4.75
4.80
10.77
6.25
5.65
7.24
2.32
32.03

Stage 2
8.06
11.85
10.67
11.97
10.50
11.56
13.32
7.13
6.48
10.17
2.08
20.44

Stage 3
7.34
12.97
12.42
16.13
14.22
16.90
12.74
6.33
5.93
11.66
3.79
32.46

Stage 4
9.99
20.88
19.63
25.78
24.69
27.84
17.62
7.97
7.13
17.95
7.22
40.21

Stage 5 Stage 6 Stage 7
8.39
10.61
8.00
18.33 25.94 16.64
16.81 23.87 14.28
21.40 25.22 16.53
23.36 32.46 22.03
22.99 27.84 17.03
13.66 18.71 13.81
6.27
7.76
5.80
4.87
7.08
5.61
15.12 19.94 13.30
6.49
8.57
5.21
42.93 43.00 39.15

Stage 8
8.04
12.31
12.58
10.03
13.69
10.14
9.99
4.96
5.50
9.69
2.79
28.80

Stage 9 Stage 10 Stage 11 Stage 12
5.90
8.14
10.86
17.92
11.89 15.01
15.55
20.80
12.50 12.93
11.75
14.80
9.10
12.31
17.50
25.42
9.70
10.09
11.46
17.18
7.77
8.29
13.43
27.90
8.62
10.73
11.08
14.75
3.46
4.27
3.98
6.81
4.17
4.79
4.50
7.38
8.12
9.62
11.12
17.00
2.97
3.35
3.99
6.63
36.61 34.81
35.91
38.98

111.91
191.93
170.93
197.24
194.14
196.49
155.79
70.98
69.08
150.94
53.39
35.37

83.13
155.57
144.4
154.31
165.49
155.16
129.97
60.2
57.21
122.83
43.66
35.55
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A.V.

Calculation of Number Concentration of Albuterol Particles using the Mass
of Albuterol Depositing Within the ELPI

The calculation of the particle volume of albuterol is simplified by assuming that albuterol
particles are spherical. The volume of a spherical particle is:
V = π .d 3 6
where V is the volume of the particle and d is the cut-off diameter of the ELPI stages
calculated in Chapter VII.
The mass of one particle is calculated by utilizing the known density of albuterol,
D = 1.31 g/cm3 (D = 1.31 x 10-12 g/μm3).
M=D*V
Where M is the mass of one particle and D is the density of albuterol.
The number of particles depositing on each ELPI stage is calculated as:
Number of particles = FPD / mass per particle
The volume of air that has been pulled through the ELPI during the sampling time of 20
seconds at a flow rate of 29.04 L/min i.e. the sample volume is calculated to be 9680 cm3.
The number concentration of albuterol particles per cm3 for each ELPI stage is calculated
as:
Number concentration (per cm3) = Number of particles / 9680 cm3

Can Shot
#
#
1

1
2
3
2
1
2
3
3
1
2
3
Mean
SD
% CV

A.V.1. Number Concentration (per cm3) for 0.2% Albuterol sulfate / 100% HFA 134a pMDI Aerosols
Total
(3 shots / can, 3 cans) based on mass of albuterol deposited in the ELPI
(Stages 112)*
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Stage 7 Stage 8 Stage 9 Stage 10 Stage 11 Stage 12
2009 1702 1175
71
163
321
246
212
98
46
4
1
6048
893
1123 1046
58
94
255
252
211
105
50
5
1
4093
2033
356
634
52
94
312
244
203
97
35
4
1
2330 1994
65
163
325
254
213
99
46
4
1
5495
2121 4207 1867
98
275
439
367
295
146
70
9
1
9895
6883
5009
735
50
120
308
260
235
110
49
5
1
1744 1094
75
150
328
261
275
103
41
5
1
4077
1570 1350
58
158
311
297
240
118
60
6
1
4168
2518 1337
76
162
330
289
237
115
55
6
1
5126
1674 2284 1248
67
153
325
274
236
110
50
5
1
5313
679
1474
456
15
54
48
39
31
15
10
1
0
2212
41
65
37
22
35
15
14
13
14
21
27
33
42

Total
(Stages
1-4)
4958
3120
1043
4389
8293
5794
2913
2978
3931
4158
2069
50

*Number Concentration of albuterol particles depositing on Stage 13 was not detected.
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A.VI. SCIENTIST Model and Output and the Modified ELPI recalibration cut-off
diameters calculated from individual calibration aerosols
A.VI.1 SCIENTIST Model file and an example of the Parameter File
Model File name: c:\scientis\lognmcdf.eqn
//Lognormal Cumulative distribution function - fitting Model (Mean and Sigma not conventional)
//MEAN is the mean of the (ln x) values; SIGMA is the std dev of the (ln x) values
//Take EXP(MEAN,SIGMA) for best fits for (MMAD,SIGMAG) respectively
//The ERF function below performs the integration of the usual pdf expression but the function removes
//2/SQRT(PI) from the pdf equation by using it as a coefficient in front of the integration symbol
IndVars: X
DepVars: Y
Params: MEAN,SIGMA
Y=100*(0.5+0.5*ERF((1/(SIGMA*SQRT(2)))*(LN(X)-MEAN)))

***
Parameters File Name: c:\scientis\lognmdif.par

Parameter Name
MEAN
SIGMA

Lower Limit
0.000000000
0.000000000

Value
0.903279562
0.428846956

Upper Limit
5.00000000
10.0000000
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A.VI.2

Example of a SCIENTIST Plot of the Overlay of Experimental and
Calculated Data
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A.VI.3 Example of the SCIENTIST Statistical Report for the non-linear regression
analysis
*** MicroMath Scientist Statistics Report ***
Model File Name: c:\scientis\lognmcdf.eqn
Data File Name:
c:\scientis\qvarargb.mmd
Param File Name: c:\scientis\lognmdif.par
Goodness-of-fit statistics for data set:

c:\scientis\qvarargb.mmd

Data Column Name: Y
Weighted
267773.3192
309.439812
2.68258731
0.998844396
0.995795932
0.997951600

Unweighted
267773.3192
309.439812
2.68258731
0.998844396
0.995795932
0.997951600

c:\scientis\qvarargb.mmd
Weighted
Sum of squared observations:
267773.3192
Sum of squared deviations:
309.439812
Standard deviation of data:
2.68258731
R-squared:
0.998844396
Coefficient of determination:
0.995795932
Correlation:
0.997951600
Model Selection Criterion:
5.38281365

Unweighted
267773.3192
309.439812
2.68258731
0.998844396
0.995795932
0.997951600
5.38281365

Sum of squared observations:
Sum of squared deviations:
Standard deviation of data:
R-squared:
Coefficient of determination:
Correlation:
Data Set Name:

Confidence Intervals:
Parameter Name: MEAN
Estimate Value =
Standard Deviation =
95% Range (Univar) =
95% Range (S-Plane) =

-0.0748528851
0.0113635050
-0.0977695770
-0.103665501

-0.0519361932
-0.0460402690

Parameter Name:
Estimate Value =
Standard Deviation =
95% Range (Univar) =
95% Range (S-Plane) =

SIGMA
0.496699907
0.0180281352
0.460342707
0.450988858

0.533057107
0.542410956

Variance-Covariance Matrix:
0.000129129246
1.65836853E-5
0.000325013659
Correlation Matrix:
1.00000000
0.0809502015

1.00000000

Residual Analysis:
The following are normalized parameters with an expected value of 0.0. Values are in units of standard deviations from the
expected value.
The serial correlation is -2.14 which is probably not significant.
Skewness is -1.79 indicating the likelihood of a few large negative residuals having an unduly large effect on the fit.
Kurtosis is 0.00 which is probably not significant.
The weighting factor was 0.00 leading to a heteroscedacticity of -0.79 which suggests an optimal weight factor for this fit of
about -0.79
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A.VI.4

Mean values for the 50% Cut-off Aerodynamic Diameters (μm) of the
Different ELPI Stages Based on the Replicate Results (n=5) for Each of the
4 pMDI Products studied as Calibration Standards Along with 95%
Confidence Intervals

A.VI.4.1 Mean Calculated Cut-off Diameters of the ELPI Stages using Qvar
Manufacturer-Reported Calculated Cut-Off Diameter (μm) for ELPI Stages
Stage Cut-Off Diameter (μm)
from QVAR
No.
Mean
SD
Lower 95% CI Upper 95% CI
1
0.03
2
0.06
0.28
0.01
0.26
0.29
3
0.1
0.35
0.01
0.34
0.37
4
0.16
0.44
0.02
0.41
0.46
5
0.27
0.56
0.01
0.55
0.57
6
0.39
0.70
0.02
0.68
0.72
7
0.62
0.98
0.06
0.91
1.05
8
0.96
1.37
0.14
1.21
1.54
9
1.62
2.10
0.12
1.94
2.25
10
2.42
2.64
0.24
2.34
2.94
11
4.05
3.39
0.22
3.12
3.66
12
6.67
13
10.08
A.VI.4.2 Mean calculated cut-off diameters of the ELPI Stages using Ventolin CFC
ManufacturerCalculated Cut-Off Diameter (μm) for ELPI Stages from
Stage
Reported Cut-Off
Ventolin CFC
No.
Diameter (μm)
Mean
SD
Lower 95% CI Upper 95% CI
1
0.03
2
0.06
3
0.1
4
0.16
5
0.27
6
0.39
0.77
0.03
0.73
0.80
7
0.62
1.03
0.02
1.01
1.06
8
0.96
1.42
0.01
1.41
1.44
9
1.62
2.08
0.04
2.03
2.13
10
2.42
3.15
0.15
2.96
3.34
11
4.05
5.08
0.31
4.69
5.47
12
6.67
13
10.08
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A.VI.4.3 Mean calculated cut-off diameters of the ELPI Stages using Flovent HFA
Manufacturer-Reported Calculated Cut-Off Diameter (μm) for ELPI Stages
Stage Cut-Off Diameter (μm)
from Flovent HFA
No.
Mean
SD
Lower 95% CI Upper 95% CI
1
0.03
2
0.06
3
0.1
4
0.16
5
0.27
6
0.39
7
0.62
8
0.96
1.39
0.02
1.36
1.41
9
1.62
2.01
0.04
1.97
2.06
10
2.42
2.93
0.06
2.86
3.00
11
4.05
4.62
0.08
4.53
4.71
12
6.67
13
10.08
A.VI.4.4 Mean calculated cut-off diameters of the ELPI Stages using Vanceril
Manufacturer-Reported Calculated Cut-Off Diameter (μm) for ELPI Stages
Stage Cut-Off Diameter (μm)
from Vanceril
No.
Mean
SD
Lower 95% CI Upper 95% CI
1
0.03
2
0.06
3
0.1
4
0.16
5
0.27
6
0.39
7
0.62
1.79
0.35
8
0.96
1.65
0.18
1.43
1.88
9
1.62
2.31
0.08
2.20
2.41
10
2.42
3.01
0.08
2.91
3.11
11
4.05
4.54
0.07
4.46
4.63
12
6.67
6.37
0.21
6.11
6.64
13
10.08
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